From: <Salvato con Microsoft Internet Explorer 5>
Subject: IL-23 promotes tumour incidence and growth : Nature
Date: Fri, 19 May 2006 11:36:53 +0200
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="----=_NextPart_000_001F_01C67B38.869A4500"
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2869

This is a multi-part message in MIME format.

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/html;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature04808.html

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" =
"http://www.w3c.org/TR/1999/REC-html401-19991224/loose.dtd">
<HTML lang=3Den xml:lang=3D"en" =
xmlns=3D"http://www.w3.org/1999/xhtml"><HEAD><TITLE>IL-23 promotes =
tumour incidence and growth : Nature</TITLE>
<META http-equiv=3DContent-Style-Type content=3Dtext/css>
<META http-equiv=3DContent-Type content=3D"text/html; =
charset=3Diso-8859-1">
<META content=3Dnoarchive name=3Drobots><LINK=20
href=3D"http://www.nature.com/favicon.ico" rel=3D"shortcut icon"><LINK =
title=3Dhome=20
href=3D"/nature/" rel=3Dhome><LINK title=3Dcopyright =
href=3D"/nature/copyright/"=20
rel=3Dcopyright><LINK title=3Dhelp =
href=3D"/common/accessibility_statement.html"=20
rel=3Dhelp>
<META=20
content=3D"Nature, science, science news, biology, physics, genetics, =
astronomy, astrophysics, quantum physics, evolution, evolutionary =
biology, geophysics, climate change, earth science, materials science, =
interdisciplinary science, science policy, medicine, systems biology, =
genomics, transcriptomics, palaeobiology, ecology, molecular biology, =
cancer, immunology, pharmacology, development, developmental biology, =
structural biology, biochemistry, bioinformatics, computational biology, =
nanotechnology, proteomics, metabolomics, biotechnology, drug discovery, =
environmental science, life, marine biology, medical research, =
neuroscience, neurobiology, functional genomics, molecular interactions, =
RNA, DNA, cell cycle, signal transduction, cell signalling."=20
name=3Dkeywords>
<META=20
content=3D"Nature is the international weekly journal of science: a =
magazine style journal that publishes full-length research papers in all =
disciplines of science, as well as News and Views, reviews, news, =
features, commentaries, web focuses and more, covering all branches of =
science and how science impacts upon all aspects of society and life. "=20
name=3Ddescription><!-- HR: 2005-08-25 Replaced contents of file with =
pointer to master file in /common folder -->
<SCRIPT type=3Dtext/javascript><!--//--><![CDATA[//><!--
	var include =3D '';

	var wp =3D '157';
	if (wp !=3D '') include +=3D 'wp=3D'+wp;
	include +=3D ';';

	var rf =3D '7';
	if (rf !=3D '') include +=3D "rf=3D"+rf;
	include +=3D ';';
=09
	var sp =3D '75';
	if (sp !=3D '') include +=3D "sp=3D"+sp;
	include +=3D ";";
=09
	var ps =3D '10';
	if (ps !=3D '') include +=3D "ps=3D"+ps;
	include +=3D ";";
=09
	var adinf =3D "lg=3Dno;";

	if(include !=3D ";;;;")
	{
		adinf =3D include;
	}

	var time =3D new Date();
	ordval=3D (time.getTime());
//--><!]]></SCRIPT>
<!-- link rel=3D"stylesheet" href=3D"/common/style/no_standards.css" =
type=3D"text/css" media=3D"screen" / -->
<STYLE type=3Dtext/css media=3Dscreen>@import url( =
/common/style/layout.css );
@import url( /common/style/layout_wide_banner.css );
@import url( /common/style/main.css );
@import url( /common/style/header_footer_smallfonts.css );
@import url( /nature/style/site.css );
@import url( /common/style/restrict_width/930px.css );
</STYLE>
<LINK media=3Dprint =
href=3D"http://www.nature.com/common/style/print.css"=20
type=3Dtext/css rel=3Dstylesheet><!-- makes IE understand css =
declarations min/max-width and min/max-height -->
<SCRIPT src=3D"http://www.nature.com/common/scripts/minmax.js"=20
type=3Dtext/javascript></SCRIPT>

<META content=3D"MSHTML 6.00.2900.2873" name=3DGENERATOR></HEAD>
<BODY class=3Dwww-nature-com-nature id=3Darticle>
<DIV class=3Dclearfix id=3Dheader><!-- global links --><!-- header -->
<DIV id=3Dhead-er>
<DIV class=3Dheader-nonad-wrapper id=3Dtop>
<DIV class=3Daccessibility-login-wrap>
<DIV class=3Daccessibility-login><!--<a href=3D"/" =
class=3D"rollover"><img =
src=3D"/common/includes/header/images/nature.com.gif" alt=3D"Nature.com =
homepage" class=3D"nature-logo" /></a>--><A=20
class=3Dnature-link href=3D"http://www.nature.com/">nature.com<SPAN =
class=3Dhidden>=20
homepage</SPAN></A>=20
<UL class=3Djumplinks>
  <LI class=3Dfirst><A=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#content">Jump&nbsp;to&nbsp;main&nbsp;content</A>=20

  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#journalnav">Jump&nbsp;to&nbsp;navigation</A>=20
  </LI></UL>
<DIV class=3Dlogon>
<P>Welcome back: Giovanni Camporeale. <SPAN class=3Dhidden>- </SPAN><A=20
class=3Dlogoff title=3D"log out of Nature.com"=20
href=3D"http://www.nature.com/foxtrot/svc/logout">Logout<SPAN =
class=3Dhidden> of=20
nature.com </SPAN><!-- following space necessary for Mac IE --></A><SPAN =

class=3Donlyformacie>&nbsp;</SPAN></P></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<HR>

<DIV class=3Dimage-user-services-wrap>
<DIV class=3Dimage-user-services><A =
href=3D"http://www.nature.com/nature/"><IMG=20
class=3Djournal-header alt=3D"Nature homepage"=20
src=3D"http://www.nature.com/nature/images/journal_header.gif"></A>=20
<DIV class=3D"user-services div1"><!-- whitespace removed to deal with =
IE 5.0 bug -->
<UL class=3Dlist1>
  <LI class=3Dli1><A href=3D"http://www.nature.com/myaccount/">My =
account</A>
  <LI class=3Dli2><A title=3D"sign up to receive Nature email alerts"=20
  =
href=3D"http://www.nature.com/nams/svc/myaccount/save/ealert?list_id=3D1"=
>E-alert=20
  sign up</A></LI></UL></DIV>
<DIV class=3D"user-services div2"><!-- whitespace removed to deal with =
IE 5.0 bug -->
<UL class=3Dlist2>
  <LI class=3Dli1><A title=3D"Register with Nature.com"=20
  href=3D"http://www.nature.com/register/">Register</A>
  <LI class=3Dli2><A title=3D"Subscribe to Nature"=20
  =
href=3D"https://secure.nature.com/subscribe/nature">Subscribe</A></LI></U=
L></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<HR>

<DIV class=3D"publications-search-wrap clearfix">
<DIV class=3Dpublications-search>
<UL class=3Dpublications>
  <LI class=3Dfirst><A =
href=3D"http://www.nature.com/siteindex/">Publications A-Z=20
  index</A>
  <LI><A href=3D"http://www.nature.com/browse/">Browse by subject</A> =
</LI></UL>
<HR>

<DIV class=3Dsearch>
<FORM class=3Dsearch action=3Dhttp://search.nature.com/search/? =
method=3Dget>
<DIV><LABEL for=3Dsearchtext>Search</LABEL> <INPUT id=3Dsearchtext =
name=3Dsp-q> <INPUT=20
type=3Dhidden value=3Dcat name=3Dsp-x-9> <INPUT type=3Dhidden =
value=3Ddate name=3Dsp-s>=20
<SELECT name=3Dsp-q-9> <OPTION value=3DNature selected>This =
journal</OPTION>=20
  <OPTION value=3D"">All of Nature.com</OPTION></SELECT> <INPUT =
class=3Dbutton title=3D"search now" type=3Dsubmit value=3Dgo =
name=3Dsubmit> <A=20
href=3D"http://search.nature.com/search/?sp-a=3Dsp1001702d&amp;sp-t=3Dadv=
anced&amp;sp-x-1=3Dujournal&amp;sp-q-1=3DNature">Advanced&nbsp;search</A>=
=20
<INPUT type=3Dhidden value=3Dsp1001702d name=3Dsp-a> <INPUT =
type=3Dhidden=20
value=3Dsubject|ujournal name=3Dsp-sfvl-field> <INPUT type=3Dhidden =
value=3Dresults=20
name=3Dsp-t> <INPUT type=3Dhidden value=3Dujournal name=3Dsp-x-1> <INPUT =
type=3Dhidden=20
value=3Dphrase name=3Dsp-p-1> <INPUT type=3Dhidden value=3Dall =
name=3Dsp-p>=20
</DIV></FORM></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV></DIV><!-- leaderboard =
ad -->
<DIV class=3Dheader-leaderboard-wrap>
<DIV class=3Dheader-leaderboard>
<SCRIPT type=3Dtext/javascript><!--//--><![CDATA[//><!--
	ord=3DMath.random()*10000000000000000;
	document.write('<script type=3D"text/javascript" =
src=3D"http://ad.doubleclick.net/adj/nature.com/article;type=3Dlt;artid=3D=
nature04808;date=3D20060510;issue=3D;prod=3Dyes;subco=3D;chaco=3D;keywd=3D=
;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D10;pl=
aid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue};proq=
u=3D${dcFieldValue};abr=3D!webtv;ord=3D' + ord + '?" ><\/script>');

	if ((!document.images && navigator.userAgent.indexOf('Mozilla/2.') >=3D =
0) || (navigator.userAgent.indexOf("WebTV") >=3D 0)) {
		document.write('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/keywd=3D;sz=3D728x90;or=
d=3D' + ord + '?">');
		document.write('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/keywd=3D;sz=3D728x90;ord=3D=
' + ord + '?" width=3D"728" height=3D"90" border=3D"0"></a>');
	}
//--><!]]></SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Dlt;artid=
=3Dnature04808;date=3D20060510;issue=3D;prod=3Dyes;subco=3D;chaco=3D;keyw=
d=3D;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D1=
0;plaid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue};=
proqu=3D${dcFieldValue};abr=3D!NN2;ord=3D123456789?"><IMG=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Dlt;artid=3D=
nature04808;date=3D20060510;issue=3D;prod=3Dyes;subco=3D;chaco=3D;keywd=3D=
;njdis=3D;njreg=3D;crstg=3D;pos=3Dtop;sz=3D728x90;fidid=3D7;posid=3D10;pl=
aid=3D157;maact=3D${dcFieldValue};prisp=3D75;secsp=3D${dcFieldValue};proq=
u=3D${dcFieldValue};abr=3D!NN2;tile=3D1;ord=3D123456789?"></A></DIV></NOS=
CRIPT></DIV></DIV><!-- end leaderboard ad --><IMG=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 1px; HEIGHT: 14px; BORDER-RIGHT-WIDTH: =
0px"=20
alt=3D"" =
src=3D"http://www.nature.com/common/images/clear.gif"><BR></DIV><!-- end =
header --><!-- end global links --></DIV>
<DIV id=3Dconstrain>
<DIV class=3Dconstrain>
<DIV id=3Dbreadcrumb>
<DIV><A href=3D"http://www.nature.com/nature/index.html">Journal =
home</A><SPAN=20
class=3Ddivider> &gt; </SPAN><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/index.html">Ad=
vance=20
online publication</A><SPAN class=3Ddivider> &gt; </SPAN><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/index.html#lt"=
>Letter</A><SPAN=20
class=3Ddivider> &gt; </SPAN><SPAN class=3Dthisitem>Full =
Text</SPAN></DIV></DIV>
<DIV id=3Dcontent-journalnav>
<DIV id=3Dcontent>
<H1 class=3Dpage-header>Letter</H1>
<P id=3Dcite><I>Nature</I> advance online publication 10 May 2006 | =
<ABBR=20
title=3D"Digital Object Identifier">doi</ABBR>:10.1038/nature04808; =
Received 22=20
November 2005; Accepted 11 April 2006; Published online 10 May 2006</P>
<H2 id=3Datl>IL-23 promotes tumour incidence and growth</H2>
<P id=3Daug>John L. Langowski<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a2">2</A></SUP>,=20
Xueqing Zhang<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A>,</SUP><SUP><A=20
title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a2">2</A></SUP>,=20
Lingling Wu<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Jeanine D. Mattson<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Taiying Chen<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Kathy Smith<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Beth Basham<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Terrill McClanahan<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>,=20
Robert A. Kastelein<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>=20
and&nbsp;Martin Oft<SUP><A title=3D"affiliated with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP></P>
<DIV id=3Darticlebody>
<DIV id=3Dabs><A class=3D"backtotop hidden"=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#top">Top<SPAN=20
class=3Dhidden> of page</SPAN></A>
<H3 class=3Dhidden>Abstract</H3>
<P class=3Dlead>Chronic inflammation has long been associated with =
increased=20
incidence of malignancy and similarities in the regulatory mechanisms =
have been=20
suggested for more than a century<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B1">1</A></SUP>.=20
Infiltration of innate immune cells, elevated activities of matrix=20
metalloproteases and increased angiogenesis and vasculature density are =
a few=20
examples of the similarities between chronic and tumour-associated=20
inflammation<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B2">2</A></SUP>.=20
Conversely, the elimination of early malignant lesions by immune =
surveillance,=20
which relies on the cytotoxic activity of tumour-infiltrating T cells or =

intra-epithelial lymphocytes, is thought to be rate-limiting for the =
risk to=20
develop cancer<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B3">3</A></SUP>.=20
Here we show a molecular connection between the rise in =
tumour-associated=20
inflammation and a lack of tumour immune surveillance. Expression of the =

heterodimeric cytokine interleukin (IL)-23, but not of its close =
relative IL-12,=20
is increased in human tumours. Expression of these cytokines =
antagonistically=20
regulates local inflammatory responses in the tumour microenvironment =
and=20
infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes=20
infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses =
such as=20
upregulation of the matrix metalloprotease MMP9, and increases =
angiogenesis but=20
reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated=20
elimination of IL-23 leads to increased infiltration of cytotoxic T =
cells into=20
the transformed tissue, rendering a protective effect against chemically =
induced=20
carcinogenesis. Finally, transplanted tumours are growth-restricted in =
hosts=20
depleted for IL-23 or in IL-23-receptor-deficient mice. Although many =
strategies=20
for immune therapy of cancer attempt to stimulate an immune response =
against=20
solid tumours, infiltration of effector cells into the tumour tissue =
often=20
appears to be a critical hurdle<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B4">4,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B5">5,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B6">6,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B7">7</A></SUP>.=20
We show that IL-23 is an important molecular link between =
tumour-promoting=20
pro-inflammatory processes and the failure of the adaptive immune =
surveillance=20
to infiltrate tumours.</P></DIV>
<P class=3Dnorm>IL-12 and IL-23 are members of a small family of =
pro-inflammatory=20
heterodimeric cytokines<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B8">8</A></SUP>.=20
Both cytokines share a common p40 subunit that is covalently linked =
either to a=20
p35 subunit to form IL-12 or to a p19 subunit to form IL-23 (ref. <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B9">9</A>).=20
The receptor for IL-12 is comprised of an IL-12R<IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>1 and IL-12R<IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>2 subunit, whereas the receptor for IL-23 is comprised of the =

IL-12R<IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>1 subunit and a novel component termed IL-23R<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B10">10</A></SUP>.=20
Both cytokines are expressed predominantly by activated dendritic cells =
and=20
phagocytic cells. Receptors for both cytokines are expressed on T cells, =
natural=20
killer cells and natural killer T cells, but low levels of IL-23 =
receptor=20
complexes are also found on monocytes, macrophages and dendritic-cell=20
populations<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B10">10</A></SUP>.=20
Despite these similarities, there is increasing evidence that IL-12 and =
IL-23=20
drive divergent immunological pathways. Whereas IL-12 leads to =
development of=20
'classical' interferon-<IMG alt=3Dgamma=20
src=3D"http://www.nature.com/__chars/gamma/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>-producing Th1 cells and enhances cytotoxic, antimicrobial =
and=20
antitumour responses, IL-23 drives a pathway that leads to the =
generation of=20
IL-17-producing CD4<SUP>+</SUP> T cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B11">11,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B12">12,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B13">13</A></SUP>.=20
The induction of IL-23-derived processes leads to recruitment of a range =
of=20
inflammatory cells as well as T<SUB>H</SUB>IL-17 T cells, and has been =
shown to=20
be crucial to the pathogenesis of a number of immune-mediated =
inflammatory=20
diseases<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B14">14</A></SUP>.</P>
<P class=3Dnorm>Given the combined evidence of a causal relationship =
between=20
chronic inflammation and cancer as well as the pivotal role IL-23 plays =
in=20
autoimmunity, we hypothesized that IL-23-mediated responses may be =
important in=20
tumour promotion. To test this, we employed a comprehensive examination =
of=20
messenger RNA expression within various human cancer panels. =
Surprisingly,=20
IL-23p19 mRNA was found significantly upregulated in the overwhelming =
majority=20
of carcinoma samples from various organ types when compared with their =
adjacent=20
normal tissue (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f1">Fig.=20
1a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f1">b</A>).=20
Significant mRNA upregulation was observed for both subunits of IL-23 =
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f1">Fig.=20
1c</A>), but not for the IL-12-specific subunit p35 (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S2</A>). The expression of IL-17, a cytokine central to =
tumour-promoting=20
angiogenesis<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B15">15</A></SUP>,=20
was also found to be significantly elevated in human tumours, consistent =
with=20
activation of IL-23-induced processes (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S2</A> and data not shown). Additionally, human colorectal tumours =
present=20
a high degree of correlation between increased IL-23p19 expression and =
increased=20
macrophage and neutrophil infiltration activation<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B16">16</A></SUP>=20
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S3</A>). Expression of IL-23p19 protein was localized within human =
tumour=20
tissue but not in the surrounding stroma, and observed on infiltrating=20
CD11c<SUP>+</SUP> dendritic cells as a dominant source of the cytokine =
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S4a, b</A>). Supporting this, tumour-infiltrating macrophages=20
(CD11b<SUP>+</SUP>) and dendritic cells (CD11c<SUP>+</SUP>) isolated =
from mouse=20
syngeneic tumour models expressed preferentially high amounts of =
IL-23p19 mRNA=20
rather than IL-12p35 when compared to those isolated from the spleen (<A =

href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S4c, d</A>).</P>
<DIV class=3Dfigure-table id=3Df1>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F1.html">Figure=20
1:&nbsp;<B>Overexpression of IL-23 but not of IL-12 in human=20
cancer.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F1.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 1 : Overexpression of IL-23 but not of IL-12 in human =
cancer. Unfortunately we are unable to provide accessible alternative =
text for this. If you require assistance to access this image, or to =
obtain a text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04=
808-f1.0.jpg"></A>
<P class=3D""><B>a</B>, Quantitative mRNA expression of IL-23p19 in =
human colon=20
tumour (red) compared to normal adjacent tissue of the same individual =
(green,=20
connected by a line), or tissue from cancer-free individuals (black, =
yellow).=20
<B>b</B>, Significant upregulation of IL-23p19 expression in various =
human=20
cancers. The table shows number of individual paired cancerous and =
normal=20
adjacent samples with average fold increase in expression, number of =
samples=20
with five- and ten-fold increase, and <I>P</I>-value. <B>c</B>, =
Expression of=20
both IL-23 subunits is increased in human cancer; each <I>y</I>-axis =
position=20
signifies expression within an individual sample. Histological =
classification of=20
samples as normal, normal adjacent and cancerous (with stage =
classification) is=20
given.</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F1.html">High=20
resolution image and legend (106K) </A><SPAN=20
class=3Dcleardiv><!-- --></SPAN></DIV><BR class=3Dclear>
<P class=3Dnorm>To examine more directly the role of IL-12 and IL-23 in =
epithelial=20
tumorigenesis, we employed a strategy of genetic deletion, analysing the =

susceptibility of mice deficient in either IL-12 or IL-23=20
(<I>p35</I><SUP>-/-</SUP> or <I>p19</I><SUP>-/-</SUP> mice) or mice =
deficient in=20
both cytokines (<I>p40</I><SUP>-/-</SUP> mice) to tumour formation =
during=20
chemical carcinogenesis<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B17">17</A></SUP>.=20
Whereas <I>Il12p35</I><SUP>-/-</SUP> mice showed earlier appearance and=20
developed significantly increased numbers of papillomas compared to =
C57BL/6=20
control mice (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2a</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">b</A>),=20
mice deficient in IL-23p19 were resistant to tumour induction. =
Surprisingly,=20
<I>p40</I><SUP>-/-</SUP> mice, deficient in both cytokines, were =
resistant to=20
tumour induction, emphasizing the importance of IL-23 for increased =
tumour=20
incidence. Papillomas generated by this protocol persisted well over=20
100&nbsp;days after cessation of TPA promotion (see Methods) and often=20
progressed towards malignancy (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2b</A> and data not shown); however, the low overall incidence of benign =
tumours=20
in the absence of IL-23 prevents a statistically relevant comparison =
with WT=20
mice in this regard.</P>
<DIV class=3Dfigure-table id=3Df2>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F2.html">Figure=20
2:&nbsp;<B>Tumour resistance with reduced inflammation in =
IL-23-deficient=20
animals.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F2.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 2 : Tumour resistance with reduced inflammation in =
IL-23-deficient animals. Unfortunately we are unable to provide =
accessible alternative text for this. If you require assistance to =
access this image, or to obtain a text description, please contact =
npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04=
808-f2.0.jpg"></A>
<P class=3D""><B>a</B>, <B>b</B>, IL-23-deficient mice are resistant, =
whereas=20
IL-12-deficient mice are more susceptible, to cutaneous chemical =
carcinogenesis.=20
Papillomas persisted more than 100&nbsp;days following cessation of =
treatment=20
(<B>b</B>, right panel). <B>c</B>, Cutaneous IL-17 and G-CSF mRNA =
expression=20
following 140&nbsp;days of carcinogenesis. <B>d</B>, Increased =
granulocyte=20
infiltration in the dermis of WT and <I>Il12p35</I><SUP>-/-</SUP> mice.=20
<B>e</B>=96<B>l</B>, Cutaneous expression of activated MMP9 =
(<B>e</B>=96<B>h</B>)=20
and the endothelial marker CD31 (<B>i</B>=96<B>l</B>) following =
140&nbsp;days of=20
carcinogenesis. We note increased angiogenesis in C57BL/6 and=20
<I>Il12p35</I><SUP>-/-</SUP> mice. Data are mean <IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> s.d.; scatter plots show incidence with bars =
depicting=20
the mean. The significance of results in the figures is represented by:=20
*<I>P</I> &lt; 0.05, **<I>P</I> &lt; 0.01 and ***<I>P</I> &lt; 0.001; =
<I>n</I>=20
<IMG=20
src=3D"http://www.nature.com/__chars/greater/special/ge/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 7 (<B>a</B>, <B>b</B>), <I>n</I> =3D 3 =
(<B>c</B>, <B>d</B>)=20
per group.</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F2.html">High=20
resolution image and legend (221K) </A><SPAN=20
class=3Dcleardiv><!-- --></SPAN></DIV><BR class=3Dclear>
<P class=3Dnorm>To explore the role of IL-23 in tumour susceptibility, =
we examined=20
the expression of inflammatory immune cell products in =
carcinogen-treated skin.=20
IL-23 is known to modulate the homeostasis of neutrophil infiltration =
into=20
tissues by inducing expression of IL-17 and G-CSF<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B18">18</A></SUP>=97two=20
cytokines that are also linked to tumour growth<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B15">15,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B19">19</A></SUP>.=20
We found IL-17 highly expressed in the hyperplastic skin of both =
wild-type=20
C57BL/6 (WT) and <I>Il12p35</I><SUP>-/-</SUP> mice, but barely =
detectable in=20
<I>Il23p19</I><SUP>-/-</SUP> and <I>Il12p40</I><SUP>-/-</SUP> mice. =
Similarly,=20
G-CSF levels were decreased in <I>Il23p19</I><SUP>-/-</SUP> mice (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2c</A>). The number of granulocytes (GR1<SUP>+</SUP>) and macrophages=20
(CD11b<SUP>+</SUP>, F4/80<SUP>+</SUP>) in the dermis of=20
<I>Il23p19</I><SUP>-/-</SUP> and <I>Il12p40</I><SUP>-/-</SUP> mice was =
also=20
decreased compared to the skin of C57BL/6 and =
<I>Il12p35</I><SUP>-/-</SUP> mice=20
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2d</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S5a, b</A> and data not shown). In murine cancer models, tumour =
development=20
is dependent on MMP9 activity produced by inflammatory macrophages and =
mast=20
cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B20">20</A></SUP>.=20
Additionally, MMP9 and IL-17 have been identified as both markers and =
mediators=20
of tumour angiogenesis<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B15">15,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B21">21</A></SUP>.=20
The expression of activated MMP9 was elevated in carcinogen-treated skin =
of=20
tumour-prone WT and <I>Il12p35</I><SUP>-/-</SUP> animals, but =
dramatically lower=20
in skins of <I>Il23p19</I><SUP>-/-</SUP> and =
<I>Il12p40</I><SUP>-/-</SUP> mice=20
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2e=96h</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S5d, e</A>). Angiogenic markers also followed this pattern, with=20
significantly lower vessel density in IL-23p19-deficient animals (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Fig.=20
2i=96l</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S5c</A>). Thus, the absence of IL-23 resulted in a significant =
reduction in=20
numerous inflammatory factors and cell types essential for tumour =
promotion.</P>
<P class=3Dnorm>Because the incidence of macroscopic tumours can be =
viewed as the=20
result of a disturbed balance between tumour-promoting factors and=20
tumour-cell-eliminating mechanisms, our observations raised the question =
of=20
whether endogenous IL-23 would have a direct role in immune surveillance =
against=20
tumours. Immune surveillance and anti-tumour responses are vigorously =
promoted=20
by IL-12, which induces proliferation and cytotoxic activity of natural =
killer=20
cells and CD8<SUP>+</SUP> T cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B22">22</A></SUP>.=20
Surprisingly, the carcinogen-induced hyperplastic skin of=20
<I>Il23p19</I><SUP>-/-</SUP> and <I>Il12p40</I><SUP>-/-</SUP> mice were=20
infiltrated with a dramatically increased number of cytotoxic =
CD8<SUP>+</SUP> T=20
cells in both the dermis and the epidermis when compared to WT and=20
<I>p35</I><SUP>-/-</SUP> mice (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f3">Fig.=20
3a=96e</A>). The expression of markers associated with the activity of =
cytotoxic T=20
cells such as Fas ligand, perforin and granzymes were decreased in=20
<I>Il12p35</I><SUP>-/-</SUP> animals but increased in=20
<I>Il23p19</I><SUP>-/-</SUP> mice (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S6</A> and data not shown). Although deficiency of IL-12 or IL-23 =
does not=20
alter the development of CD8 cells (ref. <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B13">13</A>=20
and data not shown), it may alter the response necessary for tissue=20
infiltration. To test this, we changed the microenvironment of the=20
carcinogen-treated skin of C57BL/6 mice by serial intradermal injection =
of IL-12=20
and IL-23. While administration of IL-12 led to increased immune =
surveillance,=20
as shown by the influx of greater numbers of CD8<SUP>+</SUP> T cells in =
the=20
epidermis, IL-23 injection caused a significant decrease of CD8 T cells =
in the=20
hyperplastic skin (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f3">Fig.=20
3f</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S7a=96c</A>). Cytotoxic activity markers such as perforin, =
granzyme, Fas=20
ligand and interferon-<IMG alt=3Dgamma=20
src=3D"http://www.nature.com/__chars/gamma/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0> increased on IL-12 administration, whereas IL-23 greatly =
raised mRNA=20
levels of IL-17 (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S7d, e</A>). Systemic treatment with neutralizing antibodies =
specific to=20
IL-23p19 led to a marked down-modulation of MMP9 expression and =
increased=20
surveillance of CD8<SUP>+</SUP> T cells within the carcinogen-treated =
skin (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f3">Fig.=20
3g=96h</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S8</A>). Taken together, these results provide evidence that IL-23=20
negatively influences both the number and activity of cytotoxic T cells =
within=20
transformed tissue.</P>
<DIV class=3Dfigure-table id=3Df3>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F3.html">Figure=20
3:&nbsp;<B>IL-12 stimulates, but IL-23 decreases, immune surveillance by =
CD8 T=20
cells.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F3.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 3 : IL-12 stimulates, but IL-23 decreases, immune =
surveillance by CD8 T cells. Unfortunately we are unable to provide =
accessible alternative text for this. If you require assistance to =
access this image, or to obtain a text description, please contact =
npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04=
808-f3.0.jpg"></A>
<P class=3D""><B>a</B>=96<B>e</B>, Increased immune surveillance by CD8 =
T cells in=20
the epidermis of <I>Il23p19</I><SUP>-/-</SUP> mice (<B>c</B>) and=20
<I>Il12p40</I><SUP>-/-</SUP> mice (<B>d</B>) treated with carcinogen for =

140&nbsp;days, compared to WT (<B>a</B>) and <I>p35</I><SUP>-/-</SUP>=20
(<B>b</B>). Quantification of infiltrating CD8 T cells for each genotype =
is=20
shown in <B>e</B>. <B>f</B>, Alterations in epithelial CD8 infiltration=20
following treatment with exogenous IL-23 or IL-12 compared to =
control-treated=20
animals. <B>g</B>, <B>h</B>, Systemic treatment with anti-IL-23p19 =
antibody=20
shows marked decrease in MMP9 expression (<B>g</B>), but increase in=20
CD8<SUP>+</SUP> T cells (<B>h</B>), compared to control. Scatter plots =
show=20
incidence or density with bars depicting the mean. Significance of =
results in=20
figures is represented by: *<I>P</I> &lt; 0.05 and ***<I>P</I> &lt; =
0.001;=20
<I>n</I> =3D 3 per group.</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F3.html">High=20
resolution image and legend (96K) </A><SPAN=20
class=3Dcleardiv><!-- --></SPAN></DIV><BR class=3Dclear>
<P class=3Dnorm>To further investigate the effects of IL-12 and IL-23 on =
immune=20
surveillance, IL-12- and IL-23-cytokine-deficient mice were challenged=20
intradermally with PDV squamous carcinoma cells<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B17">17</A></SUP>.=20
In accordance with the dominant role of IL-12 in tumour immunity, =
deficiency of=20
IL-12p35 or IL-12p40 dramatically increased tumour incidence, indicating =
the=20
diminished ability of the host to reject the nascent carcinomas (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4a</A>). IL-23p19-deficient mice, however, had a strong resistance to =
tumour=20
challenge, similar to that of C57BL/6 control mice. Although previous =
reports=20
suggest genetically engineered tumours overexpressing an artificially =
linked=20
IL-23p19 and p40 construct are rejected more efficiently<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B23">23</A></SUP>,=20
our results show that at the very least IL-23 deficiency does not impair =
the=20
ability of the immune system to eliminate nascent tumours.</P>
<DIV class=3Dfigure-table id=3Df4>
<H5 class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F4.html">Figure=20
4:&nbsp;<B>Functional ablation of IL-23p19 signalling restricts tumour=20
growth.</B></A></H5><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F4.html"><IMG=20
class=3Dthumb=20
alt=3D"Figure 4 : Functional ablation of IL-23p19 signalling restricts =
tumour growth. Unfortunately we are unable to provide accessible =
alternative text for this. If you require assistance to access this =
image, or to obtain a text description, please contact npg@nature.com"=20
src=3D"http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04=
808-f4.0.jpg"></A>
<P class=3D""><B>a</B>, Persistence of immune-sensitive PDV squamous =
carcinoma in=20
IL-12-deficient but not WT or <I>p19</I><SUP>-/-</SUP> mice. <B>b</B>, =
B16F10=20
melanoma and <B>c</B>, LL/2 lung carcinoma cells exhibit reduced growth =
in=20
<I>Il23R</I><SUP>-/-</SUP> mice. <B>d</B>, Tumour growth of =
immune-resistant=20
PDV6 squamous carcinoma cells in IL-12- or IL-23-receptor-deficient =
mice.=20
<B>e</B>, Growth restriction of PDV6 tumours is CD8-dependent only in=20
<I>Il23R</I><SUP>-/-</SUP> mice. <B>f</B>, Antibody ablation of IL-12p40 =

increases both tumour incidence and size compared to anti-IL-23p19 =
treatment.=20
<B>g</B>, EP2 breast tumour growth is increased by ablation of IL-12p40 =
or=20
reduced by anti-IL-23p19 treatment (***/* for days 18 and 21). Data are =
mean=20
<IMG alt=3Dplusminus=20
src=3D"http://www.nature.com/__chars/plus/special/plusmn/black/med/base/g=
lyph.gif"=20
align=3Dbottom border=3D0> s.d.; scatter plots show incidence with bars =
depicting=20
the mean. Significance of results in figures is represented by: =
*<I>P</I> &lt;=20
0.05 and ***<I>P</I> &lt; 0.001; NS, not significant; <I>n</I> <IMG=20
src=3D"http://www.nature.com/__chars/greater/special/ge/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 5 (<B>a</B>=96<B>e</B>, <B>g</B>), <I>n</I> =
<IMG=20
src=3D"http://www.nature.com/__chars/greater/special/ge/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 14 (<B>f</B>) mice per group with two tumours =
per mouse=20
for all studies.</P><A class=3Dhigh-res=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_F4.html">High=20
resolution image and legend (73K) </A><SPAN=20
class=3Dcleardiv><!-- --></SPAN></DIV><BR class=3Dclear>
<P class=3Dnorm>To explore the respective importance of the host's =
immune response=20
to IL-12 and IL-23 and to control tumour growth, we challenged mice =
incapable of=20
responding to IL-23 (<I>Il23R</I><SUP>-/-</SUP> mice) with subcutaneous=20
transplantation of murine tumour cell lines. The growth of B16F10 =
melanoma and=20
LL2 lung carcinoma was inhibited in <I>Il23R</I><SUP>-/-</SUP> mice =
incapable of=20
responding to IL-23, compared to either WT or mice incapable of =
responding to=20
IL-12 (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4b</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">c</A>=20
and data not shown). We then used an immune-resistant subclone of the =
PDV=20
squamous carcinoma (termed PDV6), to investigate the role of IL-12 and =
IL-23=20
signalling in the host on tumour growth and CD8 T-cell function. Growth =
of=20
squamous carcinomas in <I>Il23R</I><SUP>-/-</SUP> was reduced compared =
to that=20
in WT mice, but increased in mice not able to respond to IL-12 (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4d</A>). Although depletion of CD8 T cells in WT mice did not alter PDV6 =
tumour=20
growth kinetics, it potentiated tumour growth in =
<I>Il23R</I><SUP>-/-</SUP> mice=20
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4e</A>). These results demonstrate that the absence of IL-23 signalling=20
attenuates tumour growth and suggests an essential role for CD8 T cells =
in=20
restricting tumour growth in <I>Il23R</I><SUP>-/-</SUP> mice.</P>
<P class=3Dnorm>We next asked whether antibody ablation of IL-23 or =
combined=20
ablation of IL-23 and IL-12 would have a different effect on the ability =
of the=20
host immune system to eliminate early malignant tumour cells. Animals =
treated=20
with anti-IL-23p19 showed a decreased risk of PDV tumour formation and =
faster=20
elimination of injected tumour cells. However, animals treated with=20
anti-IL-12p40, and thus depleted of both IL-12 and IL-23, had a =
significantly=20
increased tumour incidence and developed larger, faster-growing tumours =
(<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4f</A> and data not shown). Finally, animals bearing tumours formed by a =

transformed mammary cell line were treated with IL-23 or IL-12 =
neutralizing=20
antibodies. Mice treated with anti-IL-23p19 showed decreased tumour =
growth and=20
increased tumour rejection. However, anti-IL-12p40 treatment led to a =
marked=20
increase of tumour growth and an increase of metastasis formation (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4g</A> and data not shown). Thus, although elimination of transformed =
cells is=20
regulated by IL-12 (ref. <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B22">22</A>),=20
the contribution of the pro-inflammatory environment to tumour =
propagation can=20
be seen in the result of functional IL-23 ablation.</P>
<P class=3Dnorm>The importance of inflammatory processes in tumour =
progression and=20
initiation is exemplified by the tumour resistance of MMP9- or =
COX-2-deficient=20
mice<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B20">20,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B24">24</A></SUP>.=20
However, local expression of growth factors and cytokines in tumours may =
not=20
only aid tissue remodelling and angiogenesis, but also protect the =
tumour from=20
immune-mediated elimination<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B7">7</A></SUP>.=20
Surprisingly, our work shows that IL-23 appears not only to induce =
innate=20
inflammatory infiltration, but also to downregulate dramatically the =
ability of=20
CD8 T cells to infiltrate tumours (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S1</A>). Although the understanding of the biological role of IL-23 =
is=20
still evolving, it is known that IL-23 production by dendritic cells and =

macrophages can be elicited by bacterial exposure and Toll-like receptor =

engagement. The resulting IL-17-dependent immune response constitutes a=20
significant component for rapid neutralization of infectious =
organisms<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B9">9,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B25">25,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B26">26</A></SUP>.=20
However, inappropriate expression of IL-23 also appears to coincide with =

numerous autoimmune disorders<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B14">14,=20
</A></SUP><SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B27">27</A></SUP>.=20
IL-23-induced inflammatory processes such as induction of angiogenesis =
or=20
macrophage and neutrophil infiltration are valuable defence mechanisms =
against=20
bacterial infections. However, this regulatory pathway appears to be not =
just=20
inappropriate for eliminating tumours but instead could provide a =
protective,=20
tumour-promoting environment for nascent malignancies, suggesting that=20
anti-IL-23p19 therapy may prove efficacious for tumour treatment.</P>
<DIV id=3DMethods>
<H3>Methods</H3>
<DIV id=3D"Animal models">
<H4 class=3Dnorm>Animal models</H4>
<P class=3Dfollows-h4>C57BL/6 mice and=20
<I>Il12p35</I><SUP>-/-</SUP>&nbsp;(<I>Il12a</I><SUP><I>tm1Jm</I></SUP>), =

<I>Il12p40</I><SUP>-/-</SUP>(<I>Il12b</I><SUP><I>tm1Jm</I></SUP>), =
<I>Il12R<IMG=20
alt=3Dbeta =
src=3D"http://www.nature.com/__chars/beta/black/ital/base/glyph.gif"=20
align=3Dbottom=20
border=3D0>1</I><SUP>-/-</SUP>&nbsp;(<I>Il12rb1</I><SUP><I>tm1Jm</I></SUP=
>), and=20
<I>IL12R<IMG alt=3Dbeta=20
src=3D"http://www.nature.com/__chars/beta/black/ital/base/glyph.gif" =
align=3Dbottom=20
border=3D0>2</I><SUP>-/-</SUP>&nbsp;(<I>Il12rb2</I><SUP><I>tm1Jm</I></SUP=
>) mice=20
on the C57BL/6 background were obtained from Jackson Laboratory.=20
<I>Il23R</I><SUP>-/-</SUP>&nbsp;(<I>Il23ra</I><SUP><I>tm1dnax</I></SUP>) =
were=20
maintained on a C57BL/6 background;=20
<I>Il23p19</I><SUP>-/-</SUP>&nbsp;(<I>Il23a</I><SUP><I>tm1dnax</I></SUP>)=
 were=20
produced by DNAX<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B13">13</A></SUP>=20
and made congenic on the C57BL/6 background (see <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Methods</A>). The two-step skin carcinogenesis model was adapted from =
ref. <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B28">28</A>:=20
mice were treated with 9,10-dimethyl-1,2-benzanthracene (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p1">DMBA</A>;=20
Sigma) in 200&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>l acetone at 100&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g per mouse once at the age of 2=963 months, then treated =
twice-weekly=20
with the tumour promoter 12-O-tetradecanoyl-phorbol acetate (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p2">TPA</A>;=20
Fisher) in 200&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>l acetone, 30&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g per mouse for up to 1&nbsp;year. Tumours observed arise as =
papillomas=20
(keratoacanthomas) but statistically progressed towards carcinomas and=20
metastasized via the lymph drainage. Papilloma counts were conducted =
routinely=20
by visual examination. All experiments were repeated at least two times =
with=20
similar significance values (<I>P</I> =3D 0.0106 and <I>P</I> &lt; =
0.001,=20
respectively, <I>n</I> <IMG=20
src=3D"http://www.nature.com/__chars/greater/special/ge/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 7 for each group in each experiment, with a =
total of=20
<I>n</I> <IMG=20
src=3D"http://www.nature.com/__chars/greater/special/ge/black/med/base/gl=
yph.gif"=20
align=3Dbottom border=3D0> 21 per genotype). Mice 8=9610 weeks old were =
exposed to=20
carcinogen for five months=97they were either injected subcutaneously =
with murine=20
IL-12, IL-23 or PBS at 20&nbsp;ng per injection site or, for antibody =
ablation,=20
systemically injected with 100&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g of anti-IL-23p19 antibody or isotype control. In both =
cases, skin was=20
harvested 72&nbsp;h later for immunohistochemistry or for TAQMAN gene =
expression=20
analysis.</P>
<P class=3Dnorm>In tumour transplantation studies, transformed cell =
lines were=20
mixed 1:1 with growth-factor-reduced <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p3">Matrigel</A>=20
(Gibco) and injected subcutaneously or intradermally, typically in two =
separate=20
sites per animal. Squamous carcinoma cells (PDV<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B29">29</A></SUP>),=20
immune resistant PDV derivative (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p4">PDV6</A>;=20
DNAX), melanoma (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p5">B16F10</A>;=20
ATCC) and lung (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p6">LL2</A>;=20
ATCC) cell lines were injected into C57BL/6 mice, while breast (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p7">EP2</A>;=20
DNAX and <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p8">4T1</A>;=20
ATCC) and colon (<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p9">CT26</A>;=20
ATCC) cancer cells were injected into BALB/c mice. For persistence of =
PDV=20
transplants, tumour growth was followed for an observation period of=20
2=966&nbsp;months. Anti-cytokine antibody injections (1&nbsp;mg per =
mouse) were=20
repeated weekly, and expected serum concentrations were confirmed after =
one week=20
and at the end of the experiment. For <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p10">anti-CD8=20
antibody</A> ablation, 0.25&nbsp;<IMG alt=3Dmicro=20
src=3D"http://www.nature.com/__chars/micro/black/med/base/glyph.gif" =
align=3Dmiddle=20
border=3D0>g per mouse of antibody (DNAX) was injected subcutaneously =
once per=20
week; ablation effectiveness was judged by flow cytometry of treated =
spleens at=20
the experimental endpoint. Tumour volume was determined by electronic =
calliper=20
measure: (half-length)<SUP>2</SUP> <IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dmiddle border=3D0> width.</P></DIV>
<DIV id=3D"Antibodies, cytokines, immunohistochemistry, zymogram">
<H4 class=3Dnorm>Antibodies, cytokines, immunohistochemistry, =
zymogram</H4>
<P class=3Dfollows-h4>Recombinant <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p11">murine=20
IL-12</A> was obtained from R&amp;D, while <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p12">rmIL-23</A>=20
was produced at DNAX as previously described<SUP><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B9">9</A></SUP>.=20
For the ablation of IL-12, monoclonal antibody C17.8 (ref. <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#B30">30</A>)=20
was used. Mouse <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p13">anti-murine=20
IL-23p19</A> antibodies were developed at DNAX. Antibodies were injected =

subcutaneously in equal PBS volume at 1&nbsp;mg per mouse per week. =
Expected=20
serum concentrations of C17.8 and anti-IL-23p19 were confirmed by =
immunoassays=20
(ELISAs) specific for each antibody. Mouse skin biopsies were harvested =
from=20
macroscopically tumour-free areas of carcinogen-exposed skin, =
snap-frozen, fixed=20
and subjected to immunohistochemistry and counterstained with =
haematoxylin.=20
Antibodies used include <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p14">CD3,=20
CD8, CD11b, CD11c, CD31</A> (BD Biosciences), active MMP9, perforin and =
<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p15">F4/80</A>=20
(R&amp;D). Density of staining was determined by analysing multiple 20 =
<IMG=20
alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dmiddle border=3D0> fields with <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p16">ImagePro=20
Plus software</A> (MediaCybernetics). Gelatin <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p17">zymogram=20
gels</A> (Invitrogen) were performed following the supplier's=20
instructions.</P></DIV>
<DIV id=3D"Gene expression analysis">
<H4 class=3Dnorm>Gene expression analysis</H4>
<P class=3Dfollows-h4>For TAQMAN analysis, total RNA was isolated by =
standard=20
methodologies and reverse transcribed. Expression analysis for =
marker-specific=20
mRNA was measured using real-time quantitative PCR (ABI 5700) with <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p18">SYBR=20
Green PCR Mastermix</A> (Applied Biosystems). Ubiquitin levels were =
measured in=20
a separate reaction and used to normalize the data by the <IMG =
alt=3DDelta=20
src=3D"http://www.nature.com/__chars/_delta/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0> - <IMG alt=3DDelta=20
src=3D"http://www.nature.com/__chars/_delta/black/med/base/glyph.gif" =
align=3Dbottom=20
border=3D0><I>C</I><SUB>t</SUB> method, using the mean cycle threshold=20
(<I>C</I><SUB>t</SUB>) value for ubiquitin and the gene of interest for =
each=20
sample; the expression=20
1.8<SUP><I>C</I><SUB>t(ubiquitin)</SUB>-<I>C</I><SUB>t(gene&nbsp;of&nbsp;=
interest)</SUB></SUP>=20
<IMG alt=3Dtimes=20
src=3D"http://www.nature.com/__chars/math/special/times/black/med/base/gl=
yph.gif"=20
align=3Dmiddle border=3D0> 10<SUP>4</SUP> was used to obtain the =
normalized values=20
(see <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Methods</A>). For murine samples, punch biopsies were taken from at =
least three=20
independent, macroscopically and histologically tumour-free areas for =
each=20
condition.</P></DIV>
<DIV id=3D"Tumour-infiltrating immune cell isolation">
<H4 class=3Dnorm>Tumour-infiltrating immune cell isolation</H4>
<P class=3Dfollows-h4>Subcutaneous 4T1 and CT26 tumour masses were =
dissected and=20
digested with 2&nbsp;mg&nbsp;ml<SUP>-1</SUP> collagenase and=20
0.5&nbsp;mg&nbsp;ml<SUP>-1</SUP> <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p19">DNase</A>=20
(Sigma). Single-cell suspensions were created and live cells collected =
by=20
centrifugation over a <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p20">Histopaque</A>=20
(Sigma) gradient. Similar isolations from naive spleen were performed =
for=20
comparison. Collected cells were positively selected for CD11b or CD11c =
by <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p21">magnetic=20
selection</A> (Miltenyi Biotec) according to the manufacturer's=20
specifications.</P></DIV>
<DIV id=3D"Statistical analyses">
<H4 class=3Dnorm>Statistical analyses</H4>
<P class=3Dfollows-h4>The following statistical analyses were used. For =
data in <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f1">Fig.=20
1</A> and <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S1</A>, we used the Mann=96Whitney test (non-paired =
Wilcox)=97nonparametric,=20
group comparison. In <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f2">Figs=20
2</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f3">3</A>,=20
<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">4a=96c</A>=20
and <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Figs S3 and S4</A>, we used the Student's <I>t</I>-test. In <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4a=96c</A>, <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">e=96g</A>,=20
we used the Kruskal=96Wallis test followed by Dunn's multiple comparison =
test=20
(non-parametric), or analysis of variance (ANOVA) (parametric) followed =
by=20
Tukey's multiple comparison test. In <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#f4">Fig.=20
4d</A>, we used Wilcoxon matched pairs test. All tests (other than in <A =

href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S2</A>) were performed using <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p22">Prism=20
4</A> (GraphPad Software). Linear regression analysis (<A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Fig. S2</A>) was performed with Spotfire <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p23">DecisionSite</A>=20
software.</P></DIV>
<DIV id=3D"Human tumour panels, immunohistochemistry">
<H4 class=3Dnorm>Human tumour panels, immunohistochemistry</H4>
<P class=3Dfollows-h4>Paired human tumour and normal adjacent tissues =
were=20
obtained from patients undergoing therapeutic or routine surgery, =
respectively=20
(see <A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
Methods</A>). All sample diagnoses and staging were confirmed internally =
by a=20
pathologist. Immunohistochemistry was performed on frozen sections with =
<A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p24">murine=20
anti-human IL-23p19</A> (DNAX) with <A=20
href=3D"http://www.biocompare.com/natureproducts/go.asp?id=3Dnature04808_=
p_p25">biotinylated=20
horse anti-mouse IgG</A> (Vector Laboratories).</P></DIV></DIV></DIV>
<DIV id=3Dacknowledgements>
<H3>Acknowledgments</H3>
<P class=3Dnorm>We thank C. Strader for her comments on the manuscript. =
Author=20
Contributions J.L.L. and X.Z. contributed equally to this work.</P>
<H4 class=3Dinline>Competing interests statement: </H4>
<P class=3Dfollows-h4>The authors declared no competing interests.</P>
<P class=3Dnorm><A=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
information</A> accompanies this paper.</P></DIV>
<DIV id=3DReferences>
<H3 class=3Dsectitle1>References</H3>
<OL class=3Dnorm>
  <LI id=3DB1><A name=3DB1><!-- . --></A>Balkwill, F. &amp; Mantovani, =
A.=20
  Inflammation and cancer: back to Virchow? <I>Lancet</I> <B>357</B>, =
539=96545=20
  (2001)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Inflammation and cancer: back to Virchow?"=20
  href=3D"http://dx.doi.org/10.1016/S0140-6736(00)04046-0"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Inflammation and cancer: back to =
Virchow?"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11229684&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Inflammation and cancer: back to Virchow?"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000167011700027&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Inflammation and cancer: back to =
Virchow?"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3MXh=
sVKltb0%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D18c338ecd74c8=
96d235aad32a211b330"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB2><A name=3DB2><!-- . --></A>Coussens, L. M. &amp; Werb, Z. =
Inflammation=20
  and cancer. <I>Nature</I> <B>420</B>, 860=96867 (2002)&nbsp;|&nbsp;<A=20
  class=3Dreftxt title=3D"Article on Article - Inflammation and cancer"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nature01322"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Inflammation and cancer"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12490959&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Inflammation and cancer"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000179897300067&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Inflammation and cancer"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xp=
sFygtb4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D16a127e6898b2=
6f9ba8f8951d0be9952"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB3><A name=3DB3><!-- . --></A>Dunn, G. P. , Old, L. J. &amp; =
Schreiber,=20
  R. D. The immunobiology of cancer immunosurveillance and =
immunoediting.=20
  <I>Immunity</I> <B>21</B>, 137=96148 (2004)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"The immunobiology of cancer immunosurveillance and =
immunoediting"=20
  href=3D"http://dx.doi.org/10.1016/j.immuni.2004.07.017"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - The immunobiology of cancer =
immunosurveillance and immunoediting"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15308095&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - The immunobiology of cancer =
immunosurveillance and immunoediting"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000223441900003&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - The immunobiology of cancer =
immunosurveillance and immunoediting"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXn=
sVKltrY%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D0787d15102a5a=
3c3d38ee8ff348bcc0b"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB4><A name=3DB4><!-- . --></A>Yee, C. &amp; Greenberg, P. =
Modulating=20
  T-cell immunity to tumours: new strategies for monitoring T-cell =
responses.=20
  <I>Nature Rev. Cancer</I> <B>2</B>, 409=96419 (2002)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Article on Article - Modulating T-cell immunity to tumours: =
new strategies for monitoring T-cell responses"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nrc820"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB5><A name=3DB5><!-- . --></A>Blattman, J. N. &amp; =
Greenberg, P. D.=20
  Cancer immunotherapy: a treatment for the masses. <I>Science</I> =
<B>305</B>,=20
  200=96205 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Cancer immunotherapy: a treatment for the masses"=20
  href=3D"http://dx.doi.org/10.1126/science.1100369"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Cancer immunotherapy: a treatment for the =
masses"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15247469&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Cancer immunotherapy: a treatment for the =
masses"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000222501000040&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Cancer immunotherapy: a treatment for =
the masses"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXl=
sV2gtrw%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D7713cb6fc5288=
6a67a43b5a7c9194406"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB6><A name=3DB6><!-- . --></A>Marincola, F. M. , Wang, E. , =
Herlyn, M. ,=20
  Seliger, B. &amp; Ferrone, S. Tumors as elusive targets of =
T-cell-based active=20
  immunotherapy. <I>Trends Immunol.</I> <B>24</B>, 335=96342 =
(2003)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"Tumors as elusive targets of T-cell-based active =
immunotherapy"=20
  href=3D"http://dx.doi.org/10.1016/S1471-4906(03)00116-9"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Tumors as elusive targets of T-cell-based =
active immunotherapy"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12810110&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Tumors as elusive targets of T-cell-based =
active immunotherapy"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000183859900013&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Tumors as elusive targets of =
T-cell-based active immunotherapy"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXk=
s1ams7o%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D472213549c363=
f8b329b90a3c87b3856"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB7><A name=3DB7><!-- . --></A>Ganss, R. , Arnold, B. &amp; =
Hammerling, G.=20
  J. Mini-review: overcoming tumor-intrinsic resistance to immune =
effector=20
  function. <I>Eur. J. Immunol.</I> <B>34</B>, 2635=962641 =
(2004)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"Mini-review: overcoming tumor-intrinsic resistance to immune =
effector function"=20
  href=3D"http://dx.doi.org/10.1002/eji.200425474"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Mini-review: overcoming tumor-intrinsic =
resistance to immune effector function"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15368278&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Mini-review: overcoming tumor-intrinsic =
resistance to immune effector function"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000224517800001&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Mini-review: overcoming tumor-intrinsic =
resistance to immune effector function"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXo=
vVektLs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Dee352207833eb=
3165fc7dfe3cedee9a2"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB8><A name=3DB8><!-- . --></A>Langrish, C. L. <I>et al.</I> =
IL-12 and=20
  IL-23: master regulators of innate and adaptive immunity. <I>Immunol. =
Rev.</I>=20
  <B>202</B>, 96=96105 (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"IL-12 and IL-23: master regulators of innate and adaptive =
immunity"=20
  href=3D"http://dx.doi.org/10.1111/j.0105-2896.2004.00214.x"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - IL-12 and IL-23: master regulators of =
innate and adaptive immunity"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15546388&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - IL-12 and IL-23: master regulators of innate =
and adaptive immunity"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000225061500007&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - IL-12 and IL-23: master regulators of =
innate and adaptive immunity"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2MXh=
s1Oiug%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D357b2daac0c=
390485fa67c6e2b9a830e"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB9><A name=3DB9><!-- . --></A>Oppmann, B. <I>et al.</I> Novel =
p19 protein=20
  engages IL-12p40 to form a cytokine, IL-23, with biological activities =
similar=20
  as well as distinct from IL-12. <I>Immunity</I> <B>13</B>, 715=96725=20
  (2000)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, =
with biological activities similar as well as distinct from IL-12"=20
  href=3D"http://dx.doi.org/10.1016/S1074-7613(00)00070-4"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Novel p19 protein engages IL-12p40 to =
form a cytokine, IL-23, with biological activities similar as well as =
distinct from IL-12"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11114383&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Novel p19 protein engages IL-12p40 to form a =
cytokine, IL-23, with biological activities similar as well as distinct =
from IL-12"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000165598500013&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Novel p19 protein engages IL-12p40 to =
form a cytokine, IL-23, with biological activities similar as well as =
distinct from IL-12"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3cXo=
vV2ht7c%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D59415ba49360a=
99230ebd65efce959a7"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB10><A name=3DB10><!-- . --></A>Parham, C. <I>et al.</I> A =
receptor for=20
  the heterodimeric cytokine IL-23 is composed of IL-12R<IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0>1 and a novel cytokine receptor subunit, IL-23R. <I>J. =
Immunol.</I>=20
  <B>168</B>, 5699=965708 (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - A receptor for the heterodimeric cytokine =
IL-23 is composed of IL-12R[beta]1 and a novel cytokine receptor =
subunit, IL-23R"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12023369&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - A receptor for the heterodimeric cytokine =
IL-23 is composed of IL-12R[beta]1 and a novel cytokine receptor =
subunit, IL-23R"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000175815200041&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - A receptor for the heterodimeric =
cytokine IL-23 is composed of IL-12R[beta]1 and a novel cytokine =
receptor subunit, IL-23R"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xk=
tFCrtrw%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D805b7c3abde67=
8583e6c44f5926cec34"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB11><A name=3DB11><!-- . --></A>Harrington, L. E. <I>et =
al.</I>=20
  Interleukin 17-producing CD4<SUP>+</SUP> effector T cells develop via =
a=20
  lineage distinct from the T helper type 1 and 2 lineages. <I>Nature=20
  Immunol.</I> <B>6</B>, 1123=961132 (2005)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Article on Article - Interleukin 17-producing CD4+ effector T =
cells develop via a lineage distinct from the T helper type 1 and 2 =
lineages"=20
  href=3D"http://www.nature.com/doifinder/10.1038/ni1254"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB12><A name=3DB12><!-- . --></A>Aggarwal, S. , Ghilardi, N. , =
Xie, M. H.=20
  , de Sauvage, F. J. &amp; Gurney, A. L. Interleukin-23 promotes a =
distinct CD4=20
  T cell activation state characterized by the production of =
interleukin-17.=20
  <I>J. Biol. Chem.</I> <B>278</B>, 1910=961914 (2003)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Interleukin-23 promotes a distinct CD4 T cell activation =
state characterized by the production of interleukin-17"=20
  href=3D"http://dx.doi.org/10.1074/jbc.M207577200"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Interleukin-23 promotes a distinct CD4 T =
cell activation state characterized by the production of interleukin-17" =

  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12417590&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Interleukin-23 promotes a distinct CD4 T =
cell activation state characterized by the production of interleukin-17" =

  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000180462200073&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Interleukin-23 promotes a distinct CD4 =
T cell activation state characterized by the production of =
interleukin-17"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXi=
sFyksA%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Daf53b4918d4=
f517067bd5e28262a2815"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB13><A name=3DB13><!-- . --></A>Cua, D. J. <I>et al.</I> =
Interleukin-23=20
  rather than interleukin-12 is the critical cytokine for autoimmune=20
  inflammation of the brain. <I>Nature</I> <B>421</B>, 744=96748=20
  (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Interleukin-23 rather than =
interleukin-12 is the critical cytokine for autoimmune inflammation of =
the brain"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nature01355"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Interleukin-23 rather than interleukin-12 =
is the critical cytokine for autoimmune inflammation of the brain"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12610626&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Interleukin-23 rather than interleukin-12 is =
the critical cytokine for autoimmune inflammation of the brain"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000180938000044&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Interleukin-23 rather than =
interleukin-12 is the critical cytokine for autoimmune inflammation of =
the brain"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXh=
sV2rsbs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D9cb9e77fe138d=
47158d4dbd1225e7e6d"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB14><A name=3DB14><!-- . --></A>Langrish, C. L. <I>et al.</I> =
IL-23=20
  drives a pathogenic T cell population that induces autoimmune =
inflammation.=20
  <I>J. Exp. Med.</I> <B>201</B>, 233=96240 (2005)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"IL-23 drives a pathogenic T cell population that induces =
autoimmune inflammation"=20
  href=3D"http://dx.doi.org/10.1084/jem.20041257"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - IL-23 drives a pathogenic T cell =
population that induces autoimmune inflammation"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15657292&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - IL-23 drives a pathogenic T cell population =
that induces autoimmune inflammation"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000226726200010&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - IL-23 drives a pathogenic T cell =
population that induces autoimmune inflammation"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2MXo=
t12mtA%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Db79a33bdc6b=
7e950166ed20ae1a3a601"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB15><A name=3DB15><!-- . --></A>Numasaki, M. <I>et al.</I> =
Interleukin-17=20
  promotes angiogenesis and tumor growth. <I>Blood</I> <B>101</B>, =
2620=962627=20
  (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Interleukin-17 promotes angiogenesis and tumor growth"=20
  href=3D"http://dx.doi.org/10.1182/blood-2002-05-1461"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Interleukin-17 promotes angiogenesis and =
tumor growth"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12411307&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Interleukin-17 promotes angiogenesis and =
tumor growth"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000181823600034&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Interleukin-17 promotes angiogenesis =
and tumor growth"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXi=
vVWgu70%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D67b1c5cada695=
89c10b92942b9f8335c"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB16><A name=3DB16><!-- . --></A>Gupta, J. W. , Kubin, M. , =
Hartman, L. ,=20
  Cassatella, M. &amp; Trinchieri, G. Induction of expression of genes =
encoding=20
  components of the respiratory burst oxidase during differentiation of =
human=20
  myeloid cell lines induced by tumor necrosis factor and =
gamma-interferon.=20
  <I>Cancer Res.</I> <B>52</B>, 2530=962537 (1992)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Article on PubMed - Induction of expression of genes encoding =
components of the respiratory burst oxidase during differentiation of =
human myeloid cell lines induced by tumor necrosis factor and =
gamma-interferon"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D1568222&amp;dopt=3DAbstract=
"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Induction of expression of genes encoding =
components of the respiratory burst oxidase during differentiation of =
human myeloid cell lines induced by tumor necrosis factor and =
gamma-interferon"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3DA1992HR29000025&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Induction of expression of genes =
encoding components of the respiratory burst oxidase during =
differentiation of human myeloid cell lines induced by tumor necrosis =
factor and gamma-interferon"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK38XktV=
Grsbo%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D3075e8857b83736=
69e26054f0027dd74"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB17><A name=3DB17><!-- . --></A>Girardi, M. <I>et al.</I> The =
distinct=20
  contributions of murine T cell receptor (TCR)<IMG alt=3Dgamma=20
  src=3D"http://www.nature.com/__chars/gamma/black/med/base/glyph.gif"=20
  align=3Dmiddle border=3D0><IMG alt=3Ddelta=20
  src=3D"http://www.nature.com/__chars/delta/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0><SUP>+</SUP> and TCR<IMG alt=3Dalpha=20
  src=3D"http://www.nature.com/__chars/alpha/black/med/base/glyph.gif"=20
  align=3Dbottom border=3D0><IMG alt=3Dbeta=20
  src=3D"http://www.nature.com/__chars/beta/black/med/base/glyph.gif" =
align=3Dmiddle=20
  border=3D0><SUP>+</SUP> T cells to different stages of chemically =
induced skin=20
  cancer. <I>J. Exp. Med.</I> <B>198</B>, 747=96755 =
(2003)&nbsp;|&nbsp;<A=20
  class=3Dreftxt=20
  title=3D"The distinct contributions of murine T cell receptor =
(TCR)[gamma][delta]+ and TCR[alpha][beta]+ T cells to different stages =
of chemically induced skin cancer"=20
  href=3D"http://dx.doi.org/10.1084/jem.20021282"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - The distinct contributions of murine T =
cell receptor (TCR)[gamma][delta]+ and TCR[alpha][beta]+ T cells to =
different stages of chemically induced skin cancer"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12953094&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - The distinct contributions of murine T cell =
receptor (TCR)[gamma][delta]+ and TCR[alpha][beta]+ T cells to different =
stages of chemically induced skin cancer"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000185155500007&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - The distinct contributions of murine T =
cell receptor (TCR)[gamma][delta]+ and TCR[alpha][beta]+ T cells to =
different stages of chemically induced skin cancer"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXn=
tFeqt7g%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D17cdf60c99164=
f1d4f872d63e9298155"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB18><A name=3DB18><!-- . --></A>Stark, M. A. <I>et al.</I> =
Phagocytosis=20
  of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. =

  <I>Immunity</I> <B>22</B>, 285=96294 (2005)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Phagocytosis of apoptotic neutrophils regulates =
granulopoiesis via IL-23 and IL-17"=20
  href=3D"http://dx.doi.org/10.1016/j.immuni.2005.01.011"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Phagocytosis of apoptotic neutrophils =
regulates granulopoiesis via IL-23 and IL-17"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15780986&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Phagocytosis of apoptotic neutrophils =
regulates granulopoiesis via IL-23 and IL-17"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000228105700004&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Phagocytosis of apoptotic neutrophils =
regulates granulopoiesis via IL-23 and IL-17"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2MXj=
t1Ohsb0%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Da9fe9a4926799=
c9023ab11ab7bd9fe63"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB19><A name=3DB19><!-- . --></A>Mueller, M. M. <I>et al.</I> =
Autocrine=20
  growth regulation by granulocyte colony-stimulating factor and =
granulocyte=20
  macrophage colony-stimulating factor in human gliomas with tumor =
progression.=20
  <I>Am. J. Pathol.</I> <B>155</B>, 1557=961567 (1999)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Article on PubMed - Autocrine growth regulation by =
granulocyte colony-stimulating factor and granulocyte macrophage =
colony-stimulating factor in human gliomas with tumor progression"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D10550313&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Autocrine growth regulation by granulocyte =
colony-stimulating factor and granulocyte macrophage colony-stimulating =
factor in human gliomas with tumor progression"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000083587600022&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Autocrine growth regulation by =
granulocyte colony-stimulating factor and granulocyte macrophage =
colony-stimulating factor in human gliomas with tumor progression"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK1MXnvV=
Kis7Y%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Db04458687427882=
a1aa4bf7eeb2ad473"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB20><A name=3DB20><!-- . --></A>Coussens, L. M. , Tinkle, C. =
L. ,=20
  Hanahan, D. &amp; Werb, Z. MMP-9 supplied by bone marrow-derived cells =

  contributes to skin carcinogenesis. <I>Cell</I> <B>103</B>, 481=96490=20
  (2000)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"MMP-9 supplied by bone marrow-derived cells contributes to =
skin carcinogenesis"=20
  href=3D"http://dx.doi.org/10.1016/S0092-8674(00)00139-2"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - MMP-9 supplied by bone marrow-derived =
cells contributes to skin carcinogenesis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D11081634&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - MMP-9 supplied by bone marrow-derived cells =
contributes to skin carcinogenesis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000090144100013&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - MMP-9 supplied by bone marrow-derived =
cells contributes to skin carcinogenesis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3cXn=
vF2ksLg%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D3af4c83549515=
658dec8b136866b7d79"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB21><A name=3DB21><!-- . --></A>Bergers, G. <I>et al.</I> =
Matrix=20
  metalloproteinase-9 triggers the angiogenic switch during =
carcinogenesis.=20
  <I>Nature Cell Biol.</I> <B>2</B>, 737=96744 (2000)&nbsp;|&nbsp;<A =
class=3Dreftxt=20
  title=3D"Matrix metalloproteinase-9 triggers the angiogenic switch =
during carcinogenesis"=20
  href=3D"http://dx.doi.org/10.1038/35036374" =
target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB22><A name=3DB22><!-- . --></A>Trinchieri, G. Interleukin-12 =
and the=20
  regulation of innate resistance and adaptive immunity. <I>Nature Rev.=20
  Immunol.</I> <B>3</B>, 133=96146 (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on Article - Interleukin-12 and the regulation of =
innate resistance and adaptive immunity"=20
  href=3D"http://www.nature.com/doifinder/10.1038/nri1001"=20
  target=3Dexternal>Article</A>&nbsp;|
  <LI id=3DB23><A name=3DB23><!-- . --></A>Lo, C. H. <I>et al.</I> =
Antitumor and=20
  antimetastatic activity of IL-23. <I>J. Immunol.</I> <B>171</B>, =
600=96607=20
  (2003)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Antitumor and antimetastatic activity of =
IL-23"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12847224&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Antitumor and antimetastatic activity of =
IL-23"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000184093800015&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Antitumor and antimetastatic activity =
of IL-23"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3sXl=
tFymt7s%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Dd891ccff9ad49=
ea563773672b211e14d"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB24><A name=3DB24><!-- . --></A>Tiano, H. F. <I>et al.</I> =
Deficiency of=20
  either cyclooxygenase (COX)-1 or COX-2 alters epidermal =
differentiation and=20
  reduces mouse skin tumorigenesis. <I>Cancer Res.</I> <B>62</B>, =
3395=963401=20
  (2002)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Deficiency of either cyclooxygenase =
(COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin =
tumorigenesis"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D12067981&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Deficiency of either cyclooxygenase (COX)-1 =
or COX-2 alters epidermal differentiation and reduces mouse skin =
tumorigenesis"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000176203500014&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Deficiency of either cyclooxygenase =
(COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin =
tumorigenesis"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD38Xk=
slWqsb4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Dc17a901ea530b=
de5846934195ec1c618"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB25><A name=3DB25><!-- . --></A>Lieberman, L. A. <I>et =
al.</I> IL-23=20
  provides a limited mechanism of resistance to acute toxoplasmosis in =
the=20
  absence of IL-12. <I>J. Immunol.</I> <B>173</B>, 1887=961893=20
  (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - IL-23 provides a limited mechanism of =
resistance to acute toxoplasmosis in the absence of IL-12"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D15265921&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - IL-23 provides a limited mechanism of =
resistance to acute toxoplasmosis in the absence of IL-12"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000222807100048&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - IL-23 provides a limited mechanism of =
resistance to acute toxoplasmosis in the absence of IL-12"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXl=
vVajsbs%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Dedea242017e6a=
b3f1e7911e461f08fd2"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB26><A name=3DB26><!-- . --></A>Khader, S. A. <I>et al.</I> =
IL-23=20
  compensates for the absence of IL-12p70 and is essential for the IL-17 =

  response during tuberculosis but is dispensable for protection and=20
  antigen-specific IFN-<IMG alt=3Dgamma=20
  src=3D"http://www.nature.com/__chars/gamma/black/med/base/glyph.gif"=20
  align=3Dmiddle border=3D0> responses if IL-12p70 is available. <I>J. =
Immunol.</I>=20
  <B>175</B>, 788=96795 (2005)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - IL-23 compensates for the absence of =
IL-12p70 and is essential for the IL-17 response during tuberculosis but =
is dispensable for protection and antigen-specific IFN-[gamma] responses =
if IL-12p70 is available"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D16002675&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - IL-23 compensates for the absence of =
IL-12p70 and is essential for the IL-17 response during tuberculosis but =
is dispensable for protection and antigen-specific IFN-[gamma] responses =
if IL-12p70 is available"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000233647600019&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - IL-23 compensates for the absence of =
IL-12p70 and is essential for the IL-17 response during tuberculosis but =
is dispensable for protection and antigen-specific IFN-[gamma] responses =
if IL-12p70 is available"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2MXl=
vFSjsb4%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D6882966f5754a=
a53bfade14c22793598"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB27><A name=3DB27><!-- . --></A>Lee, E. <I>et al.</I> =
Increased=20
  expression of interleukin 23 p19 and p40 in lesional skin of patients =
with=20
  psoriasis vulgaris. <I>J. Exp. Med.</I> <B>199</B>, 125=96130=20
  (2004)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Increased expression of interleukin 23 p19 and p40 in =
lesional skin of patients with psoriasis vulgaris"=20
  href=3D"http://dx.doi.org/10.1084/jem.20030451"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Increased expression of interleukin 23 =
p19 and p40 in lesional skin of patients with psoriasis vulgaris"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D14707118&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Increased expression of interleukin 23 p19 =
and p40 in lesional skin of patients with psoriasis vulgaris"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3D000188065700013&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Increased expression of interleukin 23 =
p19 and p40 in lesional skin of patients with psoriasis vulgaris"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD2cXj=
vFWktw%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3De7925981886=
1b1986df1b3e0f6de58cb"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB28><A name=3DB28><!-- . --></A>Nagase, H. , Mao, J. H. &amp; =
Balmain, A.=20
  A subset of skin tumor modifier loci determines survival time of =
tumor-bearing=20
  mice. <I>Proc. Natl Acad. Sci. USA</I> <B>96</B>, 15032=9615037=20
  (1999)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"A subset of skin tumor modifier loci determines survival time =
of tumor-bearing mice"=20
  href=3D"http://dx.doi.org/10.1073/pnas.96.26.15032"=20
  target=3Dexternal>Article</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - A subset of skin tumor modifier loci =
determines survival time of tumor-bearing mice"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D10611333&amp;dopt=3DAbstrac=
t"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - A subset of skin tumor modifier loci =
determines survival time of tumor-bearing mice"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DC%2BD3cXh=
tFaksQ%3D%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3Ddb21c171ccc=
837482e706c3d43944240"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB29><A name=3DB29><!-- . --></A>Fusenig, N. E. , Am, S. M. , =
Boukamp, P.=20
  &amp; Worst, P. K. Characteristics of chemically transformed mouse =
epidermal=20
  cells <I>in vitro</I> and <I>in vivo</I>. <I>Bull. Cancer</I> =
<B>65</B>,=20
  271=96279 (1978)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Characteristics of chemically transformed =
mouse epidermal cells in vitro and in vivo"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D102384&amp;dopt=3DAbstract"=
=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Characteristics of chemically transformed =
mouse epidermal cells in vitro and in vivo"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3DA1978FV23300005&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Characteristics of chemically =
transformed mouse epidermal cells in vitro and in vivo"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:STN:280:CSaD283ovF=
E%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D19c7989f0f4635af15b=
a033b5bafadb6"=20
  target=3Dexternal>ChemPort</A>&nbsp;|
  <LI id=3DB30><A name=3DB30><!-- . --></A>Wysocka, M. <I>et al.</I> =
Interleukin-12=20
  is required for interferon-gamma production and lethality in=20
  lipopolysaccharide-induced shock in mice. <I>Eur. J. Immunol.</I> =
<B>25</B>,=20
  672=96676 (1995)&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on PubMed - Interleukin-12 is required for =
interferon-gamma production and lethality in lipopolysaccharide-induced =
shock in mice"=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=3Dnpg&amp;c=
md=3DRetrieve&amp;db=3DPubMed&amp;list_uids=3D7705395&amp;dopt=3DAbstract=
"=20
  target=3Dexternal>PubMed</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ISI - Interleukin-12 is required for =
interferon-gamma production and lethality in lipopolysaccharide-induced =
shock in mice"=20
  =
href=3D"http://links.isiglobalnet2.com/gateway/Gateway.cgi?&amp;GWVersion=
=3D2&amp;SrcAuth=3DNature&amp;SrcApp=3DNature&amp;DestLinkType=3DFullReco=
rd&amp;KeyUT=3DA1995QY50700006&amp;DestApp=3DWOS_CPL"=20
  target=3Dexternal>ISI</A>&nbsp;|&nbsp;<A class=3Dreftxt=20
  title=3D"Article on ChemPort - Interleukin-12 is required for =
interferon-gamma production and lethality in lipopolysaccharide-induced =
shock in mice"=20
  =
href=3D"http://chemport.cas.org/cgi-bin/sdcgi?APP=3Dftslink&amp;action=3D=
reflink&amp;origin=3Dnpg&amp;version=3D1.0&amp;coi=3D1:CAS:528:DyaK2MXksl=
Sms7o%3D&amp;pissn=3D0028-0836&amp;pyear=3D2006&amp;md5=3D996325d0fbeaae8=
6095bc28cd8ccaddc"=20
  target=3Dexternal>ChemPort</A>&nbsp;|</LI></OL></DIV>
<DIV class=3Dno-header-art></DIV>
<DIV id=3Daffiliations-notes>
<OL>
  <LI id=3Da1>Schering-Plough BioPharma (formerly DNAX Research, Inc.), =
901=20
  California Avenue, Palo Alto, California 94304, USA
  <LI id=3Da2>*These authors contributed equally to this work</LI></OL>
<P class=3Dcaff>Correspondence to: Martin Oft<SUP><A title=3D"affiliated =
with "=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#a1">1</A></SUP>=20
Correspondence and requests for materials should be addressed to M.O.=20
(Email:&nbsp;<A=20
href=3D"mailto:martin.oft@spcorp.com">martin.oft@spcorp.com</A>).</P>
<P class=3Dprdates></P></DIV>
<TABLE cellSpacing=3D0 cellPadding=3D10 width=3D448 border=3D0>
  <TBODY>
  <TR>
    <TD class=3Dblacksml vAlign=3Dtop bgColor=3D#eaeaea><A =
name=3Dmore></A><SPAN=20
      class=3Dheading3>MORE ARTICLES LIKE THIS</SPAN><BR>These links to =
content=20
      published by NPG are automatically generated <BR>
      <P><SPAN class=3Dcite>NEWS AND VIEWS</SPAN><BR><A=20
      href=3D"http://www.nature.com/doifinder/10.1038/ni1105-1069"=20
      target=3D_New><B>TH-17: a giant step from TH1 and =
TH2</B></A><BR><SPAN=20
      class=3Dcite><I>Nature Immunology</I> News and Views (01 Nov=20
      2005)</SPAN><BR><A =
href=3D"http://www.nature.com/doifinder/10.1038/84732"=20
      target=3D_New><B>Interleukin 12 and autoimmune =
diabetes</B></A><BR><SPAN=20
      class=3Dcite><I>Nature Genetics</I> News and Views (01 Feb =
2001)</SPAN><BR>
      <P><SPAN class=3Dcite>RESEARCH</SPAN><BR><A=20
      href=3D"http://www.nature.com/doifinder/10.1038/ni1092" =
target=3D_New><B>NOD2=20
      is a negative regulator of Toll-like receptor 2=96mediated T =
helper type 1=20
      responses</B></A><BR><SPAN class=3Dcite><I>Nature Immunology</I> =
Article (01=20
      Aug 2004)</SPAN><BR><IMG height=3D8=20
      src=3D"http://www.nature.com/rl_images/red_arrow.gif" width=3D9><A =
class=3Dred=20
      =
href=3D"http://sherman.nature.com/arls/Query?src_jrnl=3DNature&amp;src_vo=
l=3Daop&amp;query=3Dhttp://www.nature.com/doifinder/10.1038/nature04808&a=
mp;type=3DLT&amp;src_pp=3D-&amp;prod=3DNATURE&amp;src_date=3D2006&amp;src=
_title=3DIL-23 promotes tumour incidence and =
growth&amp;showall=3Dresearch">See=20
      all 12 matches for Research</A></P></TD></TR></TBODY></TABLE>
<DIV class=3Dno-header></DIV></DIV>
<DIV class=3Daop id=3Djournalnav>
<H1 class=3Dhidden>Main navigation</H1><!-- whitespace removed to deal =
with IE5.0 PC bug. --><MAP=20
class=3Djournal-nav id=3Dmain-journal-nav title=3D"main journal =
navigation">
  <UL>
    <LI class=3Djn-home><A =
href=3D"http://www.nature.com/nature/">Journal home</A><!--<ul =
class=3D"subnav"><li class=3D"jn-about-cover"><a =
href=3D"/nature_CSS/about_cover.html">About the cover</a></li></ul>-->
    <LI class=3Djn-aop><A=20
    =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/index.html">Ad=
vance=20
    online publication</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-about-aop><A=20
      =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/about.html">Ab=
out=20
      AOP</A></LI></UL>
    <LI class=3Djn-issue><A=20
    href=3D"http://www.nature.com/nature/current_issue">Current =
issue</A>
    <LI class=3Djn-archive><A=20
    =
href=3D"http://www.nature.com/nature/archive/">Archive</A></LI></UL></MAP=
><!-- whitespace removed to deal with IE5.0 PC bug. --><MAP=20
class=3D"journal-nav supplementary" id=3Dsupplementary-journal-nav=20
title=3D"supplementary journal navigation">
  <UL>
    <LI class=3Djn-supplements><A=20
    href=3D"http://www.nature.com/nature/supplements/">Supplements</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-insights><A=20
      =
href=3D"http://www.nature.com/nature/supplements/insights/">Insights</A>
      <LI class=3Djn-outlooks><A=20
      =
href=3D"http://www.nature.com/nature/supplements/outlooks/">Outlooks</A>
      <LI class=3Djn-collections><A=20
      =
href=3D"http://www.nature.com/nature/supplements/collections/">Collection=
s</A>
      <LI class=3Djn-tech-features><A=20
      href=3D"http://www.nature.com/nature/supplements/tech/">Technology =

      Features</A></LI></UL>
    <LI class=3Djn-web-focuses><A =
href=3D"http://www.nature.com/nature/focus/">Web=20
    focuses</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-biological-sciences><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_biologicalsciences.html"=
>Biological=20
      sciences</A>
      <LI class=3Djn-earth-environment><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_earthandenvironment.html=
">Earth=20
      and environment</A>
      <LI class=3Djn-physical-sciences><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_physicalsciences.html">P=
hysical=20
      sciences</A>
      <LI class=3Djn-science-politics><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_scienceandpolitics.html"=
>Science=20
      and politics</A>
      <LI class=3Djn-science-culture><A=20
      =
href=3D"http://www.nature.com/nature/focus/index_scicult.html">Science, =
art=20
      and culture</A></LI></UL>
    <LI class=3Djn-multimedia><A=20
    href=3D"http://www.nature.com/nature/multimedia/">Multimedia</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-podcast><A=20
      href=3D"http://www.nature.com/nature/podcast/">Nature podcast</A>
      <LI class=3Djn-video><A=20
      href=3D"http://www.nature.com/nature/videoarchive/">Video =
streaming</A>
      <LI class=3Djn-google><A=20
      =
href=3D"http://www.nature.com/nature/multimedia/googleearth">Google=20
earth</A>
      <LI class=3Djn-blogs><A=20
      =
href=3D"http://www.nature.com/blogs/index.html">Blogs</A></LI></UL><!--<l=
i class=3D"jn-press-releases"><a href=3D"/nature/press_release/">Press =
releases</a></li>-->
    <LI class=3Djn-about-journal><A=20
    href=3D"http://www.nature.com/nature/about/">About the journal</A>
    <UL class=3Dsubnav>
      <LI class=3Djn-contact-journal><A=20
      href=3D"http://www.nature.com/nature/about/contact/">Contact the =
journal</A>
      <LI class=3Djn-about-editors><A=20
      href=3D"http://www.nature.com/nature/about/editors/">About the =
editors</A>
      <LI class=3Djn-nature-family><A=20
      href=3D"http://www.nature.com/nature/about/family/">Nature family =
of=20
      journals</A><!--<li class=3D"jn-first-issue"><a =
href=3D"/nature/about/first/"><span =
class=3D"journalname">Nature</span>'s first issue</a></li>-->
      <LI class=3Djn-for-advertisers><A=20
      href=3D"http://npg.nature.com/media/nature/index.html">For =
advertisers</A>
      <LI class=3Djn-for-librarians><A=20
      =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/07_home.xml&=
amp;style=3Dxml/07_home.xsl">For=20
      librarians</A></LI></UL>
    <LI class=3Djn-for-authors-and-referees><A=20
    href=3D"http://www.nature.com/nature/authors/">For authors and =
referees</A>
    <UL class=3Dsubnav><!--<li class=3D"jn-getting-published"><a =
href=3D"/nature/authors/get_published/">Getting published</a></li>-->
      <LI class=3Djn-guide-authors><A=20
      href=3D"http://www.nature.com/nature/authors/gta/">Formatting =
guide</A>
      <LI class=3Djn-publication-policies><A=20
      href=3D"http://www.nature.com/nature/authors/policy/">Publication=20
      policies</A>
      <LI class=3Djn-submissions><A=20
      =
href=3D"http://www.nature.com/nature/authors/submissions/">Submissions</A=
>
      <LI class=3Djn-for-referees><A=20
      href=3D"http://www.nature.com/nature/authors/referees/">For =
referees</A><!--<li class=3D"jn-scientists"><a href=3D"#">Scientists at =
nature.com</a></li>--></LI></UL>
    <LI class=3Djn-online-submission><A class=3Dsubmission=20
    href=3D"http://www.nature.com/nature/authors/submissions/">Online=20
    submission</A>
    <LI class=3Djn-permissions-and-reprints><A=20
    =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/01_reprints.=
xml&amp;style=3Dxml/01_reprints.xsl">Reprints</A>
    <LI class=3Djn-help><A=20
href=3D"http://www.nature.com/conferences">Conferences</A>
    <LI class=3Djn-help><A=20
    =
href=3D"http://nature.custhelp.com/cgi-bin/nature.cfg/php/enduser/std_alp=
.php">Help</A></LI></UL></MAP>
<H2 class=3Dnpg-resources>Gateways</H2>
<UL class=3Dnpg-resources>
  <LI><A href=3D"http://www.natureasia.com/home.html">Asia gateway</A>
  <LI><A href=3D"http://deutsche.nature.com/">German gateway</A>
  <LI><A href=3D"http://www.nature.com/omics/index.html">Omics =
gateway</A></LI></UL>
<DIV id=3Dglobal-subject-areas>
<H2><ABBR title=3D"Nature Publishing Group">NPG</ABBR> Journals</H2>
<H3 class=3Dview>by Subject Area</H3>
<UL class=3Dcategory-list>
  <LI>
  <H4>Chemistry</H4>
  <UL>
    <LI><A =
href=3D"http://www.nature.com/chemistry/index.html">Chemistry</A>=20
    <LI><A href=3D"http://www.nature.com/drugdisc/index.html">Drug =
discovery</A>=20
    <LI><A =
href=3D"http://www.nature.com/biotech/index.html">Biotechnology</A>=20
    </LI></UL>
  <LI>
  <H4>Clinical Practice &amp; Research</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/cancer/index.html">Cancer</A>=20
    <LI><A =
href=3D"http://www.nature.com/cardio/index.html">Cardiovascular=20
    medicine</A>=20
    <LI><A =
href=3D"http://www.nature.com/dentistry/index.html">Dentistry</A>=20
    <LI><A title=3D""=20
    =
href=3D"http://www.nature.com/endocrinology/index.html">Endocrinology -=20
    NEW</A>=20
    <LI><A =
href=3D"http://www.nature.com/gastrohep/index.html">Gastroenterology=20
    &amp; Hepatology</A>=20
    <LI><A href=3D"http://www.nature.com/pathology/index.html">Pathology =
&amp;=20
    Pathobiology</A>=20
    <LI><A href=3D"http://www.nature.com/urology/index.html">Urology</A> =
</LI></UL>
  <LI>
  <H4>Earth &amp; Environment</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/earthsciences/index.html">Earth =

    sciences</A>=20
    <LI><A href=3D"http://www.nature.com/evoeco/index.html">Evolution =
&amp;=20
    Ecology</A> </LI></UL>
  <LI>
  <H4>Life sciences</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/cancer/index.html">Cancer</A>=20
    <LI><A =
href=3D"http://www.nature.com/development/index.html">Development</A>=20
    <LI><A href=3D"http://www.nature.com/drugdisc/index.html">Drug =
discovery</A>=20
    <LI><A href=3D"http://www.nature.com/evoeco/index.html">Evolution =
&amp;=20
    Ecology</A>=20
    <LI><A =
href=3D"http://www.nature.com/genetics/index.html">Genetics</A>=20
    <LI><A =
href=3D"http://www.nature.com/immuno/index.html">Immunology</A>=20
    <LI><A =
href=3D"http://www.nature.com/medicalresearch/index.html">Medical=20
    research</A>=20
    <LI><A =
href=3D"http://www.nature.com/micro/index.html">Microbiology</A>=20
    <LI><A =
href=3D"http://www.nature.com/molcellbio/index.html">Molecular cell=20
    biology</A>=20
    <LI><A =
href=3D"http://www.nature.com/neurosci/index.html">Neuroscience</A>=20
    <LI><A =
href=3D"http://www.nature.com/pharma/index.html">Pharmacology</A>=20
  </LI></UL>
  <LI>
  <H4>Physics</H4>
  <UL>
    <LI><A href=3D"http://www.nature.com/physics/index.html">Physics</A> =

    <LI><A =
href=3D"http://www.nature.com/materials/index.html">Materials</A>=20
  </LI></UL></LI></UL>
<H3 class=3Dview><A title=3D"View A to Z list of Nature Publishing Group =
journals"=20
href=3D"http://www.nature.com/siteindex/index.html">by A - Z=20
Index</A></H3></DIV></DIV></DIV>
<DIV class=3Darchive id=3Dextranav>
<H1 class=3Dhidden>Extra navigation</H1><SPAN =
class=3Dpage-header-spacer>.</SPAN>=20
<DIV class=3Dsubscribe-to-nature>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.write ('<ilayer id=3D"layer1" visibility=3D"hidden" =
width=3D"158" height=3D"60"></ilayer>');
document.write ('<nolayer>');
document.write ('<iframe =
src=3D"http://ad.doubleclick.net/adi/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;subc=
o=3D;chaco=3D;keywd=3D;dcopt=3Dist;sz=3D158x60;ord=3D' + ordval + '?" =
width=3D"158" height=3D"60" marginwidth=3D"0" marginheight=3D"0" =
frameborder=3D"0" scrolling=3D"no">');
document.write ('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Dlt;artid=
=3Dnature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;s=
ubco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D158x60;ord=3D' + =
ordval + '?">');
document.write ('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;subc=
o=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D158x60;ord=3D' + =
ordval + '?" style=3D"max-width:158px; height:60px; border:0;" =
/></a></iframe>');
document.write ('</nolayer>');
//--><!]]>
</SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Dlt;artid=
=3Dnature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;s=
ubco=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D158x60;tile=3D1;ord=3D07893195?=
"><IMG=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 158px"=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;subc=
o=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D158x60;tile=3D1;ord=3D07893195?"><=
/A></DIV></NOSCRIPT></DIV>
<DIV id=3Darticlenav>
<H2><SPAN class=3Dhidden>ARTICLE NAVIGATION - </SPAN>FULL TEXT</H2>
<DIV class=3Dprevnext><A class=3Dprev title=3D"previous article in this =
issue"=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature047=
67.html">Previous</A><SPAN=20
class=3Ddivider> | </SPAN><A class=3Dnext title=3D"next article in this =
issue"=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature046=
82.html">Next</A></DIV>
<UL>
  <LI class=3Dtoc><A class=3Dtoc=20
  href=3D"http://www.nature.com/nature/journal/vaop/ncurrent">Table of=20
  contents</A>=20
  <LI class=3Ddownload-pdf><A class=3Ddownload-pdf=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/pdf/nature0480=
8.pdf">Download=20
  PDF</A>=20
  <LI class=3Dsendtofriend><A class=3Dsendtofriend=20
  =
href=3D"http://www.nature.com/foxtrot/svc/mailform?file=3D/nature/journal=
/vaop/ncurrent/full/nature04808.html">Send=20
  to a friend</A>=20
  <LI class=3Dexport><A class=3Dexport=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/ris/nature0480=
8.ris">Export=20
  citation</A>
  <LI class=3Dexport><A class=3Dexport=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/ris/nature0480=
8refs.ris">Export=20
  references</A>=20
  <LI class=3Dpermissions><A class=3Dpermissions=20
  =
href=3D"https://s100.copyright.com/AppDispatchServlet?publisherName=3DNPG=
&amp;publication=3DNature&amp;title=3DIL-23 promotes tumour incidence =
and growth&amp;author=3DJohn L. Langowski, Xueqing Zhang, Lingling Wu, =
Jeanine D. Mattson, Taiying Chen<i> et =
al.</i>&amp;contentID=3D10.1038/nature04808&amp;publicationDate=3D$date.f=
ormat('MM/dd/yyyy',$rb.getIssueDate(),$system.getLocale(),$system.getTime=
Zone())&amp;Vol=3Daop&amp;Issue=3Dcurrent">Rights=20
  and permissions</A>=20
  <LI class=3Dsave><A class=3Dsave=20
  =
href=3D"http://www.connotea.org/add?uri=3Dhttp://www.nature.com/nature/jo=
urnal/vaop/ncurrent/full/nature04808.html">Bookmark=20
  in Connotea</A><!--<li class=3D"purchase-article"><a href=3D"" =
class=3D"purchase-article">Buy this article</a></li><li =
class=3D"purchase-issue"><a href=3D"" class=3D"purchase-issue">Buy this =
issue</a></li><li class=3D"purchase-issue last"><a href=3D"" =
class=3D"purchase-issue">Buy this supplement</a></li>-->=20

  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#abs">Abstract</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#Methods">Methods</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#References">References</A>
  <LI><A class=3Dpage=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#acknowledgements">Acknowledgements</A>
  <LI><A class=3Dfigures=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/fig_tab/nature=
04808_ft.html">Figures=20
  and tables</A>
  <LI><A=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/suppinfo/natur=
e04808.html">Supplementary=20
  info</A></LI></UL></DIV>
<DIV class=3D"extra grey">
<H2>SEARCH PUBMED FOR</H2>
<UL>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DLangowski+J">John=20
  L. Langowski</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DZhang+X">Xueqing=20
  Zhang</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DWu+L">Lingling=20
  Wu</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DMattson+J">Jeanine=20
  D. Mattson</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DChen+T">Taiying=20
  Chen</A>
  <LI><A=20
  =
href=3D"http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=3Dsearch&amp;te=
rm=3DSmith+K">Kathy=20
  Smith</A>
  <LI class=3Dmore><A=20
  =
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/pubmed/nature0=
4808.html">more=20
  authors of this article</A></LI></UL></DIV><!-- old nature.vm template =
being used, should use new njobs.vm instead -->
<DIV class=3Dbox id=3Dnatjob>
<H2 class=3Dnatjob><A href=3D"http://www.nature.com/naturejobs/"><SPAN=20
class=3Dfirst>nature</SPAN><SPAN class=3Dhidden> </SPAN><SPAN=20
class=3Dsecond>jobs</SPAN></A></H2>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--

var jobs  =3D [=20
["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D4460b0b9=
4a0b0&lookid=3Dnature", "Laboratory Head", "Sanofi Aventis", "Frankfurt =
am Main, Germany D-65926", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D4460c59c4a0360&lookid=3Dnature", "Research Scientist", "VASTox plc", =
"Abingdon, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D4446449c4a0d190&lookid=3Dnature", "Director", "National Institutes of =
Health", "Bethesda, MD United States", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D445f18844a0260&lookid=3Dnature", "Senior Staff Scientist", =
"National Institutes of Health", "Bethesda, MD United States", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D4458ac8f4a02d0&lookid=3Dnature", "Non-Clinical Lecturer", =
"University of Sheffield", "Sheffield, United Kingdom", =
"Dentistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D4458ac8c4a0300&lookid=3Dnature", "Post-Doc Physiological =
Chemistry", "UMC", "Utrecht, Netherlands", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4458ac904a06c0&lookid=3Dnature", "Research Associate", "University =
of Leicester", "Leicester, United Kingdom", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4460b0b64a0a0&lookid=3Dnature", "Post-Doctoral Fellows", "Leland =
Stanford Junior University", "Stanford, CA United States", =
"Bioinformatics"],["http://naturejobs.nature.com/texis/jobsearch/details.=
html?id=3D4460b0b84a0420&lookid=3Dnature", "Senior Research Officer", =
"The University of Queensland", "Brisbane, Australia", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
4460b0b94a020&lookid=3Dnature", "Director", "The University of =
Queensland", "Brisbane, Australia", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
4458ac8b4a07200&lookid=3Dnature", "Preliminary Scientific Program", =
"Nerviano Medical Sciences", "Milan, Italy", "Cancer Research / =
Oncology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D445f7bce4a0410&lookid=3Dnature", "Staff Investigator", "Vertex =
Pharmaceuticals Incorporated", "Cambridge, MA United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d364a03e0&lookid=3Dnature", "Surgical / Cytopathologist", =
"Emory University Hospital", "Atlanta, GA United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d364a01f0&lookid=3Dnature", "Chair", "Stony Brook University", =
"Stony Brook, NY United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d354a0e2b0&lookid=3Dnature", "Director of Surgical Pathology", =
"University of Kansas", "Kansas, KS United States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44524d354a0e200&lookid=3Dnature", "Head of New Cancer Genomics =
Lab", "Instituto Tecnologico de Monterrey", "Monterrey, Mexico", =
"Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D445f18844a0e0&lookid=3Dnature", "Scientific Project Manager", =
"National Institutes of Health", "Bethesda, MD United States", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D445ba2fe4a0160&lookid=3Dnature", "PhD student position in =
Cardiovascular Physiology", "University of Heidelberg, Inst. Physiology =
Pathophysiology", "Heidelberg, Germany", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D4450d1654a0b0&lookid=3Dnature", "Research Leader", "USDA", =
"Parlier, CA United States", =
"Agriculture"],["http://naturejobs.nature.com/texis/jobsearch/details.htm=
l?id=3D444fc5464a0a00&lookid=3Dnature", "President", "Institute of =
Ecosystem Studies", "New York, NY United States", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D44509ab74a0220&lookid=3Dnature", "Manager", "University of South =
Alabama", "Mobile, AL United States", =
"Zoology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D44509ab74a0190&lookid=3Dnature", "Academic Pathologist and Anatomical =
Pathologist", "University Health Network", "Toronto, Canada", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D44509ab74a0100&lookid=3Dnature", "Postdoctoral Position", =
"Karolinska Institute", "Sweden", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444ff6bd4a0e0&lookid=3Dnature", "Drug Discovery Team Leader - Renal =
Fibrosis", "ICOS Corporation", "Bothell, WA 98021 United States", =
"Biotechnology"],["http://naturejobs.nature.com/texis/jobsearch/details.h=
tml?id=3D444fc97b4a0570&lookid=3Dnature", "Postdoctoral Research =
Associate", "Loyola University", "Chicago, IL United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc97b4a0280&lookid=3Dnature", "Postdoctoral Fellow", "University of =
Arkansas for Medical Sciences College of Medicine", "Little Rock, AR =
United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9794a03f0&lookid=3Dnature", "Professor of Structural =
Bioinformatics", "University of Zurich", "Zurich, Switzerland", =
"Bioinformatics"],["http://naturejobs.nature.com/texis/jobsearch/details.=
html?id=3D444fc9794a0230&lookid=3Dnature", "Postdoctoral Scientist", =
"The Hospital for Sick Children Research Institute", "Toronto, Canada", =
"Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9784a0680&lookid=3Dnature", "Postdoctoral Fellow", "The Children's =
Hospital of Philadelphia", "Philadelphia, PA United States", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9774a04f0&lookid=3Dnature", "Research Program Managers", =
"U.S. Department of Energy", "Germantown, WA United States", "Env. Earth =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0220&lookid=3Dnature", "Research Laboratory Manager", =
"Channing Laboratory", "Boston, MA United States", "Clinical =
Medicine"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0190&lookid=3Dnature", "Tenure Track Positions", "Montana =
State University", "Bozeman, MT United States", =
"Microbiology"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9774a0120&lookid=3Dnature", "Director", "University of =
Hawaii-Manoa", "Honolulu, HI United States", "Earth =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9774a0b0&lookid=3Dnature", "Director of Stem Cell Biology", =
"University of Medicine and Dentistry of New Jersey", "Newark, NJ United =
States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc9774a040&lookid=3Dnature", "Scientific Investigator =
Positions", "Van Andel Research Institute", "Grand Rapids, MI United =
States", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9764a0160&lookid=3Dnature", "Member", "Natural Environment Research =
Council", "Swindon, United Kingdom", =
"Ecology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9744a0540&lookid=3Dnature", "Postdoctoral Research Associate", =
"University of Manchester", "Manchester, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9744a0330&lookid=3Dnature", "Research Fellow", "University of St =
Andrews", "St Andrews, United Kingdom", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9744a01a0&lookid=3Dnature", "Research Scientists & Engineers", =
"Lucent Technologies", "Dublin, Ireland", "Materials =
Science"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9734a0420&lookid=3Dnature", "Professor", =
"Martin-Luther-University", "Halle / Saale, Germany 06120", "Life =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9734a0150&lookid=3Dnature", "Research Fellow", "University of =
Birmingham", "Birmingham, United Kingdom", =
"Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc9724a04a0&lookid=3Dnature", "Senior Research Fellowships", =
"Wellcome Trust", "London, United Kingdom", "Medical =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9714a0330&lookid=3Dnature", "Professor", =
"Georg-August-Universitat Gottingen", "Gottingen, Germany 37073", =
"Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a0350&lookid=3Dnature", "Director", "University of Leeds", =
"Leeds, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9704a0250&lookid=3Dnature", "Laser Spectroscopy Facilities =
Manager", "University of Leeds", "Leeds, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9704a01c0&lookid=3Dnature", "Lecturers in Biological Sciences", =
"University of Stirling", "Stirling, United Kingdom", =
"Conservation"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9704a0150&lookid=3Dnature", "Postdoctoral Position", =
"Friedrich Miescher Institute", "Basel, Switzerland", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a0e0&lookid=3Dnature", "Professor of Cardiovascular Medicine", =
"University of Glasgow", "Glasgow, United Kingdom", "Cardiovascular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9704a050&lookid=3Dnature", "Career Development Fellowship", =
"Medical Research Council", "Cambridge, United Kingdom", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96f4a0490&lookid=3Dnature", "Research Scientist", "DKFZ", =
"Heidelberg, Germany D-69120", =
"Biophysics"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc96f4a0210&lookid=3Dnature", "Postdoctoral Position", =
"University of Cambridge", "Cambridge, United Kingdom", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96f4a00f0&lookid=3Dnature", "Dual Masters Degree in Brain and Mind =
Sciences", "University College London", "London, United Kingdom", =
"Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96e4a0400&lookid=3Dnature", "Director", "DKFZ", "Heidelberg, =
Germany D-69120", "Optics / =
Lasers"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96e4a0370&lookid=3Dnature", "Postdoctoral Position", "Friedrich =
Miescher Institute", "Basel, Switzerland", =
"Genomics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc96e4a0240&lookid=3Dnature", "Postdoctoral Researcher", =
"University of Liverpool", "Liverpool, United Kingdom", =
"Geophysics"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc96e4a01d0&lookid=3Dnature", "W3-Professor for Experimental =
Physics / Non-Linear Optics", "Friedrich-Schiller-Universitat Jena", =
"Jena, Germany D-07743", =
"Physics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96e4a0160&lookid=3Dnature", "W3-Professor for Experimental =
Physics / Quantum Electronics", "Friedrich-Schiller-Universitat Jena", =
"Jena, Germany D-07743", =
"Physics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a0820&lookid=3Dnature", "ILL Fellow", "Institut =
Laue-Langevin", "Grenoble, France", "Computer =
Science"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0780&lookid=3Dnature", "Research Group Leaders", "Friedrich =
Miescher Institute", "Basel, Switzerland", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0560&lookid=3Dnature", "Chair in Biostatistics", "University =
of Bristol", "Bristol, United Kingdom", =
"Mathematics"],["http://naturejobs.nature.com/texis/jobsearch/details.htm=
l?id=3D444fc96d4a02f0&lookid=3Dnature", "Post-Doctoral Position", =
"University of Rennes", "Rennes, France", "Gene =
Therapy"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0280&lookid=3Dnature", "PhD Studentship", "King's College =
London", "London, United Kingdom", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc96d4a0210&lookid=3Dnature", "Research Studentships", "University of =
Warwick", "Warwick, United Kingdom", =
"Ecology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a0c0&lookid=3Dnature", "Senior Research Fellowships", =
"Wellcome Trust", "London, United Kingdom", "Biomedical =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc96d4a050&lookid=3Dnature", "Research Technician", "University of =
Oxford", "Oxford, United Kingdom", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc96c4a0830&lookid=3Dnature", "Neurophysiologist / =
Neurocytologist", "University of Oxford", "Oxford, United Kingdom", =
"Neuroscience"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc96c4a07b0&lookid=3Dnature", "Postdoctoral Research Fellow", =
"Royal Veterinary College", "London, United Kingdom", =
"Immunology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9604a0650&lookid=3Dnature", "Researchers", "Tokyo Women's =
Medical University", "Tokyo, Japan", "Molecular =
Genetics"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc9604a05e0&lookid=3Dnature", "Assistant / Associate / Professor", =
"University of Kuwait", "Safat, Kuwait", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9604a0550&lookid=3Dnature", "Assistant / Associate / =
Professor", "University of Kuwait", "Safat, Kuwait", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc95f4a020&lookid=3Dnature", "Faculty Positions", "Christian =
Medical College", "Vellore, India", =
"Biotechnology"],["http://naturejobs.nature.com/texis/jobsearch/details.h=
tml?id=3D444fc95d4a040&lookid=3Dnature", "Post Doctoral Fellows", "Marie =
Curie Research Training Network", "Vienna, Austria", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc9594a0a00&lookid=3Dnature", "New Academic Posts", "University of =
Wales", "Bangor, United Kingdom", =
"Physiology"],["http://naturejobs.nature.com/texis/jobsearch/details.html=
?id=3D444fc9594a08e0&lookid=3Dnature", "Postdoc Position", "Charite", =
"Berlin, Germany", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc9594a0600&lookid=3Dnature", "Full Professor", "Wageningen =
University", "Wageningen, Netherlands", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a0330&lookid=3Dnature", "Lecturer in Chemistry - Centre =
for Magnetic Resonance", "University of York", "York, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a02a0&lookid=3Dnature", "Professor of Medicinal =
Chemistry", "University of Strathclyde", "Strathclyde, Scotland", =
"Medicinal and pharmaceutical =
chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59c4a0210&lookid=3Dnature", "Master of Science in Micro and =
Nanotechnology", "University of Neuchatel", "Neuchatel, Switzerland", =
"Microtechnology"],["http://naturejobs.nature.com/texis/jobsearch/details=
.html?id=3D444fc59c4a0170&lookid=3Dnature", "Postdoctoral Researcher", =
"University of Liverpool", "Liverpool, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59c4a0e0&lookid=3Dnature", "Formulation Development =
Scientists", "SSL", "Peterlee, United Kingdom", "Life =
sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc59c4a050&lookid=3Dnature", "Thermal Analysis Technology Leader", =
"SRG", "Teesside, United Kingdom", =
"Catalysis"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0ac0&lookid=3Dnature", "C1, Head of Chemistry", "Scottish =
Agricultural Science Agency", "Edinburgh, Scotland, UK", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59b4a0840&lookid=3Dnature", "Senior Chemist", "Nalco", "Fawley, =
United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0750&lookid=3Dnature", "Various", "Matchtech", =
"Nationwide, United Kingdom", "Analytical =
Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc59b4a03b0&lookid=3Dnature", "Polymer Scientist", "Huntsman", =
"Wilton, Teesside, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a01f0&lookid=3Dnature", "Materials Formulation Chemist", =
"Gurit", "Newport, Isle of Wight, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0160&lookid=3Dnature", "Production Chemists", "Capcis", =
"Manchester and Aberdeen, United Kingdom", =
"Chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc59b4a0c0&lookid=3Dnature", "Chief Chemist", "Bahrain Petroleum =
Company (BAPCO)", "Bahrain", "Environmental =
chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc5804a0220&lookid=3Dnature", "Industrial Post-Doc Medicinal =
Chemistry", "Astex Therapeutics", "Cambridge, United Kingdom", "Organic =
chemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.html?i=
d=3D444fc5474a0320&lookid=3Dnature", "Postdoctoral Research Associate", =
"Loyola University", "Chicago, IL United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc5474a0b0&lookid=3Dnature", "Postdoctoral Fellow", "University of =
Arkansas for Medical Sciences College of Medicine", "Little Rock, AR =
United States", "Cell =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
4419715d4a0cdb0&lookid=3Dnature", "Postdoctoral Fellow - Protein =
Chemistry", "Genentech", "San Francisco, CA United States", =
"Biochemistry"],["http://naturejobs.nature.com/texis/jobsearch/details.ht=
ml?id=3D444fc5464a0c00&lookid=3Dnature", "Professor of Structural =
Bioinformatics", "University of Zurich", "Zurich, Switzerland", =
"Bioinformatics"],["http://naturejobs.nature.com/texis/jobsearch/details.=
html?id=3D444fc5454a06c0&lookid=3Dnature", "Research Laboratory =
Manager", "Channing Laboratory", "Boston, MA United States", "Clinical =
Medicine"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc5454a0100&lookid=3Dnature", "Director", "University of =
Hawaii-Manoa", "Honolulu, HI United States", "Earth =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc5454a070&lookid=3Dnature", "Director of Stem Cell Biology", =
"University of Medicine and Dentistry of New Jersey", "Newark, NJ United =
States", =
"Pathology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?=
id=3D444fc5444a0870&lookid=3Dnature", "Scientific Investigator =
Positions", "Van Andel Research Institute", "Grand Rapids, MI United =
States", "Molecular =
Biology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=3D=
444fc5444a0350&lookid=3Dnature", "Member", "Natural Environment Research =
Council", "Swindon, United Kingdom", =
"Ecology"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc5434a0650&lookid=3Dnature", "Postdoctoral Research Associate", =
"University of Manchester", "Manchester, United Kingdom", "Biological =
Sciences"],["http://naturejobs.nature.com/texis/jobsearch/details.html?id=
=3D444fc5434a0470&lookid=3Dnature", "Research Fellow", "University of St =
Andrews", "St Andrews, United Kingdom", "Molecular Biology"]];			 =20

if(jobs.length > 0) {
	var first =3D Math.round((jobs.length - 1) * Math.random());
	var second =3D Math.round((jobs.length - 1) * Math.random());

	if(jobs.length =3D=3D 1) {
		first =3D 0;
	} else if (jobs.length =3D=3D 2) {
		first =3D 0;
		second =3D 1;
	} else {
		while(first =3D=3D second) {
			second =3D Math.round((jobs.length - 1) * Math.random());
		}
	}
  =20
	document.write('<ul class=3D"natjob">');
=09
	document.write('<li><h3 class=3D"first"><a href=3D"');
	document.write(jobs[first][0]);
	document.write('">');
	document.write(jobs[first][1]);
	document.write('</a></h3>');
	document.write('<ul>');
	if (jobs[first][4]) {
		document.write('<li>' + jobs[first][4] + '</li>');
	}
	document.write('<li>' + jobs[first][2] + '</li>');
	document.write('<li>' + jobs[first][3] + '</li>');
	document.write('</ul>');
	document.write('</li>');

	if(jobs.length !=3D 1){	  =20
		document.write('<li><h3><a href=3D"');
		document.write(jobs[second][0]);
		document.write('">');
		document.write(jobs[second][1]);
		document.write('</a></h3>');
		document.write('<ul>');
		if (jobs[second][4]) {
			document.write('<li>' + jobs[second][4] + '</li>');
		}
		document.write('<li>' + jobs[second][2] + '</li>');
		document.write('<li>' + jobs[second][3] + '</li>');
		document.write('</ul>');
		document.write('</li>');
	}
   document.write('</ul>');
}

//--><!]]>
</SCRIPT>

<DIV class=3Dnatjobmore><A href=3D"http://naturejobs.nature.com/">More =
science=20
jobs</A></DIV></DIV>
<DIV class=3Dbox id=3Dnatprod>
<FORM action=3Dhttp://www.biocompare.com/nature/search.asp =
method=3Dpost>
<H2 class=3Dnatprod><A href=3D"http://www.biocompare.com/nature/"><SPAN=20
class=3Dfirst>nature</SPAN><SPAN class=3Dhidden> </SPAN><SPAN=20
class=3Dsecond>products</SPAN></A></H2>
<DIV class=3Dnatprodmore><LABEL class=3Dhidden for=3Dbuyerguide>enter =
buyers guide=20
search text here</LABEL><INPUT id=3Dbuyerguide name=3Dsearch><BR><INPUT =
class=3Dbutton type=3Dsubmit value=3D"search buyers =
guide"></DIV></FORM></DIV>
<DIV class=3Dad-vert>ADVERTISEMENT<BR>
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.write ('<ilayer id=3D"layer2" visibility=3D"hidden" =
width=3D"160" height=3D"600"></ilayer>');
document.write ('<nolayer>');
document.write ('<iframe =
src=3D"http://ad.doubleclick.net/adi/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dright;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;su=
bco=3D;chaco=3D;keywd=3D;;sz=3D160x600;ord=3D' + ordval + '?" =
width=3D"160" height=3D"600" marginwidth=3D"0" marginheight=3D"0" =
frameborder=3D"0" scrolling=3D"no">');
document.write ('<a =
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Dlt;artid=
=3Dnature04808;pos=3Dright;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D160x600;ord=3D' + =
ordval + '?">');
document.write ('<img =
src=3D"http://ad.doubleclick.net/ad/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dright;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;su=
bco=3D;chaco=3D;keywd=3D;abr=3D!ie4;abr=3D!ie5;sz=3D160x600;ord=3D' + =
ordval + '?" style=3D"max-width:160px; height:600px; border:0;" =
/></a></iframe>');
document.write ('</nolayer>');
//--><!]]>
</SCRIPT>
<NOSCRIPT>
<DIV><A=20
href=3D"http://ad.doubleclick.net/jump/nature.com/article;type=3Dlt;artid=
=3Dnature04808;pos=3Dright;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D=
;subco=3D;chaco=3D;keywd=3D;abr=3D!NN2;sz=3D160x600;ord=3D07893195?"><IMG=
=20
style=3D"BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 600px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 160px"=20
alt=3DAdvertisement=20
src=3D"http://ad.doubleclick.net/ad/nature.com/article;pos=3Dright;abr=3D=
!NN2;sz=3D160x600;ord=3D07893195?"></A></DIV></NOSCRIPT></DIV></DIV></DIV=
></DIV>
<DIV class=3Dcleardiv><!--  --></DIV>
<P class=3D"back-to-top hidden"><A title=3D"Return to the top of this =
page"=20
href=3D"http://www.nature.com/nature/journal/vaop/ncurrent/full/nature048=
08.html#top">Top</A></P>
<DIV class=3Dfooter id=3Dfoot-er>
<DIV id=3Dfooter-journal>
<DIV class=3D"footer-constrain clearfix">
<P class=3Djournal-name>Nature</P>
<P class=3Dissn style=3D"BORDER-RIGHT: #000 1px solid"><ABBR=20
title=3D"International Standard Serial Number">ISSN</ABBR><SPAN=20
class=3Dhidden>:</SPAN> 0028-0836</P>
<P class=3Deissn><ABBR=20
title=3D"Electronic International Standard Serial =
Number">EISSN</ABBR><SPAN=20
class=3Dhidden>:</SPAN> 1476-4687</P>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV class=3Dcleardiv><!--  --></DIV></DIV>
<DIV id=3Dfooter-links>
<DIV class=3Dfooter-constrain>
<UL>
  <LI><A class=3Dabout-npg=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/02_intro.xml=
&amp;style=3Dxml/02_intro.xsl">About=20
  <ABBR title=3D"Nature Publishing Group">NPG</ABBR></A>
  <LI><A=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/01_home.xml&=
amp;style=3Dxml/01_home.xsl">Contact=20
  <ABBR title=3D"Nature Publishing Group">NPG</ABBR></A>
  <LI><A href=3D"http://www.nature.com/naturejobs/">Nature<SPAN =
class=3Dhidden>=20
  </SPAN>jobs.com</A>
  <LI><A=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/08_privacy.x=
ml&amp;style=3Dxml/08_privacy.xsl">Privacy=20
  policy</A>
  <LI><A href=3D"http://www.nature.com/common/legal_notice.html">Legal =
notice</A>
  <LI><A=20
  =
href=3D"http://www.nature.com/common/accessibility_statement.html">Access=
ibility=20
  statement</A>
  <LI><A class=3Drss=20
  =
href=3D"http://npg.nature.com/npg/servlet/Content?data=3Dxml/02_newsfeed.=
xml&amp;style=3Dxml/02_newsfeed.xsl"><ABBR=20
  title=3D"RDF Site Summary">RSS</ABBR> feeds</A>
  <LI><A=20
  =
href=3D"http://nature.custhelp.com/cgi-bin/nature.cfg/php/enduser/std_alp=
.php">Help</A>=20
  </LI></UL>
<DIV class=3Dcleardiv><!--  --></DIV></DIV></DIV>
<DIV id=3Dfooter-copyright>
<DIV class=3Dfooter-constrain>
<P class=3Dlogo><A class=3Dfooter-copyright title=3D""=20
href=3D"http://www.nature.com/common/copyright_statement.html">=A9 2006 =
Nature=20
Publishing Group</A> =96 partner of <A=20
href=3D"http://www.nature.com/common/partners.html">AGORA, HINARI, =
Cross<SPAN=20
class=3Dhidden> </SPAN>Ref and COUNTER =
</A></P></DIV></DIV></DIV><!--extra code for 160 x 600 ad-->
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.writeln ('<layer =
src=3D"http://ad.doubleclick.net/adl/nature.com/article;pos=3Dright;type=3D=
lt;artid=3Dnature04808;pos=3Dright;issue=3D;webfo=3D;prod=3Dyes;natco=3D;=
natcl=3D;subco=3D;chaco=3D;keywd=3D;sz=3D160x600;ord=3D' + ordval + '?" =
visibility=3D"hidden" style=3D"max-width:160px; height:600px;" =
onload=3D"moveToAbsolute(layer2.pageX,layer2.pageY);clip.height=3D600;cli=
p.width=3D160;visibility=3D\'show\';"></layer>');
//--><!]]>
</SCRIPT>
<!--end of extra code--><!--extra code for 158 x 60 ad-->
<SCRIPT type=3Dtext/javascript>
<!--//--><![CDATA[//><!--
document.writeln ('<layer =
src=3D"http://ad.doubleclick.net/adl/nature.com/article;type=3Dlt;artid=3D=
nature04808;pos=3Dtop;issue=3D;webfo=3D;prod=3Dyes;natco=3D;natcl=3D;subc=
o=3D;chaco=3D;keywd=3D;sz=3D158x60;ord=3D' + ordval + '?" =
visibility=3D"hidden" style=3D"max-width:158px; height:60px;" =
onload=3D"moveToAbsolute(layer1.pageX,layer1.pageY);clip.height=3D60;clip=
.width=3D158;visibility=3D\'show\';"></layer>');
//--><!]]>
</SCRIPT>
<!--end of extra code--></BODY></HTML>

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/images/journal_header.gif
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------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;type=lt;artid=nature04808;date=20060510;issue=;prod=yes;subco=;chaco=;keywd=;njdis=;njreg=;crstg=;pos=top;sz=728x90;fidid=7;posid=10;plaid=157;maact=${dcFieldValue};prisp=75;secsp=${dcFieldValue};proqu=${dcFieldValue};abr=!NN2;tile=1;ord=123456789?
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------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/common/images/clear.gif

R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/beta/black/med/base/glyph.gif

R0lGODlhCgALAJEAAAAAAP///////wAAACH5BAEAAAIALAAAAAAKAAsAAAIWlIGmAtr72JJnNhSr
g9zFDASYNXVTAQA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/gamma/black/med/base/glyph.gif

R0lGODlhCgAMAIAAAP///wAAACH5BAUUAAAALAAAAAAKAAwAAAIThI+pFtcO3kNStZkCpov1+IVJ
AQA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04808-f1.0.jpg
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=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04808-f2.0.jpg

/9j/4AAQSkZJRgABAgAAZABkAAD/7AARRHVja3kAAQAEAAAAPAAA/+4ADkFkb2JlAGTAAAAAAf/b
AIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoKDBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxsc
Hx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8fHx8f
Hx8fHx8fHx8fHx8fHx8fHx8f/8AAEQgBOwCWAwERAAIRAQMRAf/EAK0AAAIDAQEBAQAAAAAAAAAA
AAQFAAMGAgEHCAEBAQEBAQEAAAAAAAAAAAAAAAECAwQFEAACAQMDAgQDAggKBggGAwABAgMRBAUA
IRIxE0EiFAZRYTKBFXGRQlIjMxYHobHB0WJyskM0dFSUJTU2CPDhgmNzsyQmklPEdRc3ZIS0EQEB
AAIBBAEDAwMEAwEAAAAAARECITFBEgNRYRMEcYEi8LEykaHxBeFCIxX/2gAMAwEAAhEDEQA/AP0X
7OxvunH2NzH7jyUeTu5bhpYJYkKLHCyrSPcA7MGIr8aaB9oJoJoJoJoJoJoPGBKkDYkddBnPYGB9
xYPBDH53JjKTxuBbzbkrEsaJxLMAzVdWbfpWlTTQaTQUeusj0uIj/wBtf59Apg944uaaKIRXMZlZ
VDSRFVXlz3YnoB29z81+OgcR3drI3COZHc9FVgT+IHQW6Cqa6tYSBNMkRboHYLX8FdAuyXubG2BQ
MJLjmrtW2USgcKbNQ7E8vL8d9BdY57G3cJlEohAd04TFUfyMV5UJ+lqVU+I0Bveh7Xe7i9qnLuVH
Gnxr00FGSspby27MVw9q/JWE0Z8woenUVr89Bn54LuxyFhjrrLziynsLgXEhZI+L27wBZVkIMise
6QauRo1rrdriTNZ7DYr93o94Zq6sfcl4c1KsKZBWu3VQI9hxZgEbltXifDXOe3W3GXt9n/Wfkaev
Xe6Xx26f8df9TuD9mcbkjPJkZrmUzkxo4eVY3q0fBaKafrFFPHiNdHgaq0uo7qLuxhwtSBzVkO3j
RgNjoLtAuiyscmbnxgmtzLBEszQK9ZwrkgFk8Bt/CNTPOHGe2X2XTM4mfqvly2KidklvII3QkMrS
IpBWlagnw5D8eq7CtBRe3sNnb9+bl2wyIeIqQZHCD7KtvoAcb7iw2YtJDZXKPIIy0tuWAmjBqAZI
wSy1p46DE3iZm/ht0vMY0dnGDH6iIyw0ilPaaQ8Atf0J5ivQ/PRWmNnaYBbdZb23SO+vUiRLoUMk
tw36uJndjyNDxUaIfGxtu7FKsao8LFlKgDcqV32+DaAO49yYe2uza3M4gdWKu8o4RqQivvI1F3Di
m+/2aBX7kuMst9DJiLeO8d4G5hhyAXzNGQaMKM9B+Dfw0C3257VZ3aaUvZ3NnMojiZpJQVVGKMwd
gDXvPtv4fAUDWWNrMsTreJE8gdgjogXkn5JI3odBZ932/o/SUPZrWm353OnSnXQSDJ2M97cWUUoe
6tOJuIgDVOYqtdqbjQKcvJFH7oxTyqWjWzv+SqhkJHO2/JUMT+LSpdvGZB4/I+zxn8jFa4t4ciix
NeXIsJVMgkBK1YR8jSn5Q/BrnPHN45Z//X23/wDldt7NO38sc/DlM5i1uILexwjyx90iObgoAcPQ
SAkHqTXlWvx10baezluZYeVxB6eSp/R8g+3huugHv8vbWQk7iuzooKoqk82Y8URT0LM3lGpa5ez3
TXqU23tQveSZW6ZYsvcKpe8gqJYyOkasaq0aii8WWjUqd9Z8e/d5tfxM7ed/zvedZ9P0/uBuI4E9
yWWNymLE8t6Jma9gt0e3l4hatPyVmjYhFDCpGy7/AAZ5wfe319uum0vOeZ0/f4bLW3uC/eNg+QbG
91WvEjEzQUNQhNA3SnXQKhDEnvZFRFUfdjiigAf4hfhoHxRCvAqCvTjTan4NAn915WfFYxb2HDzZ
p4pAfTW5hV0orHu1neNAFp1rXfQN4nLxo5UoWAJRqVWo6GhI2+WgAzdjYz428aa3ilbsyGrorH6K
eI+Q0HPtdV/ZvEmm/orcV+XaXQMwqgkgAE9T8dAHjMvj8mtw1lKZVtLiS0nqrpxmhPF184WtD4jb
QGaDKxWM117kzQhle2atqRKrMQSi1KtQrsRtxB+e2g8a0vbD3Fhy88t9LHjbxBB5AGdGtqsrP5qv
/TkI1YLIPd2Wlz11iv2bv0FvDHKt4xhELsxPJFkLiMlQV6N8fhrvfTr4zbyjPlz0WHO+5JpoVtsK
0du7MrTTOKABgF8ooy1FSTSnwrrztHtp6ztf+r7fdqf1VStPD6qdNBnY4Zbz37NO95zssfbLFDYk
LQXLVZ5ARvVY2A3/ADjrH/s+fJdvybc/x1nT6/8AH92o1t9BTJah7iOfuOrRggKCOJr1qKfLRi6Z
uV2jbOh44/es0shEcYskRpGbbk0g4jeiitdvE/D4h3HNDP7zilhkWWJ8Y/GRCGU/+oXoRoH+gx3u
z71kmuMfdqL7CXrQ9yxTGS3amzClbqCR1fjzlJBU8fKPA6DW2xjNtEY4zFHwXhEV4lRTZSvhT4aA
XKXNt6G7h7qd0wygR8hyqI+RFOvQg6Bd7Vv52scbYGymWCPF2k4yB49hmdOPaXfnzXjyPlpQjQP9
An9svcNHke+985F/cCP7wjSIhA3lEHbA5QD+7Y7kddA40CLEXSP7kzVsLYRNEYXNwGJ7vOMeBJFV
pTb7dB3f/wDF+H/yl/8A27bQOtBNABnMk+Nxs18AhWABnDkioJpQUB3qdtS3Ecff7fDS7fDzC25t
rGKOcr62Ss10BSvdlJd/sBag+Wkh6NLrrM9et/WmGq7OWmiWvJ1FOtSB030HWgzzemufdl3j5rUE
Nawz+pDMCSklQpFaVUqG230ADRYj257lnvXaSKzt8RJNdOzTT8UimUswSrnpUngtT1NToNdDKk0S
SpUpIodSQVNGFRUGhH26DPe7PbTZaS3khi7rSK9hfcru5tgthdEeoaIQGhmHbXgTSm+40GhjjWON
Y1rxQBVqSTQCm5NSdAjz3tvF3Nve3brIk7RSO7wyyREntBPqjKt9KDx0F/te6tjg8VbCZDcrYW0j
QBhzCGNQGK9aV8dA0njMsMkYdoy6lRIlAy1FOS1BFR4aBL7ZsMpA13JkJr0lZpIbeK7ngnV4UbyT
r2Y4+PcH5LbjQPdBnMb3pfdObHbiRUjiSG5WNBJyZKsGdQGam2xPw0A9rjb+x9z4SO7yEl6VsL1K
OqgchJbkvWnMkggHkxG2g1egmgzXvSztcvb2mHeD1neuEnmgUgERWxDualkpUlV6+OsbzPDw/m6T
2SaY8s3P7T+sFU2Yz0P7x57e1xMV7h7XGwvcS2/AXsU0rsFiPdkjjYcU5Hia0prb3Tolr76x37aX
lhPj81bGK0in7s1vcta1dmWiJGZPMeNK8KeU7/EA8lkPbWR97Y3EpiLm5XLpcSXVw9gUgrHGiv3Z
bgRuOSKq+UHw0H0YAAAAUA2A0GfjMj++JVMMRiisgwn4J3A7MBx5050K+FdAp915u8xfuu3OPt7a
+yM+PdYbC5u0s+4izqZGR3V+XAUqKeOg02Bv7+/xcNzf20dndvyEttDOtyicWIFJVVA1VAPTbpoP
MzDDJ6Hu5KTHcLuJ07ciR+oYVpbtzB5LJ4qu58NAx0AuV/3Xef8AgSf2DoMD7O94+0ZPcFjj48ti
2yb4y0sBaIrfeJnhVpHieSvExqpqq0rXlor6RohTiW91HIX4y6WK44P/ALMa0aUzFOTfrxIAoPHj
9PjXQNtBmsBPK/urPJInbCtFxXejDiRz6U6AdPt0Bd//AMX4f/KX/wDbttA60Cn3TmbbDYSfI3Ms
kMUPGrwp3HqzBQONG6k6ztcTLz/le6er13a3GGfsb5sdmcp7izksdpjZLaFLZWgcSRovJ2Msirx5
N1alfAeGprnOXn/G13vt2326WTHHP7mvtXEUh++7nupksmWuriMu/FRLTtxFK8axRBE6dRrb6BpH
b365WW4aSI2skaRrGFbuDgWIJblx6ufDQdz2BlvoLv1EidgMohUJwYNTlyqpbwHRtAVoMvG9xN72
yNtU26tYgRyr1JJADbjjVa/h+ymgV3Htaa4z5sLu8S4uFw8sePvpbaKWS2dpVBkAm7qyHkAfMPDQ
bSwsbextI7aBEREG/BFjBb8puKBVBY7mg0Ht3YWN52fV28dx6eVZ4O6iv25U+mROQPFlrsRvoL9A
l9yY7IXFvNcWd8bVo7aZOBTuI3IVqULItduugW+xsti7/F4iOGxmjuDi7S8FxNbGMcJFMajuEfX5
CePWm/joNZoJoJoEOIxF1FnMvkrmIRzXbKlvMrB1MSCi+U7q23m3odAJFYX1p7swy3N+95SwvUo6
Io5CS3Jeoq1WBoQWp8NBqdBmfcl7BJMwnm7NhjWRp5eKsDcuKxpRiB+jU8vwlfhrN5eT2a32beM6
a/3/APHX/RkfcFz/APkbIX/spbJZ8ZiZLO7yV+7cEk3EqQwyRmUcn4ssn5q8h1OtPXH1KMcY1XiE
oAOI6D5DQdaCaCaBHa4m4/ay7ytxCAnYWCzmVwRx2LBkO4aviPDQDZXIW+O9zy5C4Dm3tMRLNMIk
aV+CTKzcUQMzGg6AV0HuS/eD7axtzLbXkk6TwQ2txKgtp3ol7N2IfpQ7mTZh1XqaDQaTQCXWWx1p
e2Vjc3CxXeQZ0soW+qVokMjhf6qCug9yv+67z/wJP7B0Cr2rfXbWWOsjZSLaJi7SZciWXtu7pxMI
WvPkoXkdqUI0A3te55+4vcYaW+ZJLmI2wu5opLZlEChvQIh5JGD9Yb8uug1GgUftGv7PffX3df0p
X7v9O/rP1nb/AFH1f0v6u+gb6BLff8XYj/KX/wDbttAP7y9ywYnD3zRSJ6yCAylnYpFAKbSTyL+r
T+E+Gs7X46vN+R7bi66c7/11/rllPuWX3x7LixckMN1hLhY57+5eQqMhc8hKzQyGN2EKyD6+NX6K
QoqbrOGvxtLppJt/l3/Xu3mNw2Ox1JLeEWlY0iNvG7dhFQbJHH5UULvSijVdxoubczmASoZwORi5
DmB8ePXTLXhcZxwHjzWIlyc2LjvIXyMCiSe0DgyohoQzJ1A8w1nymcd3Xb8b2TSey63wvS9lEvub
29FlrfDyZGBcpdBjb2fcUyuEFTRR+DXTwuM44cppbMwz1llxN3ey/ZoZeJ7YbpyptX5V0GPuJfeF
lfNmpcTHeC1x7xOkVwFlkIYS+WMI45UWlA3XQZ397CfvSy+DtIMJi3tVE6S3T2mQEVx5WXtqGEYP
EsfOPh10VqbPOe+rbGWH3ngY5b+btxXJhulKrK48xIEdAinx0Qg92ft82ax93Z2GTJnkRDaY+/sR
bRCHk5eT1FsSOYchvN5qAfDRWwyx9yS26ra2sTd63dbi3eUKBI4pTu8SfLXaib79NtEInts/eYJv
aeSwCT2hx8dvdSpfPFHIjKYmVJEiVw3krtuARoEntT2hLiveWXzdn7KtrDIKsdnDerkZSs0BhiJI
RojGpHbAJUeG/jorQX7e5fcFsI5MRLY+iuyyPDkWtpGeGqBgVh88bcqiux0Rncevuj9hMpDP7by8
cZMXpbR8wJL6QCdOXblC84gKszcjUgUpvoPqcqs8TqjcGZSFcCpUkbGh+Gg+RfvK9p5jM3GHxMfu
NrO+twx7jROQ3edQArr52+mjcm22+OrNdLf55x9Hp/F/L9no2u3rxm8czPfPf9B+W/cjJkMfJbTe
7swwYElHaBoi56s8axx9wn4sa/PTTxnWZZ9X5G3rufXNdL8zWZ5+pdjf3a3ec9qjAr7vykIsu2Kc
EVBECTBxTytvHStHpWtK66T2a5/xmPhZ+V7Jtd8/yvcp94fut92KLqK995yz2lw0ElmlxE7Ki25V
ZWdYxw5cWNAgX511i+v03GZfrz/XR6/T/wBx7/V/h4y/PjM/N7dzuz/dNe5L3MfccXuGZbG4tRbE
9tDd9yMhDVpFdePkpSlfnqa+v1SZxnf6/Cbf9v8Ak31/b8pNOuJJOf8AQNjf3de27f3hPeSZCe4n
uRHbW63NtDOiujMjtIssZVW5RUU+Oun3rNfGST9Jh49/yPZt/lttf3/r5aPKfu6xdhdRe4I50hy1
kCtjcxWVuoR3BVSywxioq1Caaz9zbFmbi/VPu7ePj2/Sf7XrP2bDA5q3ytmssTFnRVEx48QXp5qD
+sCNYcjLQJfclvmrtbezsUAtZ3AvZu4Y3WMbkArRhypSor+CmgFyVzf3t3Fh7NhPFEYxlZ/oYrUc
gKABTTfb8G1NBzkchc3mYiwlhEHsYqDIOhKlQCKKDQBePyrU7baCHIXGWzy4+1gL4eyINzcDyo0i
18gJpXiQAVWoIO+g0xrQ0FT4DpoM3aPlbKTIZnMsIFr24rZXLoUBpFt5+Jqeq9eR5DYUDywvLu1s
73OZdFSZyFtUrQdogcIxQNQlzQtvXY9KaCm1zF3Z4e5zmSt6X9xVbOAFv0lFLRoqgMVr0r4gVOgv
gTOx+3bi99OfvqcrMYTwLEKy0UJXgp4D6eXX5nQaTQVva2zyCV4kaUUpIVBYcdxQ9dq6CjKz3sNm
z2UQmn5KAhHLYsATxBSu3z0CewzWWNwUf2+9rVgLiQOh8oVgjbL5vop12BGgj5jN3KxBvb5YPxJM
rqQvRq8StfD8eg8fLe5Lcdu3wIEMbMFVZEFUDEDiooAab9afxaCq3yObeZppPbKrKaOj84w1QCTV
uP1CtPt/DoNQyI68XUMp6qRUaDiG3t4AVhiSIHchFCgkCnh8hoLNBNAmyUOaguZp8Tb27NcdrvO/
lc8A4J60YjyUrT+YAppvddpM1xbYq3laVImu3DhHkdY/N0JqR9IFPtPgDbCx3aQTNd2kVpcSzO7p
CeSvWgDk/nMBvoGGgGycAuMfcw9lZy8bBYXAKsabA1IHX56BM8XuadGhvLe3ubWSJu5CwUAuEFAf
MesnT5eI20FKXHu25aGDIYi2dUkikdy4oAjqeairAODVl38NBqNAm9q+68X7nxz5DGiQW6StD+mU
KxKgGvEFiuzDZqMOhAOgc6CaCaCaCaCaCaCaCaDOe5/e+PwGVw+Lmgknu81cJBbhOKoqtNHEzszH
fiZgeKgk/Ib6DR6CaCaCaCaCaCaCaBfl4st6ZBhzFHP3OUncA4lSDWux/KIOgC9vZjI3WQyeMv0Q
T4z04M0Z+vvxdw8hQAFTttsfloHpIAJJoBuSdAovPcNk+PupMTdW97dwJyEUTielSByZIiXIHXbQ
BRZzLG5gjSWC77jFWiS1uYTTgzA9x3dR5gOo0BmGyuYvpAbvGtYQlWNJGJcFSvEHYDcN/AdAzuJJ
kt2kt4xPKBVI+QQN/wBog00AuDyU+SxsN7LbelE6rJFGXEh4MoIJKigO/TQL7fJZjI3uTjteEMWM
uXtFFQxkY20Uis3JdqNP4H8n57A4sBeCygF6VN2EHfKfSXpuRsNBcyIxUsoJU1UkVofloEeWxnuO
e6L2GREEBYHtttQcVBUURupFd/5dg69p5LJXtperkZI5riyvri070MZiV1iYcW4FpKGh382gd6Ca
BXkrbPPlcbcWV/FbYu3Mpyto8Pce4VkpGEk5Dt8H3OxroLMB7gxHuDFRZXEXAurCcusUwVlqY3KN
s4VtmUjpoGGgmgFyOVx+OhE17MsMZZUUmpJZugAFToM97WuoLr3Z7nngfnG5sKHoR/6boQdwR4g6
B9m98NfA/wCjy/2DoMVmLGykxt9Cy9iOa0njkkgjQyUbiNlJjDb+BYa1WYQ+3/Ztvis9ZXrTXMDx
vIscr29siK7QSAFmjuZGoOv06VZGkt39vT38Ci6vsjIqMW4hqS/o2XfcOKUby9fs1lW1sRGtpEI4
mgQDaF+q/Lx0APtQ/wDtrF/5aL+yNAJ7V/3h7m/+7H//ABWug0GgGyV8tjYTXjIZFhXkUBVSR8ix
A0FUOax7Wltczypai6QPFHM6qxBpsN9+vhoMrj77NWNllJ8XBbzUz84v2upewkNoXHenDUNTGvm4
nroNfYZTGZCNpLC7hu40PF3gkSUA0rQlCaHQE6CMQASeg3NN/wCLQZz2f769ve6PUph0uUFmEMou
LWa1H6UtTj3VQN9BrTQaPQTQZL2Zb293Hl2nhWSCW9Z0jl4y9BQGrVeu1fN06DQL4/V2/un3HFjJ
mtnSTGqYYrfvDtGJUJoB5eK8iPwaDV38gk9vXTdwyn00qtIV4EsqlWJWgpuOmgyebjzEuKyEeFhj
ucu9lcjH284Ronn4jgrrIQhUn87bWqkYb2Jj/wB/ae6bN/dHt/FRYNVmN29vDYrLXsOEVWjdnHJ6
KaDodZafUbS293tdxl4bGyg4Acok5sp4kGoJFPyQArEbddEPXuI7K1Rr24XaitMw4BmPTbfc6Bb7
Pu7aXAWMEbgzW9vEs0e4ZCVp5gdx0OgW4HMWFnmPccE8nGWTKSOAATQR2Fs5qR08vQePhoNRaXUV
3bR3EVe3IKgMKEeBBB8RoA/ciq2Bvw0naj7L9x+POiAVei1WtVr46AayxGHyGDsENbi1SBVgkJZS
VPE1pWoJ4D56BL7ZtLO09u+5bWGw9TaRX+QUY2MD9Kh3aJQxA89SN/joG3srE4bH4C3fFYYYKK+R
LqbHcVR43eNVpKFJHMIiq2/hoH2gXX3uHC2GUx2KvLpYchlTIuPt2DcpTCvOShAIHFd99Bxjc1Pe
5bI2Rx88FrZdr0+Scxm3uu6pLdkqzN+jI4tUDfQNNBNBkbKK/uTlYsTMbS8S+LTyTFXG5aqjiGqP
gDTw+FNBV7RiuovefuaO7lE06x44O4FKnsN4+P4aD8GgfXf/AA/f/wBS6/tPoF2J/wB7wf1Zf4hr
VSNNrKpoFPuX/Bwf5iP+XViUkhzsOInuZ5onnV1t04xvCrDlJIin9NJFUcmHTSkX+0Vtr669wzzQ
I3+1SUDhHK8rK1qKguv4eJ1FaiOKOKNY4kEcaCiIoAUAeAA0APuGe3gwl9LccjCIWDhSAxBFKAkE
Ctab7aBRD7gjxeHxSrazTpcQBo6FX4AceKsyqopRtjxpt89AJ7MzmMjtcpNdzCx9Rlb144rukElF
ZQao5B20Gos8ti712Szu4bh1HJlidXIB2qaE6ArQC5DGWt+qLOZF7ZJVopZIW3FD5o2U0poF/tz2
dgfbdtFaYaKW1s4efatfUTyRL3GLsQkjstSxJroHWgmgxWFzEGMu89cXykA3wjrF5gzFWaoHU7de
tBoO/aV5Bee9fdFzAaxvHjzv1B7DGh+ege3f/D9//Uuv7T6Bdif97wf1Zf4hrVSNNrKpoFHub/Bw
f5iP+XViV+WP+acf+48B/kZf/O02XV9l/wCWP/8AWUf+Y/8ApoNSLX1nRAOcETYe7SY0ikiaNyBy
2ccelV+Px0HeJtUtMZa20brIkMaorp9JAGxG7fx6D5xNL7dyH31gcjkLvG3sGQvs1DdWomj7cVo4
DStKimNlVmHKNjv8NFPP3UekfC3k9rJkLxJ7oyPlsiwYXzGJCbq1UEhLeT6kUADc7aIfXWdvoZ5o
0w15OkRYLLH2eMgVUIK8pFPm5kCv5p+WgbuaIxqV2O43I/j0GK/dbi8UMVLnrPK5HNT5c/8Aqb/J
9yN39O7xqFt2CLFxHl8qitK6AjIZK0bOZWwHup7G5sLZb67teFvxtreZDGjlpEOwaJn3O1d9iNBr
P7v6vD69vh1+GgzXtVLW4us03ZDxC+dld1NC+9ePLbatKj8HzIVe3VVPfnupFAVVjx4VRsABA2wG
gb3f/D9//Uuv7T6Bdif97wf1Zf4hrVSNNrKlt5mZLbKW9gLCeY3VTHOjQiOiUL15SK/lB/N/BoKv
c3+Dg/zEf8urEr8sf803/EeA/wAjL/52my6vqv8Ay6WF/cfu6tpILswRpM4aMBhUvZwKD5SAaV5b
jrSnzi19hx9vNbWMEE0pnliQK8xrViPE1JOiA/c8M8+DuooAxlYLx4KXOzg14gEmnyFdAC8HuebH
Y30TrZyLCPVJIa+fy0WjIzU671BHw+AAe1FyCYf3C5igvsmmQyASMAwxSvUER+YylFagBqToDfal
jNhcBPf5aaW3NxW/ubOeczw49O0pa1gaigQw8TSg0HyzOp+9H3Z7kxHuLE43F+4fbOPvzfe28ja3
r23GEuEPfRmXusAnQCmivu5IAJJoBuTojO+1MxdZua+zFrk7PJe2LoouFNqjrIhi5R3IldjR/wBK
vloBoEXvvMey7q6t7DJe4Mdb2kFxEmdxU6RXHq47pmtorearAoolHImhoVBbbQbHuYX7np3YPunt
drnzXsdr9Xx5V40/J66CXmMWW2aK0k9DIzczLCOJJoR5gvGvXQZv2hbT2/vL3NFNMbiRI8eplbqa
QH8J/GSfnoHt3/w/f/1Lr+0+gXYn/e8H9WX+Ia1UjTaypDex38sjZVJ40OM9SIoTEWDClPM3Mfme
A0F3uJuWPtmOxaeI/jB1Ylfln/mm/wCI8B/kZf8AztNl1fZf+WT/APWUf+Y/+mg1ItfWdETQcyyx
RIZJXWNB1diFArt1Ogz/ALMB45v/AO73n9pdA/mhhnhkgmRZYZVKSRuAysrChVgdiCNB+ZfceG/e
N7e/fDYW2JxDT+3TIzY/29jDJFYfd1WR2moViSbcvT49Phor9NwxRwxJFGOMcahUXrQAUHXRHkUM
MMYjhRY4xWiIAqipqdh89B8P/eX+7yO3ukscPa4y2jyd0r4yxmnmSbK3biWW/t7yQjn2pIieFJQF
belSo0V9l9Mv3J6b0pp6bh6Lub/RTt92vXw51+eiCbq4W3tpbhgWWJGcqOpCiu1dBh8bnRZe685f
z47ItbZCOye2lt7O4uI24QUcB4kdTxJpsdBnsr7192vkLmC19tZtsaxnjFIJFSQSP5JeDW5dRxLV
XlvXw1UNLr3fdY50u7P29mb+VeaLCmPuE+oDdi6rtt4atpIcYP8AeLJeWImyft/MY665EG2bH3Um
1AahkRgetNZV6/uy2OOvoRjMt3J+/wBsfdt5v3K8f7v56BXc++7nIJDav7XztqkciN35LGRlIQHw
Tk38GrB8X/f37Y93e7M1iLnA+3srdQ2trJFOxs5ouLtLyApIq1202WPqf7gYcngPZlnhsxjbqwvp
7lwIriMxEBLeIcqNQkEoemoV9a0RNAPkMfbX9q1tcAmJiCeJKmqmo3GgzV97C9jWVlcTNYtCjcnd
oppw7O3UqA+7nQe4v2H7Omx1s6Wssg7agvNPP3SVHFu55x56jzfPQVn2R7Nky6QRW8zmGNxPFHdT
dlS5QqZV7leY4+T5FtAa/sD2ciM72ZVFBLMbicAAbkkmTQBYb2F7QezotpcSojMEuLi4nLyDkTyB
Diq/mn4aCrLexPYy3lgrWMkl2speG3jnlLMCjIWcM9RGpYMSPygv4NA7g9m+3ILS5tIrUrb3fD1C
d6Y8u23Jdy9RQ/A6B1oJoF91jLmXJx3sV48KrEYXgA5KQW5chU8Q3hUqdtB7jsSllLLL3nlaUKvn
ZjQKzMOpO/npX5DQH6DiaMyQvGHMZdSoddmWopUfMaBD+yt0bVIHyUjhO4BVSoUSGvk4urAjpVmO
1emgYYTEHGWrRNcPdSyMXkmk2+QAG9ABtoGOgmgmgmgBy+Ex+WhjhvULxxusgUEgEg1ow6EHoa6A
i5W4WzkWzC+oWMiAPUryA8tflXQLfbuFWwha6lDC/u0Q3ZZi1CKtxrU14lzvoPPc+OyGStobG3Kr
bTycbx9+SpSoIAZKio3H4PCugZWNnBZWkdrACIohRQdz1roE+Iwd2cvdZjJuTdlzHbQox7KxICqu
Fqd2DHr+Kugf6CaDmSWOJDJI4RF+p2IAH4SdAjPvTDgkcLnbbaCT+bQT9tcP+Zc/6vJ/NoJ+2uH/
ADLn/V5P5tBlvvrPnkPviXdQgpZyVABqG+j6jSh8KE+Oga4X3L6N7lb+8ur6JuHpi1rIrrQHnyot
NyQB+CpNToGn7a4f8y5/1eT+bQT9tcP+Zc/6vJ/NoCLH3RiryYxI0kTUqGnRolO4FAXoCd+mg8vf
dOJtJu0zSSmleUEbSr1pTklRXbpoKP20w/5lz/q8n82gn7aYf8y5/wBXk/m0CfLe5pJ7nlZT3EUP
FKL2pUIIY8ukb15bb/KnjXQXYf3QLcOchc3NyWqFAtpKDzE1+heoOgZftph/zLn/AFeT+bQT9tcP
+Zc/6vJ/NoPV954dmC8LkVIFTBIBv8TTQOfUW/Z7/dTsUr3eQ40+PLpoLNABnWC44seJpLB9X0/r
k66sA7XNtJGO1FGr7VJVaaviZA3000DRc4o5LU+WeiAMtacXFBXynr8t/DTAKsrxHLie2RI4zTuk
JxcEbMpHz2odTCqb1LWSQoUUIxqqKoBZh13pXbW9YzQqRWcTcIlWE8inlAHnWvIb9aaZyYowESJJ
bXcEclvODH3QiggOKbilKamPgXe2xbyYK076R9+FfTzsQv6yEmNvxla6zZyojL29t903bLEn6lyC
FH5p1ANY32Dixls00kKhY41dmApyKjatOur40C3HujBI/CG39Q+1VRF8dbnror+95blmiisUthSn
ckQHr02oNX7eEyCnyj2+Dnu8XEuQ9OXVYIYkEjsj8JOPNVBo1flrF2mMyZdNdLnF4Z9PdnuG4lki
ucVNjWZgccjm3aa5UqS/6GPlwC025OPw6x9yfDp9n65E4rN+6bmcQSWT2yvyWK4kgWSFiDQhmA5x
sKf3iAfAnTzz2Zums7myZzE+ugxtxcRLlphUWU2xagJNAV4/SpIp4a15TperF0vWdFmQ9wW1tbTS
X9vHDZQpWeYMimNKEl5G2KeVagjUu0i6+q7J94Wn/wCN/vD1A9Jx73qqbdv1HLnT+rvqeU69k8Ln
x7ti7qiM7kKiglmPQAbk6rJLlMtiby2NpBdRTyu8R4IQ3lWdFb4rsdAFNaRG97aReWNCvdQ0XYbV
UeI1c8t9nAsrexhIiMjtKwVVd3k4kj+kWP2V1J/Et8qkQC0MYZSDzIFSlf6VNtdXMQl2o3PllLIK
147Go2ryrTrTWNuF1mQN5lMc6i3knZJo1EgleMqoINCzEgfnb765beyO2vr2644HWd2JLdS6sqkl
BzpuQSKjiehG411ly47TCWlswmuo5DzhuZRICwpQuiq2x+a1OtVA2atJoLGRreR1ADJIgY8SvWu/
y0zkKbfD3zQwMi9lnMSPR2kSSEhm2DFAhrJyZgpP5PmFKYzXaWPbX23HZ4m1s7aaK0SOQPcSIzTA
h2byo7Mr0LV35bfwaxjiL582maB5JGMdOCsxNwfMeSsBQgMPL5Tt1/l1rbGLIoyNsJMjayTdx0hJ
ZYkkZFVnUipUECSP82oqp1vwlY13s4JMTDe467vL27sZZspeTmFryIKlulshJRV89Yo0oCeRLOx8
fDl69bLzOXo9m0skl4n92ptpldHWOsMho5Vh5XrStKGtKfDfx11uuHn8gJfGSXpt2vhJeSskbWDS
xsvKFmYgIxKiQ18y/BdcrZa6yWTOA+exWUvMtaiC9dreGZJZLHsK0KqlSe67Hr4p+SGAO+2s7a3P
Fa03knMOqxfslXn+i7ledRXj6rrWlP4NdHHnLRkAih3B6jRCK9w2NxuLK4+BbakkIXjWgLSxKep/
7tfxasHlxbhpCVekYXlJUly21DQ11YuXNtb2TwpQGXjJyj7lCUdaDblv08dS6/J5V3JGY4WLScz1
Wtab9RT7NXKA7UCO9VWZmjesYbcV2qGPzqNdLzGY8lsI7ZjIsRkhuCe9xP09zyluJINPlrjZJ2dd
bb3L7KW6xdrKl4vfiMwiWdUChEbYNIBsAF8R8tcpbpOXXaTe8fA6C/S4i78cyukMoVmB2PFjy6j4
jXp1svR59tbOKIz3JsfMFavKMu0YrTbYkE021nXolYy7k/eHaQQx4+CPJWkx7ndaUQmOIxjhEqAE
0Wm7FvMT0prn7Nd+z1eq+u/5cKcZ7ygMc1nnse2IubZQQTGz28q1Pb4vE3Glaf0a/A6xPZ22mG9v
Tc51vllI8llIJVubado4JR22M8FxwKKSAyqoVWkQr8tvH458rDwl/Vpsbl8VkytvDKHnVAIpCHiP
NhyPFXAPIflD8evRpu8u/rs6hs7eZGyv7dzPEmOCd3Jx8SbhY4gWqijlzDFaHitQNxq7bYXTWWfU
ZdjHZJLeS2yBhniBuIVidWDxupAJU1Dx+II8dal5Z5nYHhMxkchPcWtzYrDMI3FjkoihhuCTx5oP
MVNRy6Up+LV21mMypm5xRWIv7S8yU9tIYLnK42NatZzGWZOQHOKR3CLzPEFtvs155ecV12nGZ0pn
6O1/ZP0vZj9P3uPYoO3x9X9NOlNbc8tHogDOQmfHmESNEXlgAlSnJf0ybjkGH4xoMxY56xyd1dx4
vIXNzPibyOwvEuIY442LSmJ1DCJeW6MKg9R8KasoYQQ3GPyMvq94Jn52/wCUNxRhXw4+Gt9YWmE/
Zk84o6o3JW48uJ3NTTcV8D11kAzMO6ULFe3IOXHfjVQwJ3qOQ6autLBlykUtk4pRjGQ6CrbAHwPX
WbCcUowy3clvPaXEvdjWvZaNTCwVKUUgseRII3B1z0lxh29mM5i2a3luLW5ZTxS4oV2IKspqtAB+
SRrvMThwqi/u7q5wnfrxkjDxTr1NeNKGh8aauJMiuCftySYy2uZjc29tj7p1cQ9sreytDx/Vch+p
bx1zyoke2LhxdSCL00vLjEHlWdJE47sylV47k+WurNvlq15BLfxRRiSSKsoEiyBg6sg35IUNKbjz
cda4rODNLmWe7RI1S0kLI8rugkE8RUgrG4cEMCBUkdNZsAN+0E+UOIjEH32ES55hQ7i1rwLMWU9s
OeaAAn46zlqTEz2CXOM9lx3sXtd0CXM0SyG1tEmBaKPyqJXirwSiUXuOOXhrNk6NTfbqmft8fjbO
GS4CLatNHDFA/LtxMNkQbnirceOxprpNdbMVmbbZzOpp7fvbW7cmaS2+8Yv1ltCKGMmtWBejtzr+
DUvrs6p5Ts975/Z3vdqSvqa9rj5/8ZSnHUQ+0C73AXGKlKFg4eLiU+oHurTj8/hoMknr3CzTXnGO
SRJXROKyF1I4sXoA7bbV+Gut9aeR6uPW6tVdsxP2iafpOCkMp6GoqGGufRRC4K4VWK5W4Abdm8u/
zrTUAF5jlksbmeDKy3LwIW4oVc1APgu51qZyFlvjMk9mb2DIytIg48atsDuG4cjsfx01q6zPJ5XC
y3S6R6G8uGietFgoWBG45+FG+On2y7D8fZ+rZ4hkbuKdfM8TlSRy3qCNt/lrNlgCyNnZWQuljvLm
eRlPfVQGjLCnlkpT4DpuBpi2CqHGy3llE0l3dLbsiM0btQHgQyBRuSqt0rrXh9WPMSuMmixptWyN
zJFRko8vcDB61BaQmTx+J1Pt9l+5epa3sbEXGaXJmMSXtvEsdvNKis0UUNAvCNvJHT+iK7al9UnP
dr722Mdja3wYldkmyE4kcndAFjcg12XoG+OtXLMr0+3LTH3ovUv7lLuROy8q0JMQIP6TwIQ/TXpX
bqdZ8c8r58YcGDIRTmYX8will4yuAvKijirFv5Ka3NJ+7PnTC5xkot3afKXDwsKMjLGysD4cSKGu
sSL5Elv7Sw88kUBnnjkVW7K1GyVHJKqfp6eXprf8pOvCeWaY+lf9h/SUbuV7X1Pz5ep4158uXKu9
eWueJn6NZvVqdRQGdi72NaIbF5YADSv98nhUasAkFhHDZtbtKrmXlzcgHYjjxUb7bA9a61ds3KYB
JirpS3eRGUVZeRBVmbcha71b4mlNau0TAN7js46e3uZZRFZs0rRMGUmAEmhoCfIfq+Q+GreLknwJ
Eay21tk8JIrRsv6NlIk2OzAAkchT4HY76kvarhfi8fPaSPK78JJAzJEgr+UWYtuep2AH49N9pSQf
LbRXUwkeFZEX8sseXUeXiNqdNYlsUnzODN3FMkRI58eYWQpIvE1XtMhVlZSBSpr+HprU2l4qfoW2
zqLK7tZw0jNG7CaSjSFkA877L5qr5thre2uIZyb4KC6azVru0W3MSR+nm7wuAyleRbiypwp89c/K
l1i+7LzXLQx23JeKySXXJFUmo/RGnm5U824pTx1M0xMBYmnhuGVPLLFUUNSGX8nl8jUa73Fjl0oh
mWd0MEEiF95JkoUjlFWKyLUlfk3Gm+ueccVvGVcs1+80XdQSOoIFFb9IpPTYcP4dbkmGORAMSQt2
FF1HK6RleQUBeRDcTvyZfhtrl556Ok1+Qcvfggleb9FbQuzUMiEGND9W42qKEhdbm061nxvSJZ3l
tdLBdwzJIzK8aRAlXZUAV/K1Gqu1fHptrOvsli7eu61x6Vf2C9N35OPLh6jke5T1XXl1r89T/wBl
7HOSzjWl2LSGzlup+2sp4CiKrPwFW332J6aw0DXKZK+sIriewNnbySQMvN6yV9QoHk4qdwK76C++
ne2aE8UiVmKNMw5BQFqKLTblQjW9ZlHNjmIJVa3mZVlQ0B3AI23+XX46XUy9yNmlyp5ko8dGWUGv
EA9SBSo/l6aa7YKW4p2gv5LRgoRxyjKbJVa+au25G/x21vbmZQe91NDcen4PGF8woNqHbqBtvrGO
Fd29xIxVwHIUkALTjQ/FR8D5dtSxVxkDlQfrp+mjBBAan0mvm2rqAPMW0a2t3Oyp3u0R3KEV5AjV
yAsVmGFvbLcpFEAiRkmcE0IHEshVOpFOullnVOOxz3LbgRzTk3EqSwAYn6eh31WSqbG3sMSmJlkl
ZmM8jeWokJLMVXYkMRsDrWu2ODbkukvbm1lNwbeY9iQBhGSwkVhxLcEqGAr0YV1rfGE0nZfcZyCz
Zrq7iMMcgVXuImdo+IBaLuRivbZqkVpv0r8OO+016umml26LUx8l6wure4ns716PQdxEPHoZLdyK
qw+AB+epdc8zhqbY4szP67icblFdkjuZoJJy/ZX0bPLH0PEsSPJXg3U0+ddWbZZ20x0z+414ZO44
DlxKwKg0HGq8SNgD8660wG7f/tbt8d+9x4VP+ldK9ft1nu00Oopfni4xrGNGkcSwcUSnInvJsORA
/GdACb2O4mS1nhlRWJCiTtMA6AMVcxySGorXcasqOZcbIZQ0cJCNQyAEEUA2oa/ZtrU2A0OYWG4U
TV7Ug4rMalC5BJjov0N8OQofjq3UMZbOzu41kjNFAUq43FAPEHxptqZsUJOlxJEzNKlONG+Hl6Cn
2+GrECWFneQ3vdkbvRTpQPUhgylSnkBrTZumtbWWEG3N1HiJ7y7muBDbuqSySSEmMEngNz9IJIG2
sYzFW31/bXeIuOLq3KBmjlWhR/Kd1P8AJrOAghsjClteW+KSK6WFAWcoxZ5TxTkyuXCuzbnj/FrU
2xMM2Zoz23irW0PBpjELiaWR8dKzOhm2YiPu/mULEL47+GseMl4b23tnI0Xcazs1u0hQ9UcFVIO9
UBAI12kzHK3l4TjpLn0UcjyX5LXMLyLI1AzM1DIAFCAinCuwprE2xcNXW2ZV5CeGBWURAZCiyG3B
Q9xVI3FSF2PTkRrUmWVUzZCcx3GLR15yL942pkCzKjKKMhl5ooBAJ402rTzaxvrY6aWXqObZ1t4y
0HNkZ7jitXjUjqRxrz+PhqzXjhi7c8hMzNanEvZ3uTlxU927xW15FKolXk5MYRwtK0FKEV8KnrrG
9knNw6+uXOZM4e+kuP2I9L6qb1Fe362g7/P1FO5SlOdd/wAOs4uMZ5+TMznH7NRrTIHNSPHYGRIz
K6SwssS0BYiZKKK7b6DI4Czkxk8jY3FXEkcmQvb29LPDyE14eTKKNvxqBv4aB42XvykkJw1wsVKS
ESxKQGH9bb8elIXy5CzWy7kmIlMFutGJkhbiF8u7c+ZO3jrUyq2X3TdRTG1XCTAKFLBSh2I6ELsp
+VdJqjmT3SO0qLiLoMaVVQrbjahFa/j08aLF9xFIwRhbkKADyftk06b1bb4aYoGyGftb2OSC7w9x
2JV7R7ix9sg1qGJPGh+Z0koVwYu9trO/ZLC69JeKJAJZYmijYEkzin6SpU+bqTQddW7C+3TNnIXO
QjsZZYbi1x1vbRAqAPRSySvIxL/3ndoKDw31iDQnM5LiGfCXApu1XhoPiQS2qmCm/wAkl5MrHH3i
8FZZApjZHDdASSR5fkdam1iWKIcndxtH/s2dhCfL9IPEfhLa1dp8JNTVPcl28nH7snCnYIxiBNf6
zDWFwDurJrm7FzLir2qf3SywKnGlCpoa0bx31Lc8NTh394ZH1AjtsPMLSzt1SKEdpm5V28xJ2VV2
A8euk4v0LzPq7+8mu7cW15g2uYZTx7MhgYMyeanF23K0rptJU1zOgvuN+yvc7J593l6avmr6mvbr
0r4fDUVodALk/wDDJ/49v/5yaC2O3ijidPyGqW2A69elNAginkyEzl6CN2IjiYEr20JUEg0Bbau+
ulmEI/dUGPggZbyNp7TlHJ+jjJoyOsilQu5HlG1aeG2sb+6aTNy6+r17bXEV4S8jycKXLWTx2jO6
AzsQ6DjQM6A9XNa/Zrlp7bvzjh09npnr4zyM9VPEtz6STmi0KrIGdi7VLCOrfqxtTpq3ezKTSXGQ
OLsbvKuZp7xsnGHVJYWl42wUEFwUT6ioPRq/PXn0m23Nuf7O/s2104k8f7tOlhjZY3ihZVMZ4stO
RQsAVVhUihVvHXtm/Lw3UtvGvrS1ngNw5RompG36SIp08hPmFNbuLMpK9sBci3jkErCBYkqObhy1
AOPFtgtPGusYFtqI7uSQCYtPEwWUPyoGIrQV2Yj5aZhivEvVkubu3SKd5LSVImaibl1VuSgHoFau
9Dt06VzN2rpwAGTSR7svFLDJaS8Cky05oCSsiMKgo4+k/wAHhrppcs7a4H28qmxEktwsrsXpwjYA
CpYAJyZtkoCa/Maxb49Vkz0VW99aXMESTc7eSgc2bKTKiyOUUsI+YI5L4EinXSbRbrYMtntZoYpY
6sHBaJ2DI9AaE8Xo43Hw1WXFzam4ura6dyZLOXvRKDSpKNHv8+LnVF/P/wBr86/3/Kv/APbrrPdT
u5vrO1XlczpCOtXYLtUCu/zOoFOWzFhc45lsruOSUtC6FGDbGZRyFDqzqVQuOEwUTEOCeVK8wOni
TQmmt+WEFx9q2iKRIVbzEvTkVbYbk+OsbW1ZCu5C5JWEciyw25McoYGvd8AKbCg66xnN4dZ/Hr3c
4KeEKIWAjcjg1aAcxXifDc1O2u22uOjlbkm9x5az9vPeXUiqYe0A6g8grEGmxPl5eJCnodeL3ezx
5e30ev7mIFxuYhixlveR3Bt05q00dtDSInlXh9JNTXzdN/t1NN/45a39f8rMZaDGZD71tpDcQTQO
5PeCKY3DADy8lHhTrU18DrtpfJ5/Zr4X5TNo0jXfE8ooogo8KALUj8ba9M41efuGtJZxHamdVj7s
MdKHbyrxah/BTTXolplBdMbeB/IscbN33alFTc/wt16fHWN+K1r0UQTxiz7VlLV527wueX69mNW5
PwoQVFNvDYaxrM9Gtr8rLiEXttJZkEI1VVtqiniACa111nHLm8gtBb4e1gxbwT3CyLWWchCwBPcK
cfpkAJA/h1jbbNy1rMdUw2MysWHhVzG13bqUBifiSUckK5UlakfV4VJ1iRva8uTc3UIgkuI0jmVA
bmFS3bDtWtGIqafGnTXTXOGNsZ4GWveeyieYIksqq/6NxIiht6K5CFhQ9ab6mu1q7SPNv2T6/wB7
12/0rTuhlf8At/FX916m8iMsnbEQBdwoUFjTipA35GuoBc9bW9j7dlS3URJEYuJPJv75Tud2O51Z
cXkxkutMmyERqtI5H5RVJoCw5FSd/KR4667aMym+OW5nieS4RVmUmnAEKRU7gNvv+I9dcZ0buM8F
LcZpp45IaW/c7R5qaysabrwI2oSKmmpeW5wFzVm62zdQ8XnWRQAWpuBvtXXXS8sFl/kMVn8VPbSW
3dnhhFxKq8aypUpQE/0hT7def8r1yW639Xf8bazG0/RmsfeyyWvrbeYHEyVimsCtLlCvJX7LxuAN
1+lgPs6a8elmM54e7fTnGOfns0+OzNnkJljtJCtspQh4GR0YEUqwFDQny/DpT469Ou826V5N/Xde
aLvJLhMbcSzkd2ZqtQ9e5XanQbAa91xenw8SGa2kt7aSWSixwpGAK0q3EUoPs1nU2S5vIILo28bm
GW7ZljqEDycKEtF3Kq4A3rTprPWfDUmL8u8ubd8fLZ0BjuFaGIc2jqXB27iBiu5+oDWb8Na9ci7R
LqKHlNPFCQAElVixUGmx5gbk6ZvdOMk3uO9GNvsfc2sJkucjdxW054mTmpR2HFRxHJivGu3Xc657
3FldfXr5Sz4htlLuSwx80PdV7qYVSLlxaOEAd1mPwTxbfXXXGeXK/QLhLK7t8agvWM08knceTapR
a8QdhQMKV/Fpr05NsZ4KsTkIzlFuLMRRWd5Cbq9tYpI5CJeQHcfsclHMVq3QkUHx1wmbtx3dtpPH
ns1XJf2P578e5y+dPVV11y4YaXQA5pYHsQtwFMBmg7gkpwK95PqrtTQfOoM1BkoPcUEuJs8Q+KvI
IcdeR8V7hNyV5K/EfkKjEr+dTWtdsXNPHPEaLF5O4mm81/bBLR+zcKhO8pXlIKGn0joRtvrF28rf
Ho6XXxkz1oabIyTXU1vBzltHlUEpInJeBHIxkhtq7HXSTXefFjPOteXOPx2YuSkdzPCyIWS4MyqC
eVOCKSaMvHqB0/CdcPZ6s34ddPb4ztQVv7bwmBtnM+TlydxckRSW11LGeVKsOCpSjItdxrPr9Ezz
c5b3/J22nEkx8AM17Y9tXCY/O4SzjguLQpb3UAO7Wso4rNRip7kVeYPWteVdT2/jyWYjXp/K2xZt
eoQ+w3uLqK8xOXWy7ErTXNChEr1YpyRSinegYk+A1j2/iWX+NdNPzZZjaZVZj3NnIhb4y7CG8gaP
1oh4vGySHiGR0Yjfrx608Na9fs2z4Xqzt6dLLvOjRpKF9zRWTYzHS+2ZcZG7ZEi25x3o7nNGFedH
Xj5qbHb8rb0PCV2MVi0NoI5YrDIlA/p+9GZWRVCMWKluQIpQ/g1013mfqu2tx9DKbKw2zwwBDPJK
ZB30CtChBqI5H5VBb8G51zu/LU04y5y1rbXjmQX4trholjjC8GVT3OQZ615fL4axt67s1p7PHs9z
ObbDQRyy0yim5igfsMA8FsxHK4kUc3ftnduPWurdvE10m30eXGZv5sjLa29ght0aORck84hjYN5p
KLQl2UjlSo5DqRqeVzxDxmM2mck1tb2ETXV2PWy/3EDiRJJApZo05dAw/OYfM63bXNycjg7OaynV
I45rsLCpijSR2VV5ASPCrARr/SPGvTUmF5NuUf7LcuS9vvV5VHGnqvj0pqstDoFnuRrNcRK16Fa0
DwmdXFVKd5Kgjxr8NWTPQY609vnITvfmwt0SSvpbdY1RERfCtDyb+lQA66Wa68NWiILC2sqc8ZHN
Gn6wSQB69SfNxJGr4yphekVjKS0eNsUr9MTW4G9K/UV321nwgMQe3I4Wa9xFvG6kfq4UcNXxG21P
Gup4XsYFSW3s9YhKlhbTA7gRQox/EBqeNRUy+0gV/wBlxMG6EW6fGm+2r4UDXNx7TjLKmIiYjozQ
RotPiSdwPwjVnroBvb/28tpMv3RBDc8KQsgiBDt9JU7bjrtvq/aBkHtz2/JbW85sLeYSxoxYxrvJ
xHKpp4nWIzXr43CJeNEtpbCVVVzEYo3ojEgErTlQlSAdumrJDkYMf7aEfnx1qJgeJiWJGJb+jtuP
nqYMhjZ4blx+7bIN+Z2lP2cv+rV8TIiPG+3GZQ+Mt42PRuyhX/4gNMGXEth7fPNIcbakrUdxoU4V
HUDbzaeJl7FisTxq9jZr4MTCtKAVqoAqT8tMGXceNwAejY62dT/eLAqn7VNSfs1MGXXG0/ZfhwX0
ne49unl7fqqcePwptTUaaDUCv3PbrcYaWBm4rJJArN8AZk1dbigNJEQNHGSOIIUGgNFoNqU+mlB/
0Oq0sXuxkQnyxEbyMT9e5p5vH+qdEUXVpYRw3FwLdS0W5SNSXbiajyCm4rt46XeyNazNwUwXFxPe
LBaxDtlVJLBhQHqWDnb566yy65pZir1ntBmGxokuPUJGk/IxhIWVm4DhKVpsQar+PXH72dvHDV9d
8fLsOOPsXPAVWZDyL81Y7H5Dbf8A69b8qwWX9sz2Y+6kt5MgSGQ3YZ6pWjmkdRT4am+2+OGtPHP8
s4+hL7i9M4t4o4o/UxcS7qpCqR8iOoprvpnxtrNa+081hGhrG3ajrQ7Hyjiw+euEcq5vYJpUWaOT
tTpQ1IJVvDi6j6lNen4tLGpflHdu4Io3RixpxBPIU81Oh8NXMZxQBea4k9TaBjaW7P3YShBuVdFI
eFmAIMZB40+v+HWPK5y6eMkxet/2G2/c7jRllJQKW5FuVGFRyBFBreY5+NV29lNHlXnjkJtZ4ws0
FNkmjPlkT+spKv8AgU6tvCSLruG8NzbPEQbd5KXSlWLEFSRxYMAgqPEH7NYts6OkxzkP6fKQmGZI
o44IHkW5t4+bSNAd0ljYhj3FH1IdjU71A1LtssmvQVzj/ZTnybt92vOnnp6rrT46me6Y7C8xN7m7
zRYiCAr2qie4YgdwsRQBTU8QK9PHr8QDvos0MO0uSljclog1qsfj6haVZWappQGg0WOYIr+K5kuL
oR+iXa3iiU91Nt+poaHbbSeWbno3fHEx1FTWwlk/SqvCSveSSu/GlBUcgvx1rLILKXi2MBtov0l9
O36DYkry8d+nGv261prm89Auwsox8d3fTzCK35CLvzN5a8qMSWNOvhq+/wBmskzw1rrdricmdo/r
YnkKuhRiHLLSjiqkLQcq0IFd664a+ybdF21uqqxtxYWcNrbF5ZgTQyuZJSeXmMjMF8vhU/j1vXXE
wb7eVzQ2VyQhti5d4pHUhnp5VSh5OyhiKn8nauuummawRR2bT2M88zkW1qtVY9WJoUHl8dxXXXfb
tEaeC2SG29fLJcOfTwoI05OnlUH9HEo677mlfnryzjlOswLlmQ1jdSj18dhToSKddbwwBuq8qoQl
winsPUr0IPBuPVGpQg/ZpZlrW4/QdZX0d3bwTx14yJy4fiVhy6eU+GsSym2tlw8ZrlLgqeDWnCtd
w4YdRToVI8fDWuTjH1VgyJGWLIPN+SPpToo3PUasSpNdzOhNqn6dNxE5okg6lORpQnwOrhMrMblY
L+2MsLdsIxSaFtpI5FoHiceBGs2LKnE/sxSu/f60/wD5fwr/AC6w00GgBzKyNZBYmCSNNAFZlLAH
vJ1UFa/j0GZs/c9vkIrySyyEF02JuvS39mLZ45UPfa3Iq0jUFUYqwrWmqpkbqG0M07XrySSlaLUF
QUUEoqbceu9Tqa68tW5nQshFv6qO4uKrcuS6lzSlCd33pWlDrpdu0XxH21jaJDEOw0yTytOWFCoc
VZXYkjbai7HfXP2fyxLCWzOLhcWm9eojhRURCO8CeaFjULx6cTT+DV5TjADOlYj3YRRpSolhCiki
13J3WnWu+2tyWmtncoXH3GSvOzcziQKwllUoFAX8gbbVAoB+M76TfHEb6TLjPXLKkNtbGtooPlXy
A0r5tuv4Oh666azi2udOosi8TrYLPHJPZQWE80PYYDs3kphSjmQjkDE3hrhlkRkbLI3lvAY3NqQ4
aTzKXADUNG4yIQw34lftGnPZZideQ5S/TIpaPbhmMHdfJqpRDIrcO3xAYA083X7NNbzytx45+vRV
BZy2LP6WjLIT37Xk3A8iTVR+S7V6jrp4Y6Hn5dRlrmcZOIqSiKd1BSGUGNzUleNGA35ClBpN4l0s
E9lXJoVAI8/T4bV+zWmFDRSRvRjSHjTcbhvAhq/DqKauQLd2Dx3UmVxYUX/Gk8NQsV2FAosp34yA
DySfYdtEX+pP7Eep7EnLnz9PT9JX1VeHw5V21nHLXZqdZUDmefohw5c+9BThx5frk6c/L+PQYLB+
r9VmOPoq+rt+X3X6bvf7xn/xfLblX4f3nc8KaAnJ+v4j/EfUlOHo/wA5qcP+nWut69W3uO9Z21/x
XPt78fTcuo+n8ilelP4q6LT9/vLh5vW9T+s9DT7eOssO/wDaFDX11Kn6/RU6+NN/waDL5f133m1f
V8vL9fpOXVulPL+DXTs3q5T13GWvrfqXl/hOvI9KfwU21j1tbqMh6zsycvUcfL/otKUHXj5qfHx+
3XSsDn+8PXz/AOWxP0ei9XT1UlO9/wBz/wDJ8eXOuuMYrRf7R7m3qfs9DXqfjrSK2+8PPX1P2ei/
hpogG7+8Oa/4ivIf6Fy+zw1oLb31vq8b/mVp6j0la8TTsf8Aefh2+Phrn7es6Onr6Xr0d5r7z43X
c9T2eMdPVfd/pvrX/wCX+lp8a6u3Q07D09f3Rx9TXl5+Ho+z0FPq8f6n26mvVNhA+8O2aeo+k/R6
Lj4da62ws/Sfsb49zuf0K19V/wDB/JrPdX//2Q==

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/plus/special/plusmn/black/med/base/glyph.gif

R0lGODlhDQAMAJH/AP///wAAAMDAwAAAACH5BAEAAAIALAAAAAANAAwAQAISlI+pG+2+RIho0otZ
tpm91xkFADs=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/greater/special/ge/black/med/base/glyph.gif

R0lGODlhCAALAIAAAP///wAAACH5BAEAAAAALAAAAAAIAAsAAAIPhH+BGLrWHlwxuSRz2/cVADs=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04808-f3.0.jpg
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------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/jpeg
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/nature/journal/vaop/ncurrent/images/nature04808-f4.0.jpg
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------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/beta/black/ital/base/glyph.gif

R0lGODlhCwAKAIAAAAAAAP///yH5BAEAAAEALAAAAAALAAoAAAIUjAN5C9eLHIxqvsjgNXfTmk2S
WAAAOw==

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/micro/black/med/base/glyph.gif

R0lGODlhCgAMAIAAAAAAAP///yH5BAEAAAEALAAAAAAKAAwAAAITjI+pi2CeIGxPyTAxcBkz/4VL
AQA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/math/special/times/black/med/base/glyph.gif

R0lGODlhCAAJAIABAAAAAP///yH5BAEAAAEALAAAAAAIAAkAAAIPRI6gGLttjnopVvqchVsWADs=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/_delta/black/med/base/glyph.gif

R0lGODlhCAAJAJEAAAAAAP///////wAAACH5BAEAAAIALAAAAAAIAAkAAAIQlGF5moCKXhNurksj
i667AgA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/delta/black/med/base/glyph.gif

R0lGODlhBQAJAID/AMDAwAAAACH5BAEAAAAALAAAAAAFAAkAQAIMRAJ5aKdpoIuPNlkAADs=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/__chars/alpha/black/med/base/glyph.gif

R0lGODlhBwAIAIAAAAAAAP///yH5BAEAAAEALAAAAAAHAAgAAAINjG8AGdvvFJtRtopOAQA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: image/gif
Content-Transfer-Encoding: base64
Content-Location: http://www.nature.com/rl_images/red_arrow.gif

R0lGODlhCQAHAIAAAMwzAP///yH5BAAAAAAALAAAAAAJAAcAAAINRI4Hlrod1ksSzsZgAQA7

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;type=lt;artid=nature04808;pos=top;issue=;webfo=;prod=yes;natco=;natcl=;subco=;chaco=;keywd=;abr=!NN2;sz=158x60;tile=1;ord=07893195?

R0lGODlhngA8AOYAAKOjnSwsKoKCfVhYWDQ0MtbWzvv78U1OTT09O+rq4RISEWhoZM7OxlRUUsrK
wp+fmXBwbOLi2sXFvbGxqqyspm5uakBAPdTUzMHBuuHh2EFBQNjY0IaGgfPz6mVlYYWFhFFRTpiY
ktra0r6+tt/f1pKSjN3d1H5+eqamoOfn3oqKhSQkIujo30REQaioot7e1bi4sbW1rnV1cFpaV66u
qOzs401NSebm3eDg10ZGRNfa1paWkJCQi0hIReTk2+Xl3Xl5dJOTjrOzrKurpGtrZzAwLvDw55yc
l5mZk46OiUtLSCgoJjg4Nv93d/9ERNPTy+/x7M3NxP+7u/8REf8iIv8zM/9mZv/d3f/u7v/MzP9V
Vf+ZmdPW0j8/QP+qqqOjoP+IiOLi2dzc09LSytbWzbu7tNTUy9ra0YiIhI2Nh9fXz+/v5svLxMzM
xMHEwc3NxmJiXh4eHfb27fj478/Px4SEgLe3sb+/uOfn5v//+PL18NPTytDQyP///wAAAP8AACH5
BAAAAAAALAAAAACeADwAAAf/gH6Cg4SFhoeIiYqLjI2Oj5CRhn+UlZaXmJmam5ydnp+goaKjlYKk
p6ipqqusm6atsLGys6ivtLe4ubK2ur2+v528wMPEvcLDVk3KTZZNTpdOTVS/ycWfx8BZV1LclVZ9
zJZWUlW/YFLWnti/4JZVWX3tllROU3/RTeV/U8pW9vT/6u1LNo0SPn2VqjxTSKWJlXSX1vVyAs7L
lnINt8ir1KSPEy19ssDT8icLFilYsvzp+IwllStX4D0EKbIPyUpS+vzJGbPPFoil/KT7JqUJFiz2
7m2kxDJnuSZaKHq514Sfx5UevSDdeWVnn6c3KeX0Ou2KTqB/JOoC+OfbQ6Xh/zh61IIlZFWvWLa0
vMryKDezVejaTSpW51ivaNMKtVYNrsGlWJ/90ZIzXMOjVvc6iemks8DJlS2NPXwYqNpcGv156VOQ
YlymHrFcmTKlj5eOzMB8xT0lpxONVaZ46Sqbtm3Rhs+WhngaV+94WN46bubRSt0+WILnjPdzitmQ
Hp9jL2cdOkLEpM+aXpxuymdQ7iVTYmjpPSX3luInDtV8v//E/f0noDUBDmjgLwUeqCAuCcoSTUGY
OHHeKQ+S8mCF+zUYyzgTVtIHOqqwRApLHPqnISj0UJGMPe5RUYUVALWohTRKZSHffMrcxJBDldBT
hYjzWAHjfE409JZL9aS4Yv8lM96Yy4mfdHRSSO6BV5RHFKVUFxXxxEOdFPAwwxM8PwkG3o3fwNTH
Q2P6FBlLUvIk1pQ/GcPeLLjBRdEVmlH00zfMfHgJj7Whk1NZOl2BlHdXVZISJSaR9YdZb3rU0UMa
RcMXa3biAqRtFIEBW2ftuPaHoPVtgZKg6Z1aJ5B/VCFPR1W0CqelmzqxGjdhdnqLiLV5YWpkppqK
6n0pPcOqcjodF1mPfYj6h25U2Iqrpppl6hmEDN4pS0deWGXFsCwV204ffCYUrVKGMuuVFlWYdSNM
VLzUlbXYikhiOx1xewuUnnS03VTkYlkqv15WAg+6MSGG2DvYwXNjvPFcUQ7/vrdqNm2X0j3pbSwu
dYiKhJ+I3KO/qdjnsaeNLugyJgB3guHLNFMSc804X/Nxzjy3cnPPQFtyMxFdHGD00UgnrfTSTDft
9NNQRy31ASAQ0IAqNzeggx5QdO3112CHLfbYZJdt9tlop41HAwhgvbMoA3DBRxR012333Xjnrffe
fPft999/X3AEAhq4vUrcT/Ch+OKMN+7445BHLvnklFdeuRpfdFF4KjcjbvnnoIcu+uiOZ755LW+H
4jnjZbRQRBEECPB4D0GQrkIUAZDOuBoABMCGCHSEMcMJJjR+gRAYjDG66YarsvriCByRwgtGxDF7
7brnXnkPIYhBRgQRZLC4/xouxOHBHRcIf4IYF4AfBh81KBEEDi/QwQcJdJyxQfEFgC9+48zjXOpA
8TzFIQAJPlBDAULABxQQTwIL4EMOkNAAC5QABxuIgQUsgIH0CWCDEKhBBWgAAT7swAFMoIAFNMAA
PoShAhusQxjoIAIAKCAAF5jACpWwAfup4QEzaIAKXqA+H8BAAxrIgQlQoIAiTAACIjCDBwqQhAcQ
gQ8uWCEIxABAzTUvFQXkAwZaEIAZ0KF4dcjBD+5gPRDEIQQ0AEEIJICACQyhBRfgwAyGgAIicAAB
cRgBHypABgU0gAJI0IAPIAABGghhBhwQgxkYwAQIwKAFQ3hAGpTAxR9qQP8NLRBCAgYgAAb0AAk8
4EAPLoCAEQYgA2SIgwggoIAS0KAHQkBBGkDQxdOdonNcSBzjcMAGNpSgCGjggwoO4IM75K4HQ0xA
AwRAxwkAwAEZIMICWLABPmyACQBIAB9kwIcljGEDY1hBChrgAQoIoQUVEN8NDhCCGBAgAWcYwRJI
wIcfIoAFEtCAA4ZHAg4QgABFiIMRQLADGBAAB2RYwhmI4AEW9G4CKODACnr5RVSE8QFlMMMFElAE
PiThABFgQO5yAAAxhKEBdUiBBCzQghPgAAILwAEdNlADAlDgB+OkQxFYwAA2LOEGcFhCCxAAgiF0
MwLys2cG9gCDIrygnw//sEAECkADJsjgBBIIAAvE0IYAJMAGPHDoC3wQgDMsAAI3oIACcmCBHJyA
owI8XDAbV4QQsOAFa8gdGmwwhwZstGob6AAITuAACBjAAAoYwwIWsIYboCAIGvjpOAspgARsIA4p
UAIP8mAAFCChmz7QABJiUAQjZEACK+DnD7U6hsYuIQ0SWEIN+LkCOWhgB3YowhyAoAAxLKACKRhc
HjpwBiDgFXV6FebiWve62PGBAUQggAxyZwMPIIAAC2DAGICAUB6QYaAH7YEDEKBZGYxhCTIgQAAe
oAYMKOGgDeggHy4wghzcQQAI9WniZhuBfqoBAXUoaIBP4IE25GAEAvDqjAqMG08+kBd2AHjuLwf4
iTDq7sMgDrHkAghd5+1VxChOsYgx58W8mli6Ko6xjC3HYl+SonM6KMATdszjHvv4x0AOspCHTOQi
G9nIIkBBi0sMRjeg4QNQjrKUp0zlKlv5yljOspa3zOU02ngUPwta0MIs5p6Rucw5OzOaa6bmNb9M
EnCOs5znTOc6MyIQADs=

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: application/octet-stream
Content-Transfer-Encoding: base64
Content-Location: http://ad.doubleclick.net/ad/nature.com/article;pos=right;abr=!NN2;sz=160x600;ord=07893195?
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------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/layout.css

#header {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#breadcrumb {
	MARGIN-LEFT: 1%; MARGIN-RIGHT: 1%
}
#constrain {
	FLOAT: left
}
#constrain DIV.constrain {
	FLOAT: left
}
#constrain {
	FLOAT: none
}
#constrain DIV.constrain {
	FLOAT: none
}
#content-journalnav {
	BORDER-TOP: #fff 1px solid; DISPLAY: inline; FLOAT: left; MARGIN-LEFT: =
1%; WIDTH: 79%
}
#content-journalnav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #content-journalnav {
	HEIGHT: 1%
}
#journalnav {
	FLOAT: left; WIDTH: 21%
}
#journalnav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #journalnav {
	HEIGHT: 1%
}
#content {
	FLOAT: right; PADDING-BOTTOM: 1em; MARGIN-LEFT: 2%; WIDTH: 76%
}
#content:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #content {
	HEIGHT: 1%
}
#extranav {
	BORDER-TOP: #fff 1px solid; DISPLAY: inline; FLOAT: right; WIDTH: 17%; =
MARGIN-RIGHT: 1%
}
#extranav:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #extranav {
	HEIGHT: 1%
}
#footer {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 4px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#footer-copyright {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 1px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#footer-sponsor {
	CLEAR: both; PADDING-RIGHT: 1%; BORDER-TOP: black 1px solid; =
PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; TEXT-ALIGN: =
center
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: 7bit
Content-Location: http://www.nature.com/common/style/layout_wide_banner.css

 HTML #content-journalnav {
	WIDTH: 74%
}
#content-journalnav {
	WIDTH: 75%
}
#extranav {
	WIDTH: 22%
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/main.css

 HTML BODY {
	FONT-SIZE: 90%
}
 HTML BODY {
	FONT-SIZE: 89%
}
BODY {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; BACKGROUND: =
#fff; PADDING-BOTTOM: 20px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 0px; =
FONT-FAMILY: Verdana, arial, Helvetica, sans-serif
}
A:link {
	COLOR: #36c
}
A:visited {
	COLOR: #639
}
A:hover {
	COLOR: #c03
}
.print-header {
	DISPLAY: none
}
.hidden {
	LEFT: 0px; OVERFLOW: hidden; WIDTH: 1px; POSITION: absolute; TOP: =
-500px; HEIGHT: 1px
}
.clearfix:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML .clearfix {
	HEIGHT: 1%
}
DIV.cleardiv {
	CLEAR: both; PADDING-RIGHT: 0px! important; PADDING-LEFT: 0px! =
important; PADDING-BOTTOM: 0px! important; PADDING-TOP: 0px! important
}
SPAN.cleardiv {
	CLEAR: both! important; PADDING-RIGHT: 0px! important; DISPLAY: block! =
important; PADDING-LEFT: 0px! important; PADDING-BOTTOM: 0px! important; =
MARGIN: 0px; PADDING-TOP: 0px! important
}
.no-css {
	DISPLAY: none; HEIGHT: 0px
}
#npglogo {
	MARGIN-LEFT: -34px; POSITION: relative; TOP: -10px
}
#npglogo {
	DISPLAY: block
}
UNKNOWN {
	DISPLAY: none
}
UNKNOWN {
	DISPLAY: block
}
#npglogo IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; Z-INDEX: 1; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 26px; POSITION: absolute; TOP: 1em; =
HEIGHT: 26px; BORDER-RIGHT-WIDTH: 0px
}
#accessibility-bar #npglogo A {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; =
BACKGROUND-IMAGE: none; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
.button {
	FONT-WEIGHT: bold; FONT-SIZE: 80%; COLOR: #fff; BACKGROUND-COLOR: #000
}
.clear {
	CLEAR: both
}
.clearleft {
	CLEAR: left
}
OL.decimal {
	LIST-STYLE-TYPE: decimal
}
OL.decimal-leading-zero {
=09
}
OL.lower-alpha {
	LIST-STYLE-TYPE: lower-alpha
}
OL.upper-alpha {
	LIST-STYLE-TYPE: upper-alpha
}
OL.lower-roman {
	LIST-STYLE-TYPE: lower-roman
}
OL.upper-roman {
	LIST-STYLE-TYPE: upper-roman
}
OL.lower-greek {
=09
}
.align-left {
	TEXT-ALIGN: left
}
.align-center {
	TEXT-ALIGN: center
}
.align-right {
	TEXT-ALIGN: right
}
.align-baseline {
	VERTICAL-ALIGN: baseline
}
.align-sub {
	VERTICAL-ALIGN: sub
}
.align-super {
	VERTICAL-ALIGN: super
}
.align-text-top {
	VERTICAL-ALIGN: text-top
}
.align-middle {
	VERTICAL-ALIGN: middle
}
.align-bottom {
	VERTICAL-ALIGN: bottom
}
.align-text-bottom {
	VERTICAL-ALIGN: text-bottom
}
A.seealso {
	MARGIN-TOP: 1em; DISPLAY: block; FONT-SIZE: 70%; TEXT-DECORATION: none
}
A.seealso SPAN.see {
	FONT-WEIGHT: bold; COLOR: #c03
}
A.seealso SPAN.link {
	TEXT-DECORATION: underline
}
A.rss {
	PADDING-LEFT: 24px; BACKGROUND: url(/common/images/icons/rss.gif) =
no-repeat left center
}
A.rss:hover {
	BACKGROUND: url(/common/images/icons/rss.gif) no-repeat left center
}
#extranav A.rss {
	PADDING-LEFT: 22px; BACKGROUND: url(/common/images/icons/newsfeeds.gif) =
no-repeat left center; PADDING-BOTTOM: 2px; PADDING-TOP: 1px
}
#extranav A.receive {
	PADDING-LEFT: 22px; BACKGROUND: url(/common/images/icons/newsfeeds.gif) =
no-repeat left center; PADDING-BOTTOM: 2px; PADDING-TOP: 1px
}
#content SPAN.free {
	COLOR: #c03; TEXT-DECORATION: none
}
.dev-error {
	FONT-WEIGHT: bold; FONT-SIZE: 80%; BACKGROUND: #f00; COLOR: #fff
}
.b {
	FONT-WEIGHT: bold
}
.i {
	FONT-STYLE: italic
}
.latin {
	FONT-STYLE: italic
}
H1.page-header {
	FONT-WEIGHT: bold; FONT-SIZE: 140%; PADDING-BOTTOM: 4px; MARGIN: 15px =
0px 10px; BORDER-BOTTOM: #eaeaea 1px solid
}
SPAN.page-header-spacer {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 140%; VISIBILITY: hidden; =
PADDING-BOTTOM: 4px; MARGIN: 15px 0px 0px
}
SPAN.journalname {
	FONT-STYLE: italic
}
SPAN.journalnumber {
	FONT-WEIGHT: bold
}
SPAN.tm {
	VERTICAL-ALIGN: super
}
 HTML #breadcrumb DIV {
	PADDING-LEFT: 19.4%; PADDING-TOP: 1px
}
#breadcrumb DIV {
	CLEAR: left; PADDING-LEFT: 19.6%; BACKGROUND: #eaeaea; PADDING-BOTTOM: =
0.2em
}
#breadcrumb DIV A:link {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#breadcrumb DIV A:visited {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#breadcrumb DIV A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#breadcrumb SPAN.divider {
	FONT-SIZE: 70%; COLOR: #000
}
#breadcrumb SPAN.thisitem {
	FONT-SIZE: 70%; COLOR: #000
}
#login-inpage {
	MARGIN: 0px; COLOR: #000; BACKGROUND-COLOR: #eaeaea
}
#login-inpage A {
	FONT-SIZE: 70%
}
#login-inpage DIV.userpassbox {
	FLOAT: left; WIDTH: 8em
}
#login-inpage .passdetails {
	CLEAR: left
}
#login-inpage INPUT.text {
	FONT-SIZE: 80%; MARGIN: 0px; WIDTH: 9em; COLOR: #000
}
#login-inpage LABEL {
	FONT-SIZE: 70%
}
#login-inpage INPUT.button {
	MARGIN-TOP: 5px
}
#login-inpage #savepass-inpage {
	MARGIN-BOTTOM: -2px
}
#login-inpage DIV.error {
	PADDING-LEFT: 20px; FONT-SIZE: 80%; BACKGROUND: =
url(/common/images/login_error.gif) no-repeat 0px 4px; MARGIN-BOTTOM: =
5px; COLOR: #c30
}
#login-inpage DIV.error SPAN {
	FONT-WEIGHT: bold
}
#head-er HR {
	DISPLAY: none
}
#head-er .header-nonad-wrapper {
	PADDING-BOTTOM: 15px; BORDER-BOTTOM: #fff 1px solid
}
#head-er .accessibility-login-wrap {
	FLOAT: left; WIDTH: 100%; BORDER-BOTTOM: #000 1px solid; =
BACKGROUND-COLOR: #eaeaea
}
#head-er .accessibility-login {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 4px; TEXT-ALIGN: right
}
#head-er .accessibility-login A.nature-link {
	FLOAT: left; FONT: bold 160%/80% Garamond, serif; WIDTH: 4.9em; COLOR: =
#b1062e; MARGIN-RIGHT: 20px; TEXT-ALIGN: left; TEXT-DECORATION: none
}
 HTML #head-er .accessibility-login A.nature-link:hover {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#head-er .accessibility-login A.nature-link:hover {
	BACKGROUND: =
url(/common/includes/header/images/nature.com.underline.gif) no-repeat =
left bottom
}
#head-er .accessibility-login IMG.nature-logo {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 1px 20px 0px 0px; WIDTH: 82px! =
important; HEIGHT: 11px; BORDER-RIGHT-WIDTH: 0px
}
#head-er .accessibility-login .jumplinks {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 0px; WIDTH: 45%; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; =
TEXT-ALIGN: left
}
#head-er .accessibility-login .jumplinks LI {
	DISPLAY: inline; PADDING-LEFT: 15px
}
#head-er .accessibility-login .jumplinks LI.first {
	PADDING-LEFT: 0px
}
#head-er .accessibility-login .jumplinks A {
	PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/icons/b1062e/arrow_down.gif) no-repeat left center; =
COLOR: #000; TEXT-DECORATION: none
}
#head-er .accessibility-login .jumplinks A:hover {
	TEXT-DECORATION: underline
}
#head-er DIV.logon {
=09
}
#head-er .logon .onlyformacie {
	FONT-SIZE: 3px
}
#head-er .logon .onlyformacie {
	DISPLAY: none
}
#head-er .logon A.login {
	PADDING-RIGHT: 15px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/includes/header/images/logon.gif) no-repeat right center; =
PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; COLOR: #b1062e; =
PADDING-TOP: 0px; LETTER-SPACING: -0.1em; TEXT-DECORATION: none
}
#head-er .logon A.login:hover {
	BACKGROUND: url(/common/includes/header/images/logon_over.gif) =
no-repeat right center; TEXT-DECORATION: underline
}
#head-er .logon A.login:active {
	BACKGROUND: url(/common/includes/header/images/logon.gif) no-repeat =
right center
}
#head-er .logon A.logoff {
	PADDING-RIGHT: 15px; PADDING-LEFT: 15px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/includes/header/images/logoff.gif) no-repeat right center; =
PADDING-BOTTOM: 0px; TEXT-TRANSFORM: uppercase; COLOR: #b1062e; =
PADDING-TOP: 0px; LETTER-SPACING: -0.1em; TEXT-DECORATION: none
}
#head-er .logon P {
	MARGIN: 0px
}
#head-er .logon .user {
	FONT-WEIGHT: bold
}
#head-er .logon .inst {
	FONT-WEIGHT: bold
}
#head-er .image-user-services-wrap {
	FLOAT: left; WIDTH: 100%; BACKGROUND-COLOR: #d6335c
}
#head-er .image-user-services {
	BORDER-BOTTOM: transparent 1px solid
}
 HTML #head-er .image-user-services {
	BORDER-BOTTOM-WIDTH: 0px
}
#head-er .image-user-services IMG.journal-header {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px; WIDTH: 344px; HEIGHT: 74px; =
BORDER-RIGHT-WIDTH: 0px
}
#head-er .user-services {
	FLOAT: right
}
#head-er .div1 {
	WIDTH: 12.35em! important
}
#head-er .div2 {
	WIDTH: 8.7em! important
}
#head-er .user-services UL {
	BORDER-RIGHT: #fff 0px solid; PADDING-RIGHT: 0px; BORDER-TOP: #fff 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 22px 0px 21px; =
BORDER-LEFT: #fff 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #fff 0px =
solid; LIST-STYLE-TYPE: none; TEXT-ALIGN: right
}
#head-er .user-services UL.list1 {
	BORDER-RIGHT: #fff 1px solid
}
#head-er .user-services LI {
	BORDER-BOTTOM: #fff 1px solid
}
#head-er .user-services A {
	PADDING-RIGHT: 13px; DISPLAY: block; PADDING-LEFT: 0px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) #767474 no-repeat right =
center; PADDING-BOTTOM: 1px; TEXT-TRANSFORM: uppercase; COLOR: #fff; =
PADDING-TOP: 1px; TEXT-DECORATION: none
}
#head-er .user-services A:hover {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #000 no-repeat =
right center
}
#head-er .publications-search-wrap {
	BACKGROUND: #000
}
 HTML #head-er .publications-search {
	PADDING-BOTTOM: 3px; PADDING-TOP: 3px
}
#head-er .publications-search {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 4px; =
PADDING-TOP: 4px
}
 HTML #head-er .publications {
	MARGIN: 6px 0px 0px
}
#head-er .publications {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 4px 0px 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#head-er .publications LI {
	DISPLAY: inline; MARGIN-LEFT: 10px
}
#head-er .publications LI.first {
	MARGIN-LEFT: 0px
}
#head-er .publications A {
	PADDING-RIGHT: 15px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) no-repeat right center; =
TEXT-TRANSFORM: uppercase; COLOR: #fff; TEXT-DECORATION: none
}
#head-er .publications A:hover {
	TEXT-DECORATION: underline
}
#head-er .search {
	TEXT-ALIGN: right
}
#head-er .search FORM {
	DISPLAY: inline; MARGIN: 0px
}
#head-er .search FORM A {
	PADDING-RIGHT: 14px; BACKGROUND: =
url(/common/images/icons/fff/arrow_s.gif) no-repeat right center; =
TEXT-TRANSFORM: uppercase; COLOR: #fff; TEXT-DECORATION: none
}
#head-er .search FORM A:hover {
	TEXT-DECORATION: underline
}
#head-er #searchtext {
	WIDTH: 10em
}
#head-er .publications-search LABEL {
	TEXT-TRANSFORM: uppercase; COLOR: #fff
}
#head-er INPUT {
	FONT-SIZE: 100%
}
#head-er SELECT {
	FONT-SIZE: 100%
}
#head-er .publications-search INPUT.button {
	PADDING-RIGHT: 3px; PADDING-LEFT: 3px; FONT-WEIGHT: bold; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 0px; COLOR: #000; PADDING-TOP: 0px
}
#head-er .accessibility-login {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
#head-er .image-user-services {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
#head-er .publications-search {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%
}
.header-leaderboard-wrap {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%; BACKGROUND: =
url(/common/includes/header/images/bg_leaderboard.gif) no-repeat 50% 0px
}
.header-leaderboard {
	TEXT-ALIGN: center; max-height: 105px
}
 HTML .header-leaderboard IMG {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard ilayer {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard IFRAME {
	BORDER-BOTTOM-WIDTH: 1px
}
 HTML .header-leaderboard EMBED {
	BORDER-BOTTOM-WIDTH: 1px
}
.header-leaderboard IMG {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard ilayer {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard IFRAME {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard EMBED {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: 100%; PADDING-TOP: =
0px; BORDER-BOTTOM: #fff 1px solid; HEIGHT: 90px; BORDER-RIGHT-WIDTH: =
0px; max-width: 728px
}
.header-leaderboard TABLE {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: auto; WIDTH: =
100%; MARGIN-RIGHT: auto; PADDING-TOP: 0px; BORDER-BOTTOM: #fff 1px =
solid; BORDER-RIGHT-WIDTH: 0px; max-width: 728px
}
 HTML .header-leaderboard TABLE IMG {
	HEIGHT: auto
}
#global-subject-areas {
	BORDER-RIGHT: #ebebeb 1px solid; BORDER-TOP: #ebebeb 1px solid; =
BACKGROUND: #ebebeb; MARGIN: 0px 0px 20px; BORDER-LEFT: #ebebeb 1px =
solid; BORDER-BOTTOM: #ebebeb 1px solid
}
#global-subject-areas abbr {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; BORDER-RIGHT-WIDTH: 0px; TEXT-DECORATION: none
}
#global-subject-areas A:link {
	FONT-WEIGHT: bold; COLOR: #9d0006; TEXT-DECORATION: none
}
#global-subject-areas A:visited {
	FONT-WEIGHT: bold; COLOR: #9d0006; TEXT-DECORATION: none
}
#global-subject-areas A:hover {
	TEXT-DECORATION: underline
}
#global-subject-areas H2 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H3 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H4 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H5 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 110%; BACKGROUND: =
#b1062e; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: =
5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H3.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H4.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas H5.view {
	PADDING-RIGHT: 17px; PADDING-LEFT: 17px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/bg.7x1.b1062e.gif) #fff repeat-y left top; =
PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: #9d0006; PADDING-TOP: 5px; =
BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#global-subject-areas UL UL {
	FONT-SIZE: 100%
}
#global-subject-areas UL LI {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; =
LINE-HEIGHT: 150%; PADDING-TOP: 5px; BORDER-BOTTOM: #fff 1px solid
}
#global-subject-areas UL LI LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 5px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#global-subject-areas UL LI H4 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
#global-subject-areas UL LI H5 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
#global-subject-areas UL LI H6 {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
FONT-WEIGHT: normal; BORDER-LEFT-WIDTH: 0px; FONT-SIZE: 100%; =
BACKGROUND: none transparent scroll repeat 0% 0%; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #666; PADDING-TOP: 0px; =
FONT-STYLE: italic; BORDER-RIGHT-WIDTH: 0px
}
MAP.journal-nav {
	DISPLAY: block; MARGIN-BOTTOM: 20px
}
MAP.journal-nav UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
MAP.journal-nav UL LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
MAP.journal-nav UL LI.grouped {
	BORDER-BOTTOM: #eaeaea 1px solid
}
 HTML MAP.journal-nav UL LI A {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 2px
}
 HTML MAP.journal-nav UL LI A:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 2px
}
MAP.journal-nav UL LI A {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 5px; FONT-WEIGHT: =
bold; FONT-SIZE: 80%; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 4px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A:visited {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 5px; FONT-WEIGHT: =
bold; FONT-SIZE: 80%; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 4px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #c00; TEXT-DECORATION: none
}
MAP.journal-nav UL LI A.on {
	COLOR: #fff; BACKGROUND-COLOR: #c00
}
MAP.journal-nav UL LI A.on:visited {
	COLOR: #fff; BACKGROUND-COLOR: #c00
}
MAP.journal-nav UL LI A.submission {
	PADDING-LEFT: 20px! important; BACKGROUND: =
url(/common/images/online_submissions.gif) no-repeat left center
}
MAP.journal-nav UL LI UL.subnav {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none; TEXT-ALIGN: left
}
MAP.journal-nav UL LI UL.subnav LI {
	BACKGROUND: url(/common/images/nav_dots2.gif) #fafafa no-repeat 11px =
5px; BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px
}
MAP.journal-nav UL LI UL.subnav LI.on {
	BACKGROUND: url(/common/images/nav_dots1.gif) #c00 no-repeat 11px 5px; =
BORDER-BOTTOM: #fafafa 1px solid
}
 HTML MAP.journal-nav UL LI UL.subnav A {
	PADDING-RIGHT: 10px; PADDING-LEFT: 20px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px
}
MAP.journal-nav UL LI UL.subnav A:link {
	PADDING-RIGHT: 10px; DISPLAY: block; PADDING-LEFT: 20px; FONT-WEIGHT: =
normal; FONT-SIZE: 70%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 2px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A:visited {
	PADDING-RIGHT: 10px; DISPLAY: block; PADDING-LEFT: 20px; FONT-WEIGHT: =
normal; FONT-SIZE: 70%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #000; =
PADDING-TOP: 2px; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A:hover {
	BACKGROUND: url(/common/images/nav_dots1.gif) #fab934 no-repeat 11px =
5px; COLOR: #fff; TEXT-DECORATION: none
}
MAP.journal-nav UL LI UL.subnav A.on {
	COLOR: #fff
}
MAP.journal-nav UL LI UL.subnav A.on:visited {
	COLOR: #fff
}
#journalnav MAP.supplementary UL A {
	FONT-WEIGHT: normal; FONT-SIZE: 70%
}
#journalnav MAP.supplementary UL A:visited {
	FONT-WEIGHT: normal; FONT-SIZE: 70%
}
H2.society-resources {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #fab934
}
UL.society-resources {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.society-resources LI {
	MARGIN: 0px; BACKGROUND-COLOR: #eaeaea
}
UL.society-resources A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.society-resources A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.society-resources A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #fab934; TEXT-DECORATION: none
}
DIV.society-logo {
	MARGIN-BOTTOM: 20px; TEXT-ALIGN: center
}
DIV.society-logo IMG {
	WIDTH: 100%
}
H2.npg-resources {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #b1062e
}
UL.npg-resources {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.npg-resources LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
UL.npg-resources A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-resources A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-resources A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #b1062e; TEXT-DECORATION: none
}
H2.npg-subjects {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
80%; PADDING-BOTTOM: 2px; MARGIN: 0px; COLOR: #fff; PADDING-TOP: 2px; =
BACKGROUND-COLOR: #c03
}
UL.npg-subjects {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 20px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
UL.npg-subjects LI {
	MARGIN: 0px; BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #eaeaea
}
UL.npg-subjects A {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-subjects A:visited {
	PADDING-RIGHT: 5px! important; DISPLAY: block; PADDING-LEFT: 5px! =
important; FONT-SIZE: 70%; PADDING-BOTTOM: 3px! important; MARGIN: 0px; =
COLOR: #000; PADDING-TOP: 3px! important; TEXT-DECORATION: none
}
UL.npg-subjects A:hover {
	COLOR: #fff; BACKGROUND-COLOR: #c03; TEXT-DECORATION: none
}
UL.npg-subjects A.npgsubject-browseall:link {
	COLOR: #c03
}
UL.npg-subjects A.npgsubject-browseall:visited {
	COLOR: #c03
}
UL.npg-subjects A.npgsubject-browseall:hover {
	COLOR: #fff
}
A.backtotop:link {
	MARGIN-TOP: 5px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_white_up.gif) no-repeat 0px 0.6em; FLOAT: =
right; MARGIN-LEFT: 7px; COLOR: #fff; MARGIN-RIGHT: 10px
}
A.backtotop:visited {
	MARGIN-TOP: 5px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_white_up.gif) no-repeat 0px 0.6em; FLOAT: =
right; MARGIN-LEFT: 7px; COLOR: #fff; MARGIN-RIGHT: 10px
}
A.backtotop:hover {
	COLOR: #fff
}
H1.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #fab934; PADDING-BOTTOM: 3px; MARGIN: 0px 0px 10px; =
COLOR: #fff; PADDING-TOP: 3px
}
IMG.arrow {
	MARGIN-RIGHT: 5px
}
A.arrow-blue {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat 0px 0.5em
}
A.arrow-grey {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_grey.gif) =
no-repeat 0px 0.5em
}
A.arrow-red {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_red.gif) =
no-repeat 0px 0.5em
}
DIV.research-reviews {
	BORDER-RIGHT: #eaeaea 1px solid; BORDER-TOP: #eaeaea 1px solid; =
MARGIN-BOTTOM: 2em; BORDER-LEFT: #eaeaea 1px solid; BORDER-BOTTOM: =
#eaeaea 1px solid
}
DIV.research-reviews H1 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 90%; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 4px; MARGIN: 0px; COLOR: #900; PADDING-TOP: 3px
}
DIV.research-reviews P {
	FONT-SIZE: 70%; MARGIN: 1em 10px; COLOR: #900
}
DIV.research-reviews UL {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px 10px 1em; PADDING-TOP: 1em; =
LIST-STYLE-TYPE: none
}
DIV.research-reviews LI {
	MARGIN: 0px 0px 0.5em
}
DIV.research-reviews LI A {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
DIV.research-reviews LI SPAN {
	FONT-SIZE: 70%
}
DIV.ad-horiz {
	CLEAR: both; BORDER-TOP: #eaeaea 1px solid; FONT-SIZE: 70%; =
MARGIN-BOTTOM: 20px; COLOR: #ccc; PADDING-TOP: 10px; TEXT-ALIGN: center
}
DIV.ad-horiz IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px; max-width: 468px
}
DIV.ad-horiz EMBED {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px; max-width: 468px
}
 HTML DIV.ad-horiz {
	MARGIN-LEFT: auto; OVERFLOW: hidden; WIDTH: 100%; MARGIN-RIGHT: auto; =
max-width: 468px
}
#extranav A.topten:link {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; MARGIN-TOP: 0.6em; =
DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 1.2em; PADDING-BOTTOM: =
0px; PADDING-TOP: 0.8em
}
#extranav A.topten:visited {
	PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; MARGIN-TOP: 0.6em; =
DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 1.2em; PADDING-BOTTOM: =
0px; PADDING-TOP: 0.8em
}
#extranav A.topten:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 1.2em; =
TEXT-DECORATION: underline
}
DIV.ad-vert {
	FONT-SIZE: 70%; MARGIN-BOTTOM: 20px; COLOR: #ccc; TEXT-ALIGN: center
}
DIV.ad-vert IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 600px; =
BORDER-RIGHT-WIDTH: 0px; max-width: 120px
}
DIV.ad-vert EMBED {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 4px 0px 0px; WIDTH: 100%; HEIGHT: 600px; =
BORDER-RIGHT-WIDTH: 0px; max-width: 120px
}
 HTML DIV.ad-vert {
	MARGIN-LEFT: auto; OVERFLOW: hidden; WIDTH: 100%; MARGIN-RIGHT: auto; =
max-width: 160px
}
.box#natjob {
	BORDER-RIGHT: #e7e7e7 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: =
#e7e7e7 1px solid; PADDING-LEFT: 6px; BACKGROUND: #fff; PADDING-BOTTOM: =
6px; MARGIN: 10px 0px; BORDER-LEFT: #e7e7e7 1px solid; COLOR: #000; =
PADDING-TOP: 6px; BORDER-BOTTOM: #e7e7e7 1px solid
}
H2.natjob {
	PADDING-RIGHT: 7px; PADDING-LEFT: 7px; FONT-SIZE: 120%; BACKGROUND: =
#d8d8d8; PADDING-BOTTOM: 5px; MARGIN: 0px 0px 0.75em; TEXT-TRANSFORM: =
lowercase; PADDING-TOP: 5px; LETTER-SPACING: -0.04em
}
H2.natjob A {
	TEXT-DECORATION: none
}
H2.natjob SPAN.first {
	COLOR: #f00
}
H2.natjob SPAN.second {
	COLOR: #000
}
UL.natjob {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
UL.natjob H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 110%; MARGIN: 10px 0px 0px
}
UL.natjob H3.first {
	MARGIN: 0px
}
UL.natjob H3 A:link {
	COLOR: #000; TEXT-DECORATION: underline! important
}
UL.natjob H3 A:visited {
	COLOR: #000; TEXT-DECORATION: underline! important
}
UL.natjob LI H3 A:hover {
	COLOR: #c03
}
UL.natjob LI H3 A:unknown {
	COLOR: #c03
}
 HTML UL.natjob UL {
	LINE-HEIGHT: 120%
}
DIV.natjobmore {
	PADDING-RIGHT: 0px; BORDER-TOP: #cecece 1px solid; PADDING-LEFT: 0px; =
FONT-SIZE: 110%; PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
DIV.natjobmore A:link {
	DISPLAY: inline; PADDING-LEFT: 15px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/icons/next.gif) no-repeat 0px 0.3em; MARGIN: 0px; =
COLOR: #c03; TEXT-DECORATION: none
}
DIV.natjobmore A:visited {
	DISPLAY: inline; PADDING-LEFT: 15px; FONT-SIZE: 100%; BACKGROUND: =
url(/common/images/icons/next.gif) no-repeat 0px 0.3em; MARGIN: 0px; =
COLOR: #c03; TEXT-DECORATION: none
}
.box#natjob DIV.natjobmore A:hover {
	BACKGROUND-IMAGE: url(/common/images/icons/next_hover.gif); =
TEXT-DECORATION: underline
}
.box#natjob DIV.natjobmore A:unknown {
	BACKGROUND-IMAGE: url(/common/images/icons/next_hover.gif); =
TEXT-DECORATION: underline
}
UL.natjob UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
P.natjobmore {
	PADDING-BOTTOM: 5px; MARGIN: 0px
}
P.nateventmore {
	PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
.box#natprod {
	BORDER-RIGHT: #e7e7e7 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: =
#e7e7e7 1px solid; PADDING-LEFT: 6px; BACKGROUND: #fff; PADDING-BOTTOM: =
6px; MARGIN: 10px 0px; BORDER-LEFT: #e7e7e7 1px solid; COLOR: #000; =
PADDING-TOP: 6px; BORDER-BOTTOM: #e7e7e7 1px solid
}
H2.natprod {
	PADDING-RIGHT: 7px; PADDING-LEFT: 7px; FONT-SIZE: 120%; BACKGROUND: =
#d8d8d8; PADDING-BOTTOM: 5px; MARGIN: 0px 0px 0.75em; TEXT-TRANSFORM: =
lowercase; PADDING-TOP: 5px; LETTER-SPACING: -0.04em
}
H2.natprod A {
	TEXT-DECORATION: none
}
H2.natprod SPAN.first {
	COLOR: #f00
}
H2.natprod SPAN.second {
	COLOR: #000
}
.box#natprod FORM {
	MARGIN: 0px
}
DIV.natprod {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 4px; PADDING-LEFT: 4px; =
BACKGROUND: #f3f2f2; PADDING-BOTTOM: 4px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 4px; BORDER-BOTTOM: black 1px solid
}
DIV.natprodmore {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0.75em; =
PADDING-TOP: 0px
}
DIV.natprodmore A:link {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; COLOR: #c03; =
TEXT-DECORATION: none
}
DIV.natprodmore A:visited {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; COLOR: #c03; =
TEXT-DECORATION: none
}
DIV.natprodmore A:unknown {
	TEXT-DECORATION: underline
}
DIV.natprodmore A:hover {
	TEXT-DECORATION: underline
}
DIV.natprod SPAN {
	DISPLAY: block; FONT-SIZE: 70%; MARGIN-BOTTOM: 10px; LINE-HEIGHT: 110%
}
#natprod FORM {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
DIV.natprodmore FORM {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
DIV.natprodmore INPUT {
	MARGIN-TOP: 5px; FONT-SIZE: 110%; WIDTH: 98%! important
}
 HTML DIV.natprodmore INPUT {
	WIDTH: 96%! important
}
DIV.natprodmore INPUT {
=09
}
DIV.natprodmore INPUT {
=09
}
DIV.natprodmore INPUT.button {
	FONT-WEIGHT: bold; COLOR: #fff; BACKGROUND-COLOR: #000
}
#article-related #journal-header {
	DISPLAY: none
}
#article-related H2.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article-related H2.figure-title {
	CLEAR: both; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related P.from {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px; COLOR: #c03
}
#article-related P.aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related A.back-to-article:link {
	CLEAR: both; PADDING-RIGHT: 1em; PADDING-LEFT: 1em; FONT-WEIGHT: bold; =
FONT-SIZE: 70%; BACKGROUND: #000; FLOAT: right; PADDING-BOTTOM: 3px; =
MARGIN: 10px 0px; COLOR: #fff; PADDING-TOP: 3px; TEXT-DECORATION: none
}
#article-related A.back-to-article:visited {
	CLEAR: both; PADDING-RIGHT: 1em; PADDING-LEFT: 1em; FONT-WEIGHT: bold; =
FONT-SIZE: 70%; BACKGROUND: #000; FLOAT: right; PADDING-BOTTOM: 3px; =
MARGIN: 10px 0px; COLOR: #fff; PADDING-TOP: 3px; TEXT-DECORATION: none
}
#article-related A.back-to-article:hover {
	BACKGROUND: #fab934; COLOR: #fff; TEXT-DECORATION: none
}
#article-related DIV.container-image {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: #eaeaea; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; =
PADDING-TOP: 10px; TEXT-ALIGN: center
}
#article-related DIV.container-image-text {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: #eaeaea; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; =
PADDING-TOP: 10px
}
#article-related DIV.container-image-text P {
	FONT-SIZE: 90%
}
#article-related FORM {
	MARGIN: 0px
}
#article-related DIV.container-image-text UL {
	FONT-SIZE: 90%
}
#article-related DIV.container-image-text OL {
	FONT-SIZE: 90%
}
#article-related DIV.prevnext {
	CLEAR: both; BORDER-RIGHT: black 1px solid; BORDER-TOP: black 1px =
solid; BACKGROUND: #fff; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: =
black 1px solid; TEXT-ALIGN: center
}
#article-related DIV.prevnext .hide {
	DISPLAY: none
}
#article-related DIV.prevnext A {
	FONT: 70% verdana, arial, helvetica, sans-serif; TEXT-DECORATION: none
}
#article-related A.previous:link {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_blue_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#article-related A.previous:visited {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_blue_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#article-related A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#article-related A.index:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; VERTICAL-ALIGN: middle; PADDING-TOP: 2px
}
#article-related A.index:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; VERTICAL-ALIGN: middle; PADDING-TOP: 2px
}
#article-related A.index:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#article-related A.next:link {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat right center; FLOAT: right; =
PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: 10px; =
PADDING-TOP: 2px
}
#article-related A.next:visited {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat right center; FLOAT: right; =
PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: 10px; =
PADDING-TOP: 2px
}
#article-related A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#article-related DIV.container-figtab {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 0px solid
}
#article-related DIV.last {
	BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-figtab DIV.container-image IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; BORDER-RIGHT-WIDTH: 0px; max-width: 150px
}
#article-related DIV.container-figtab DIV.container-image {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: none transparent scroll repeat 0% =
0%; FLOAT: left; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; WIDTH: =
150px; PADDING-TOP: 0px; TEXT-ALIGN: right; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-figtab DIV.container-image-text {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: none transparent scroll repeat 0% =
0%; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN-LEFT: 160px; =
PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-figtab DIV.container-image-text H3 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-figtab DIV.container-image-text P {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-figtab A.full {
	MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: 25px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/full_figure.gif) no-repeat 0px 0px
}
#article-related DIV.container-figtab A.pp {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: =
25px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/fff/powerpoint.gif) no-repeat 0px 0px; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article-related DIV.container-supplementary {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
PADDING-LEFT: 0px; BACKGROUND: #eaeaea; PADDING-BOTTOM: 0px; =
BORDER-LEFT: black 1px solid; PADDING-TOP: 0px
}
#article-related A.download-plugins:link {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
BORDER-TOP: black 1px solid; DISPLAY: block; PADDING-LEFT: 17px; =
FONT-SIZE: 70%; BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat =
10px 0.45em; PADDING-BOTTOM: 3px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 0px; BORDER-BOTTOM: black 1px solid
}
#article-related A.download-plugins:visited {
	CLEAR: both; BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 0px; =
BORDER-TOP: black 1px solid; DISPLAY: block; PADDING-LEFT: 17px; =
FONT-SIZE: 70%; BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat =
10px 0.45em; PADDING-BOTTOM: 3px; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 0px; BORDER-BOTTOM: black 1px solid
}
#article-related A.download-plugins:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 10px 0.45em
}
#article-related DIV.container-supplementary H2 {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 10px
}
#article-related DIV.container-supplementary P {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; FONT-SIZE: 90%; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 0px; BORDER-BOTTOM: =
black 1px solid
}
#article-related DIV.container-supplementary P.last {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 10px; PADDING-TOP: 0px
}
#article-related DIV.container-sendfriend {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-plugins {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more2 {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more2 {
	BORDER-BOTTOM-WIDTH: 0px
}
#article-related DIV.wrapper {
	MARGIN-BOTTOM: 10px
}
#article-related P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1em
}
#article-related DIV.container-plugins P {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related DIV.container-plugins P.last {
	MARGIN: 0px
}
#article-related P.results {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#article-related A.article {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article-related P.journal {
	FONT-SIZE: 70%; MARGIN: 0px; FONT-STYLE: italic
}
#article-related P.journal SPAN {
	FONT-STYLE: normal
}
#article-related DIV.container-more2 P.journal {
	MARGIN-BOTTOM: 1em
}
#article-related H3.area {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase
}
#article-related A.allmatches:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#article-related A.allmatches:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#article-related A.allmatches:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article-related DIV.text {
	FLOAT: left; WIDTH: 210px; TEXT-ALIGN: right
}
#article-related DIV.text LABEL {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article-related DIV.text P {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.form {
	MARGIN-LEFT: 220px
}
#article-related DIV.form INPUT {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: auto; PADDING-TOP: 0px
}
#article-related DIV.form TEXTAREA {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; WIDTH: auto; PADDING-TOP: 0px
}
#article-related DIV.form INPUT {
	WIDTH: 100%
}
#article-related DIV.form TEXTAREA {
	WIDTH: 100%
}
#article-related INPUT.friend {
	CLEAR: both; FLOAT: right
}
 HTML #article-related TABLE.data {
	FONT-SIZE: 100%
}
#article-related TABLE.data {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; BORDER-LEFT: =
#999 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #999 1px solid; =
BORDER-COLLAPSE: collapse; TEXT-ALIGN: left
}
#article-related TABLE.data THEAD {
	FONT-WEIGHT: bold
}
#article-related TABLE.data THEAD TH {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0.5em; PADDING-LEFT: =
0.5em; FONT-SIZE: 90%; BACKGROUND: #f6f6f6; PADDING-BOTTOM: 0.5em; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 0px
}
#article-related TABLE.data THEAD TH.colspan {
	BORDER-RIGHT: #999 1px solid; BORDER-TOP: #999 0px solid; BORDER-LEFT: =
#999 1px solid; BORDER-BOTTOM: #999 1px solid; TEXT-ALIGN: center
}
#article-related TABLE.data THEAD TH.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.rowsep {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data THEAD TH.rowsep {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY {
	BORDER-TOP: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TR {
	BACKGROUND-COLOR: #f6f6f6
}
#article-related TABLE.data TBODY TR.odd {
	BACKGROUND-COLOR: #fff
}
#article-related TABLE.data TBODY TD {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0.5em; PADDING-LEFT: =
0.5em; FONT-SIZE: 90%; PADDING-BOTTOM: 0.15em; PADDING-TOP: 0.15em
}
#article-related TABLE.data TFOOT TD {
	PADDING-RIGHT: 0.5em; PADDING-LEFT: 0.5em; FONT-SIZE: 90%; =
PADDING-BOTTOM: 0.5em; PADDING-TOP: 0.5em; BACKGROUND-COLOR: #fff
}
#foot-er {
	BORDER-TOP-WIDTH: 0px; CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: =
0px; PADDING-BOTTOM: 0px; MARGIN: 20px 0px; PADDING-TOP: 0px
}
#foot-er #footer-journal {
	PADDING-RIGHT: 1%; BORDER-TOP: #000 1px solid; PADDING-LEFT: 1%; =
BACKGROUND: #eee; PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#foot-er #footer-journal:unknown {
	CLEAR: both; DISPLAY: block; VISIBILITY: hidden; HEIGHT: 0px; content: =
url(/common/images/clear.gif)
}
 HTML #foot-er #footer-journal {
	HEIGHT: 1%
}
#foot-er #footer-journal P {
	PADDING-RIGHT: 1em; PADDING-LEFT: 0px; FLOAT: left; PADDING-BOTTOM: =
0px; MARGIN: 0px 1em 0px 0px; PADDING-TOP: 0px
}
#foot-er #footer-journal P.journal-name {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; FONT-STYLE: italic
}
#foot-er #footer-journal P.issn {
	FONT-SIZE: 100%
}
#foot-er #footer-journal P.eissn {
	FONT-SIZE: 100%
}
#foot-er #footer-journal P.extra {
	FONT-SIZE: 100%
}
#foot-er #footer-links {
	PADDING-RIGHT: 1%; PADDING-LEFT: 1%; BACKGROUND: #000; PADDING-BOTTOM: =
5px; PADDING-TOP: 5px
}
#foot-er #footer-links UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#foot-er #footer-links UL LI {
	DISPLAY: inline
}
#foot-er #footer-links UL LI A:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 1em; BACKGROUND: =
#000; FLOAT: left; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0px 1em; =
BORDER-LEFT: #fff 1px solid; COLOR: #fff; PADDING-TOP: 0px; =
TEXT-DECORATION: none
}
#foot-er #footer-links UL LI A:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 1em; BACKGROUND: =
#000; FLOAT: left; PADDING-BOTTOM: 0px; MARGIN: 0px 0px 0px 1em; =
BORDER-LEFT: #fff 1px solid; COLOR: #fff; PADDING-TOP: 0px; =
TEXT-DECORATION: none
}
 HTML #foot-er #footer-links UL LI A:link {
	DISPLAY: inline
}
 HTML #foot-er #footer-links UL LI A:visited {
	DISPLAY: inline
}
#foot-er #footer-links UL LI A:hover {
	TEXT-DECORATION: underline
}
#foot-er #footer-links UL LI A.about-npg:link {
	PADDING-LEFT: 0px; FONT-WEIGHT: bold; BORDER-LEFT-WIDTH: 0px; =
MARGIN-LEFT: 0px
}
#foot-er #footer-links UL LI A.about-npg:visited {
	PADDING-LEFT: 0px; FONT-WEIGHT: bold; BORDER-LEFT-WIDTH: 0px; =
MARGIN-LEFT: 0px
}
#foot-er #footer-copyright {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 1%; PADDING-LEFT: 1%; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px; TEXT-ALIGN: left! important
}
 HTML #foot-er #footer-copyright .footer-constrain {
	TEXT-ALIGN: left
}
#foot-er #footer-copyright A {
	COLOR: #b1062e
}
#foot-er #footer-copyright P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 5px
}
#foot-er #footer-copyright P.logo {
	PADDING-RIGHT: 36px; PADDING-LEFT: 36px; BACKGROUND: =
url(/common/images/npg_logo.gif) no-repeat 0px 50%; PADDING-BOTTOM: 7px; =
MARGIN: 5px 0px 0px; PADDING-TOP: 7px
}
#foot-er #footer-copyright P A:link {
	FONT-WEIGHT: bold; TEXT-DECORATION: none
}
#foot-er #footer-copyright P A:visited {
	FONT-WEIGHT: bold; TEXT-DECORATION: none
}
#foot-er #footer-copyright P A.footer-copyright:link {
	FONT-WEIGHT: normal; COLOR: #000
}
#foot-er #footer-copyright P A.footer-copyright:visited {
	FONT-WEIGHT: normal; COLOR: #000
}
#foot-er #footer-copyright P A:hover {
	TEXT-DECORATION: underline
}
#content .scp {
	FONT-VARIANT: small-caps
}
DIV.ab-ad {
	PADDING-RIGHT: 3px; PADDING-LEFT: 3px; BACKGROUND: #eaeaea; =
MARGIN-BOTTOM: 15px; PADDING-BOTTOM: 3px; PADDING-TOP: 0px; TEXT-ALIGN: =
center
}
DIV.ab-ad H2.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H3.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H4.head-main {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase; COLOR: #ccc
}
DIV.ab-ad H3.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H4.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H5.head-supported {
	FONT-WEIGHT: normal; FONT-SIZE: 100%; MARGIN: 5px 0px 0px; COLOR: #000
}
DIV.ab-ad H4.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H5.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H6.head-products {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-WEIGHT: bold; FONT-SIZE: =
100%; BACKGROUND: #e0ebf9; PADDING-BOTTOM: 5px; MARGIN: 0px; COLOR: =
#333; PADDING-TOP: 5px
}
DIV.ab-ad H5.head-section {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px; COLOR: #0068b3
}
DIV.ab-ad H6.head-section {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px; COLOR: #0068b3
}
DIV.ab-ad DIV.container {
	BORDER-RIGHT: #e0ebf9 1px solid; BORDER-TOP: #e0ebf9 1px solid; =
MARGIN-TOP: 3px; BORDER-LEFT: #e0ebf9 1px solid; BORDER-BOTTOM: #e0ebf9 =
1px solid; BACKGROUND-COLOR: #fff
}
DIV.ab-ad UL {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fff; =
PADDING-BOTTOM: 5px; MARGIN: 0px; TEXT-TRANSFORM: none; PADDING-TOP: =
5px; LIST-STYLE-TYPE: none; TEXT-ALIGN: left
}
DIV.ab-ad UL UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: 5px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
DIV.ab-ad LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 2px; MARGIN: =
0px; PADDING-TOP: 2px
}
DIV.ab-ad A {
	COLOR: #0068b3
}
DIV.ab-ad A.sponsor IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px; max-width: 118px
}
DIV.ab-ad P.blurb {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
5px 5px; PADDING-TOP: 0px; TEXT-ALIGN: left
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: 7bit
Content-Location: http://www.nature.com/common/style/header_footer_smallfonts.css

#head-er .accessibility-login A.nature-link {
	FONT: bold 110%/80% Garamond, serif; WIDTH: 5em
}
#global-subject-areas H2 {
	FONT-SIZE: 80%
}
#global-subject-areas H3 {
	FONT-SIZE: 80%
}
#global-subject-areas H4 {
	FONT-SIZE: 80%
}
#global-subject-areas H5 {
	FONT-SIZE: 80%
}
DIV.ab-ad {
	FONT-SIZE: 70%
}
#global-subject-areas H3.view {
	FONT-SIZE: 70%
}
#global-subject-areas H4.view {
	FONT-SIZE: 70%
}
#global-subject-areas H5.view {
	FONT-SIZE: 70%
}
#global-subject-areas UL {
	FONT-SIZE: 70%
}
#head-er .accessibility-login .jumplinks {
	FONT-SIZE: 70%
}
#head-er DIV.logon {
	FONT-SIZE: 70%
}
#head-er .user-services {
	FONT-SIZE: 70%
}
#head-er .publications {
	FONT-SIZE: 70%
}
#head-er .search FORM A {
	FONT-SIZE: 70%
}
#head-er .publications-search LABEL {
	FONT-SIZE: 70%
}
#head-er INPUT {
	FONT-SIZE: 70%
}
#head-er SELECT {
	FONT-SIZE: 70%
}
#foot-er {
	FONT-SIZE: 70%
}
.box#natjob H2.natjob {
	FONT-SIZE: 90%
}
.box#natprod H2.natprod {
	FONT-SIZE: 90%
}
.box#natjob UL.natjob LI H3 {
	FONT-SIZE: 80%
}
.box#natjob DIV.natjobmore {
	FONT-SIZE: 80%
}
.box#natprod DIV.natprodmore INPUT {
	FONT-SIZE: 80%
}
UL.natjob UL {
	FONT-SIZE: 70%
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/nature/style/site.css

#head-er .image-user-services-wrap {
	BACKGROUND-COLOR: #db1a21
}
#head-er .image-user-services IMG.journal-header {
	WIDTH: 419px
}
#head-er .image-user-services {
	BACKGROUND: url(/nature/images/journal_header_bg.jpg) no-repeat right =
top
}
#head-er .user-services A {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #000 no-repeat =
right center
}
#head-er .user-services A:hover {
	BACKGROUND: url(/common/images/icons/fff/arrow_s.gif) #666 no-repeat =
right center
}
A:link {
	COLOR: #36c
}
A:visited {
	COLOR: #639
}
A:hover {
	COLOR: #db1a21
}
#header-login {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#header-login IMG.journal-header {
	MARGIN-TOP: 19px; WIDTH: 419px; HEIGHT: 74px
}
#header-login {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A:hover {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A.on {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI A.on:visited {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI UL.subnav LI.on {
	BACKGROUND-COLOR: #db1a21
}
MAP.journal-nav UL LI UL.subnav A:hover {
	BACKGROUND-COLOR: #db1a21
}
H2.society-resources {
	BACKGROUND-COLOR: #db1a21
}
UL.society-resources A:hover {
	BACKGROUND-COLOR: #db1a21
}
H1.page {
	BACKGROUND-COLOR: #db1a21
}
#articlenav H2 {
	BACKGROUND-COLOR: #db1a21
}
#about #content H2 {
	BACKGROUND-COLOR: #db1a21
}
#article-related #journal-header {
	BACKGROUND-COLOR: #db1a21
}
#article-related A.back-to-article:hover {
	BACKGROUND-COLOR: #db1a21
}
#toc #content H4.area {
	COLOR: #db1a21
}
#aop #content H4.area {
	COLOR: #db1a21
}
#article #content #References OL {
	LIST-STYLE-TYPE: decimal
}
.subnav {
	DISPLAY: none
}
.home .jn-home .subnav {
	DISPLAY: block
}
.about-cover .jn-home .subnav {
	DISPLAY: block
}
.aop .jn-aop .subnav {
	DISPLAY: block
}
.about-aop .jn-aop .subnav {
	DISPLAY: block
}
.supplements .jn-supplements .subnav {
	DISPLAY: block
}
.insights .jn-supplements .subnav {
	DISPLAY: block
}
.outlooks .jn-supplements .subnav {
	DISPLAY: block
}
.collections .jn-supplements .subnav {
	DISPLAY: block
}
.tech-features .jn-supplements .subnav {
	DISPLAY: block
}
.web-focuses .jn-web-focuses .subnav {
	DISPLAY: block
}
.biological-sciences .jn-web-focuses .subnav {
	DISPLAY: block
}
.earth-environment .jn-web-focuses .subnav {
	DISPLAY: block
}
.physical-sciences .jn-web-focuses .subnav {
	DISPLAY: block
}
.science-politics .jn-web-focuses .subnav {
	DISPLAY: block
}
.science-culture .jn-web-focuses .subnav {
	DISPLAY: block
}
.multimedia .jn-multimedia .subnav {
	DISPLAY: block
}
.podcast .jn-multimedia .subnav {
	DISPLAY: block
}
.video .jn-multimedia .subnav {
	DISPLAY: block
}
.google .jn-multimedia .subnav {
	DISPLAY: block
}
.blogs .jn-multimedia .subnav {
	DISPLAY: block
}
.about-journal .jn-about-journal .subnav {
	DISPLAY: block
}
.contact-journal .jn-about-journal .subnav {
	DISPLAY: block
}
.about-editors .jn-about-journal .subnav {
	DISPLAY: block
}
.nature-family .jn-about-journal .subnav {
	DISPLAY: block
}
.first-issue .jn-about-journal .subnav {
	DISPLAY: block
}
.for-advertisers .jn-about-journal .subnav {
	DISPLAY: block
}
.for-librarians .jn-about-journal .subnav {
	DISPLAY: block
}
.for-authors-and-referees .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.getting-published .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.guide-authors .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.publication-policies .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.submissions .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.for-referees .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
.publishing .jn-for-authors-and-referees .subnav {
	DISPLAY: block
}
MAP.journal-nav UL LI UL.subnav LI {
	BACKGROUND: url(/common/images/nav_dots2.gif) #fcf6f6 no-repeat 11px =
5px
}
.home .jn-home {
	BACKGROUND-COLOR: #db1a21
}
.about-cover .jn-home .subnav .jn-about-cover {
	BACKGROUND-COLOR: #db1a21
}
.aop .jn-aop {
	BACKGROUND-COLOR: #db1a21
}
.about-aop .jn-aop .subnav .jn-about-aop {
	BACKGROUND-COLOR: #db1a21
}
.issue .jn-issue {
	BACKGROUND-COLOR: #db1a21
}
.archive .jn-archive {
	BACKGROUND-COLOR: #db1a21
}
.supplements .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.insights .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.insights .jn-supplements .subnav .jn-insights {
	BACKGROUND-COLOR: #db1a21
}
.outlooks .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.outlooks .jn-supplements .subnav .jn-outlooks {
	BACKGROUND-COLOR: #db1a21
}
.collections .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.collections .jn-supplements .subnav .jn-collections {
	BACKGROUND-COLOR: #db1a21
}
.tech-features .jn-supplements {
	BACKGROUND-COLOR: #db1a21
}
.tech-features .jn-supplements .subnav .jn-tech-features {
	BACKGROUND-COLOR: #db1a21
}
.web-focuses .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.biological-sciences .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.biological-sciences .jn-web-focuses .subnav .jn-biological-sciences {
	BACKGROUND-COLOR: #db1a21
}
.earth-environment .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.earth-environment .jn-web-focuses .subnav .jn-earth-environment {
	BACKGROUND-COLOR: #db1a21
}
.physical-sciences .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.physical-sciences .jn-web-focuses .subnav .jn-physical-sciences {
	BACKGROUND-COLOR: #db1a21
}
.science-politics .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.science-politics .jn-web-focuses .subnav .jn-science-politics {
	BACKGROUND-COLOR: #db1a21
}
.science-culture .jn-web-focuses {
	BACKGROUND-COLOR: #db1a21
}
.science-culture .jn-web-focuses .subnav .jn-science-culture {
	BACKGROUND-COLOR: #db1a21
}
.multimedia .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.podcast .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.podcast .jn-multimedia .subnav .jn-podcast {
	BACKGROUND-COLOR: #db1a21
}
.video .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.video .jn-multimedia .subnav .jn-video {
	BACKGROUND-COLOR: #db1a21
}
.google .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.google .jn-multimedia .subnav .jn-google {
	BACKGROUND-COLOR: #db1a21
}
.blogs .jn-multimedia {
	BACKGROUND-COLOR: #db1a21
}
.blogs .jn-multimedia .subnav .jn-blogs {
	BACKGROUND-COLOR: #db1a21
}
.about-journal .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.contact-journal .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.contact-journal .jn-about-journal .subnav .jn-contact-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-editors .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-editors .jn-about-journal .subnav .jn-about-editors {
	BACKGROUND-COLOR: #db1a21
}
.nature-family .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.nature-family .jn-about-journal .subnav .jn-nature-family {
	BACKGROUND-COLOR: #db1a21
}
.first-issue .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.first-issue .jn-about-journal .subnav .jn-first-issue {
	BACKGROUND-COLOR: #db1a21
}
.for-advertisers .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.for-advertisers .jn-about-journal .subnav .jn-for-advertisers {
	BACKGROUND-COLOR: #db1a21
}
.for-librarians .jn-about-journal {
	BACKGROUND-COLOR: #db1a21
}
.for-librarians .jn-about-journal .subnav .jn-for-librarians {
	BACKGROUND-COLOR: #db1a21
}
.for-authors-and-referees .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.getting-published .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.getting-published .jn-for-authors-and-referees .subnav =
.jn-getting-published {
	BACKGROUND-COLOR: #db1a21
}
.guide-authors .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.guide-authors .jn-for-authors-and-referees .subnav .jn-guide-authors {
	BACKGROUND-COLOR: #db1a21
}
.publication-policies .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.publication-policies .jn-for-authors-and-referees .subnav =
.jn-publication-policies {
	BACKGROUND-COLOR: #db1a21
}
.submissions .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.submissions .jn-for-authors-and-referees .subnav .jn-submissions {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-authors-and-referees .subnav .jn-for-referees {
	BACKGROUND-COLOR: #db1a21
}
.publishing .jn-for-authors-and-referees {
	BACKGROUND-COLOR: #db1a21
}
.publishing .jn-for-authors-and-referees .subnav .jn-scientists {
	BACKGROUND-COLOR: #db1a21
}
.press-releases .jn-press-releases {
	BACKGROUND-COLOR: #db1a21
}
.for-authors .jn-for-authors {
	BACKGROUND-COLOR: #db1a21
}
.for-referees .jn-for-referees {
	BACKGROUND-COLOR: #db1a21
}
.about-the-journal .jn-about-the-journal {
	BACKGROUND-COLOR: #db1a21
}
.about-cover .jn-home .subnav .jn-about-cover {
	BACKGROUND-COLOR: #db1a21
}
.about-aop .jn-aop .subnav .jn-about-aop A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.insights .jn-supplements .subnav .jn-insights A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.outlooks .jn-supplements .subnav .jn-outlooks A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.collections .jn-supplements .subnav .jn-collections A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.tech-features .jn-supplements .subnav .jn-tech-features A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.biological-sciences .jn-web-focuses .subnav .jn-biological-sciences A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.earth-environment .jn-web-focuses .subnav .jn-earth-environment A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.physical-sciences .jn-web-focuses .subnav .jn-physical-sciences A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.science-politics .jn-web-focuses .subnav .jn-science-politics A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.science-culture .jn-web-focuses .subnav .jn-science-culture A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.podcast .jn-multimedia .subnav .jn-podcast A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.video .jn-multimedia .subnav .jn-video A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.google .jn-multimedia .subnav .jn-google A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.blogs .jn-multimedia .subnav .jn-blogs A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.contact-journal .jn-about-journal .subnav .jn-contact-journal A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.about-editors .jn-about-journal .subnav .jn-about-editors A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.nature-family .jn-about-journal .subnav .jn-nature-family A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.first-issue .jn-about-journal .subnav .jn-first-issue A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-advertisers .jn-about-journal .subnav .jn-for-advertisers A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-librarians .jn-about-journal .subnav .jn-for-librarians A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.getting-published .jn-for-authors-and-referees .subnav =
.jn-getting-published A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.guide-authors .jn-for-authors-and-referees .subnav .jn-guide-authors A =
{
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.publication-policies .jn-for-authors-and-referees .subnav =
.jn-publication-policies A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.submissions .jn-for-authors-and-referees .subnav .jn-submissions A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.for-referees .jn-for-authors-and-referees .subnav .jn-for-referees A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.publishing .jn-for-authors-and-referees .subnav .jn-scientists A {
	BACKGROUND: url(/common/images/nav_dots1.gif) #db1a21 no-repeat 11px =
5px; COLOR: #fff! important
}
.home .jn-home A:link {
	COLOR: #fff
}
.home .jn-home A:visited {
	COLOR: #fff
}
.aop .jn-aop A:link {
	COLOR: #fff
}
.aop .jn-aop A:visited {
	COLOR: #fff
}
.issue .jn-issue A:link {
	COLOR: #fff
}
.issue .jn-issue A:visited {
	COLOR: #fff
}
.archive .jn-archive A:link {
	COLOR: #fff
}
.archive .jn-archive A:visited {
	COLOR: #fff
}
.supplements .jn-supplements A:link {
	COLOR: #fff
}
.supplements .jn-supplements A:visited {
	COLOR: #fff
}
.insights .jn-supplements A:link {
	COLOR: #fff
}
.insights .jn-supplements A:visited {
	COLOR: #fff
}
.outlooks .jn-supplements A:link {
	COLOR: #fff
}
.outlooks .jn-supplements A:visited {
	COLOR: #fff
}
.collections .jn-supplements A:link {
	COLOR: #fff
}
.collections .jn-supplements A:visited {
	COLOR: #fff
}
.tech-features .jn-supplements A:link {
	COLOR: #fff
}
.tech-features .jn-supplements A:visited {
	COLOR: #fff
}
.web-focuses .jn-web-focuses A:link {
	COLOR: #fff
}
.web-focuses .jn-web-focuses A:visited {
	COLOR: #fff
}
.biological-sciences .jn-web-focuses A:link {
	COLOR: #fff
}
.biological-sciences .jn-web-focuses A:visited {
	COLOR: #fff
}
.earth-environment .jn-web-focuses A:link {
	COLOR: #fff
}
.earth-environment .jn-web-focuses A:visited {
	COLOR: #fff
}
.physical-sciences .jn-web-focuses A:link {
	COLOR: #fff
}
.physical-sciences .jn-web-focuses A:visited {
	COLOR: #fff
}
.science-politics .jn-web-focuses A:link {
	COLOR: #fff
}
.science-politics .jn-web-focuses A:visited {
	COLOR: #fff
}
.science-culture .jn-web-focuses A:link {
	COLOR: #fff
}
.science-culture .jn-web-focuses A:visited {
	COLOR: #fff
}
.multimedia .jn-multimedia A:link {
	COLOR: #fff
}
.multimedia .jn-multimedia A:visited {
	COLOR: #fff
}
.podcast .jn-multimedia A:link {
	COLOR: #fff
}
.podcast .jn-multimedia A:visited {
	COLOR: #fff
}
.video .jn-multimedia A:link {
	COLOR: #fff
}
.video .jn-multimedia A:visited {
	COLOR: #fff
}
.google .jn-multimedia A:link {
	COLOR: #fff
}
.google .jn-multimedia A:visited {
	COLOR: #fff
}
.blogs .jn-multimedia A:link {
	COLOR: #fff
}
.blogs .jn-multimedia A:visited {
	COLOR: #fff
}
.about-journal .jn-about-journal A:link {
	COLOR: #fff
}
.about-journal .jn-about-journal A:visited {
	COLOR: #fff
}
.contact-journal .jn-about-journal A:link {
	COLOR: #fff
}
.contact-journal .jn-about-journal A:visited {
	COLOR: #fff
}
.about-editors .jn-about-journal A:link {
	COLOR: #fff
}
.about-editors .jn-about-journal A:visited {
	COLOR: #fff
}
.nature-family .jn-about-journal A:link {
	COLOR: #fff
}
.nature-family .jn-about-journal A:visited {
	COLOR: #fff
}
.first-issue .jn-about-journal A:link {
	COLOR: #fff
}
.first-issue .jn-about-journal A:visited {
	COLOR: #fff
}
.for-advertisers .jn-about-journal A:link {
	COLOR: #fff
}
.for-advertisers .jn-about-journal A:visited {
	COLOR: #fff
}
.for-librarians .jn-about-journal A:link {
	COLOR: #fff
}
.for-librarians .jn-about-journal A:visited {
	COLOR: #fff
}
.for-authors-and-referees .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.for-authors-and-referees .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.getting-published .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.getting-published .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.guide-authors .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.guide-authors .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.publication-policies .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.publication-policies .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.submissions .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.submissions .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.for-referees .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.for-referees .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.publishing .jn-for-authors-and-referees A:link {
	COLOR: #fff
}
.publishing .jn-for-authors-and-referees A:visited {
	COLOR: #fff
}
.press-releases .jn-press-releases A:link {
	COLOR: #fff
}
.press-releases .jn-press-releases A:visited {
	COLOR: #fff
}
.for-authors .jn-for-authors A:link {
	COLOR: #fff
}
.for-authors .jn-for-authors A:visited {
	COLOR: #fff
}
.for-referees .jn-for-referees A:link {
	COLOR: #fff
}
.for-referees .jn-for-referees A:visited {
	COLOR: #fff
}
.about-the-journal .jn-about-the-journal A:link {
	COLOR: #fff
}
.about-the-journal .jn-about-the-journal A:visited {
	COLOR: #fff
}
.jn-about-the-journal {
	MARGIN-TOP: 1em
}
HR.separator {
	DISPLAY: block; VISIBILITY: hidden
}
#toc #content H4.subject {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 1em 0px -1em; =
TEXT-TRANSFORM: uppercase; COLOR: #db1a21
}
#aop #content H4.subject {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 1em 0px -1em; =
TEXT-TRANSFORM: uppercase; COLOR: #db1a21
}
DIV.ad-top {
	CLEAR: both; PADDING-RIGHT: 0px; BORDER-TOP: #eaeaea 1px solid; =
PADDING-LEFT: 0px; FONT-SIZE: 70%; BACKGROUND: #fff; PADDING-BOTTOM: =
7px; COLOR: #ccc; PADDING-TOP: 7px; TEXT-ALIGN: center
}
DIV.ad-top IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN: 0px; WIDTH: 100%; HEIGHT: 90px; BORDER-RIGHT-WIDTH: 0px; =
max-width: 728px
}
#logged-in {
	BACKGROUND-COLOR: #fceeee
}
#logged-in A {
	COLOR: #000
}
#login {
	BACKGROUND-COLOR: #fceeee
}
#login A {
	COLOR: #000
}
#login INPUT.button {
	BACKGROUND: #db1a21
}
#search A.adsearch:link {
	COLOR: #000
}
#search A.adsearch:visited {
	COLOR: #000
}
#search A.adsearch:hover {
	COLOR: #db1a21
}
DIV.account-buttons A:link {
	BORDER-RIGHT: #333 0.2em solid; BORDER-TOP: #eceae7 0.2em solid; =
BORDER-LEFT: #eceae7 0.2em solid; COLOR: #fff; BORDER-BOTTOM: #333 0.2em =
solid; BACKGROUND-COLOR: #757575
}
DIV.account-buttons A:visited {
	BORDER-RIGHT: #333 0.2em solid; BORDER-TOP: #eceae7 0.2em solid; =
BORDER-LEFT: #eceae7 0.2em solid; COLOR: #fff; BORDER-BOTTOM: #333 0.2em =
solid; BACKGROUND-COLOR: #757575
}
DIV.account-buttons A:hover {
	BORDER-LEFT-COLOR: #333; BORDER-BOTTOM-COLOR: #eceae7; COLOR: #fff; =
BORDER-TOP-COLOR: #333; BACKGROUND-COLOR: #757575; BORDER-RIGHT-COLOR: =
#eceae7
}
 HTML #breadcrumb DIV {
	PADDING-LEFT: 18.4%
}
#breadcrumb DIV {
	PADDING-LEFT: 18.6%; BACKGROUND: #fceeee
}
H1.page-header {
	FONT-SIZE: 120%; TEXT-TRANSFORM: none; BORDER-BOTTOM-STYLE: none
}
H1.page-header A:link {
	TEXT-DECORATION: none
}
H1.page-header A:visited {
	TEXT-DECORATION: none
}
H1.page-header SPAN.first {
	FONT-WEIGHT: bold; FONT-SIZE: 108%; TEXT-TRANSFORM: lowercase; COLOR: =
#f44; FONT-FAMILY: georgia, garamond; LETTER-SPACING: -0.02em
}
H1.page-header SPAN.second {
	FONT-WEIGHT: bold; FONT-SIZE: 108%; TEXT-TRANSFORM: lowercase; COLOR: =
#000; FONT-FAMILY: georgia, garamond; LETTER-SPACING: -0.02em
}
SPAN.page-header-spacer {
	FONT-SIZE: 120%; PADDING-BOTTOM: 4px
}
 HTML #content DIV.online-only-header {
	TOP: -2.2em
}
#content DIV.online-only-header {
	FLOAT: right; WIDTH: 16em; POSITION: relative; TOP: -2.3em; TEXT-ALIGN: =
right
}
#content DIV.online-only-header SPAN {
	PADDING-LEFT: 15px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center; COLOR: =
#666
}
DIV.hr {
	MARGIN: 1em 0px
}
DIV.hr-blank {
	MARGIN: 1em 0px; HEIGHT: 1px
}
HR {
	DISPLAY: none
}
DIV.ad-vert IMG {
	max-width: 160px
}
DIV.ad-vert {
	BACKGROUND: #eaeaea
}
DIV.ad-horiz {
	BORDER-TOP-STYLE: none
}
#content DIV.ad-box {
	TEXT-ALIGN: center
}
#content DIV.ad-box P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; PADDING-BOTTOM: =
4px; MARGIN: 0px; COLOR: #999; PADDING-TOP: 0px; BACKGROUND-COLOR: =
#eaeaea
}
#content DIV.x300x250 {
	CLEAR: right; FLOAT: right; MARGIN: 15px 0px 0px 10px; WIDTH: 300px! =
important
}
A.backtotop:link {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat 0px 0.6em; =
COLOR: #000; MARGIN-RIGHT: 0px; TEXT-DECORATION: none
}
A.backtotop:visited {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat 0px 0.6em; =
COLOR: #000; MARGIN-RIGHT: 0px; TEXT-DECORATION: none
}
A.backtotop:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#content SPAN.english {
	DISPLAY: block
}
#content SPAN.japanese {
	DISPLAY: block
}
#content .japanese {
	FONT-WEIGHT: normal! important; LINE-HEIGHT: 150%
}
 HTML #content-journalnav #content DIV.issue H2 {
	POSITION: relative
}
#content H2 SPAN.japanese {
	FONT-SIZE: 130%! important
}
#article #content H2#atl SPAN.english {
	FONT-SIZE: 90%
}
#content H4 SPAN.japanese {
	FONT-SIZE: 120%! important
}
#content H4 SPAN.english {
	FONT-SIZE: 90%! important; COLOR: #2d2d2d
}
#content DIV.container DIV.entry P.links A.japanese:link {
	FONT-SIZE: 120%! important
}
#content DIV.container DIV.entry P.links A.japanese:visited {
	FONT-SIZE: 120%! important
}
#content P.japanese {
	FONT-SIZE: 100%! important
}
#content P.english {
	FONT-WEIGHT: normal! important
}
#content DIV.no-header {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV.no-header-art {
	PADDING-RIGHT: 0px; MARGIN-TOP: -2em; PADDING-LEFT: 0px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV.no-header2 {
	PADDING-RIGHT: 1px; MARGIN-TOP: 2em; PADDING-LEFT: 1px; PADDING-BOTTOM: =
1px; PADDING-TOP: 1px
}
#content DIV.no-header3 {
	PADDING-RIGHT: 1px; MARGIN-TOP: 1em; PADDING-LEFT: 1px; MARGIN-BOTTOM: =
1em; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
#content P.links A.fulltext {
	FONT-WEIGHT: bold
}
 HTML #content TABLE.data {
	FONT-SIZE: 110%; MARGIN: 1em 0px 0px
}
#content TABLE.data {
	CLEAR: both; BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #999 1px solid; PADDING-LEFT: 10px; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px =
solid
}
#content TABLE.data TD {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 3px
}
#content TABLE.data TH {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; PADDING-BOTTOM: 3px; =
PADDING-TOP: 3px
}
 HTML #content TABLE.data CAPTION {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 0px
}
#content TABLE.data CAPTION {
	PADDING-RIGHT: 0px; PADDING-LEFT: 20px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 5px; MARGIN: 1em 0px 0px; PADDING-TOP: 0px; =
TEXT-ALIGN: left
}
 HTML #content TABLE.data THEAD TH {
	BORDER-TOP-WIDTH: 0px
}
 HTML #content TABLE.data THEAD TD {
	BORDER-TOP-WIDTH: 0px
}
#content TABLE.data THEAD TH {
	BORDER-TOP: #d6d6d6 1px solid; BORDER-BOTTOM: #d6d6d6 1px solid
}
#content TABLE.data THEAD TD {
	BORDER-TOP: #d6d6d6 1px solid; BORDER-BOTTOM: #d6d6d6 1px solid
}
#content TABLE.data TR.odd {
	BACKGROUND-COLOR: #efefef
}
#content TABLE.data TH {
	FONT-WEIGHT: bold; FONT-SIZE: 80%
}
#content TABLE.data TD {
	FONT-SIZE: 80%
}
UL.anchor {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; PADDING-BOTTOM: =
0px; MARGIN: 1em 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
UL.anchor A:link {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat 0px 0.5em
}
UL.anchor A:visited {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat 0px 0.5em
}
UL.anchor A:hover {
	BACKGROUND: url(/common/images/icons/c03/arrow_down.gif) no-repeat 0px =
0.5em
}
UL.anchor A.out:link {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
UL.anchor A.out:visited {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
UL.anchor A.out:hover {
	BACKGROUND: url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em
}
#content UL.anchor UL {
	LIST-STYLE-TYPE: none
}
#content DIV.prevnext {
	CLEAR: both; BORDER-RIGHT: black 1px solid; BORDER-TOP: black 0px =
solid; BACKGROUND: #fff; BORDER-LEFT: black 1px solid; BORDER-BOTTOM: =
black 1px solid; TEXT-ALIGN: center
}
 HTML #content DIV.prevnext {
	HEIGHT: 1%
}
#content DIV.prevnext .hide {
	DISPLAY: none
}
#content DIV.prevnext A:link {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#content DIV.prevnext A:visited {
	FONT-SIZE: 70%; COLOR: #000; TEXT-DECORATION: none
}
#content DIV.prevnext A:hover {
	COLOR: #db1a21; TEXT-DECORATION: none
}
#content A.previous:link {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#content A.previous:visited {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center; FLOAT: left; PADDING-BOTTOM: 2px; MARGIN-LEFT: 10px; =
PADDING-TOP: 2px
}
#content A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#content A.japanese:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.japanese:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.japanese:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/fff/japanese.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#content A.english:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.english:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.english:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 15px; PADDING-BOTTOM: 2px; =
PADDING-TOP: 2px
}
#content A.next:link {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black.gif) no-repeat right center; FLOAT: =
right; PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: =
10px; PADDING-TOP: 2px
}
#content A.next:visited {
	PADDING-RIGHT: 10px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black.gif) no-repeat right center; FLOAT: =
right; PADDING-BOTTOM: 2px; BORDER-LEFT: black 1px solid; MARGIN-RIGHT: =
10px; PADDING-TOP: 2px
}
#content A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#content OL.norm {
	FONT-SIZE: 90%
}
#content UL.norm {
	FONT-SIZE: 90%
}
.icon-inline {
	BACKGROUND-POSITION: left center; PADDING-LEFT: 17px; =
BACKGROUND-REPEAT: no-repeat
}
#content .download-pdf {
	BACKGROUND-IMAGE: url(/common/images/download_pdf.gif)
}
#content DIV.divider {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 1em; MARGIN: =
0px; PADDING-TOP: 1em
}
H2.npg-resources {
	BACKGROUND-COLOR: #757575
}
UL.npg-resources A:hover {
	BACKGROUND-COLOR: #757575
}
#extranav DIV.subscribe-to-nature {
	MARGIN-BOTTOM: 1em; BACKGROUND-COLOR: #eaeaea; TEXT-ALIGN: center
}
#extranav DIV.subscribe-to-nature IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px
}
#extranav DIV.produced-with-support {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; MARGIN-BOTTOM: 1em; =
PADDING-BOTTOM: 5px; BORDER-LEFT: #666 1px solid; PADDING-TOP: 5px; =
BORDER-BOTTOM: #666 1px solid
}
#extranav DIV.produced-with-support IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 100%; BORDER-RIGHT-WIDTH: 0px
}
#extranav DIV.produced-with-support H2 {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px 0px 5px; COLOR: #666
}
#extranav DIV.extra {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: black =
1px solid; PADDING-LEFT: 5px; PADDING-BOTTOM: 5px; MARGIN: 1em 0px; =
BORDER-LEFT: black 1px solid; PADDING-TOP: 5px; BORDER-BOTTOM: black 1px =
solid
}
#extranav DIV.pink {
	BACKGROUND-COLOR: #fceeee
}
#extranav DIV.pink LI {
	BORDER-BOTTOM: #fceeee 1px solid
}
#extranav DIV.grey {
	BACKGROUND-COLOR: #eaeaea
}
#extranav DIV.grey LI {
	BORDER-BOTTOM: #eaeaea 1px solid
}
#extranav DIV.blue {
	BACKGROUND-COLOR: #f7f9fd
}
#extranav DIV.blue LI {
	BORDER-BOTTOM: #f7f9fd 1px solid
}
#extranav DIV.extra H2 {
	FONT-SIZE: 70%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px 0px 0.5em; COLOR: #db1a21; TEXT-ALIGN: left
}
#extranav DIV.extra UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; BACKGROUND-COLOR: =
transparent
}
#extranav DIV.extra LI {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
2px; PADDING-TOP: 2px; BACKGROUND-COLOR: transparent
}
#extranav DIV.extra LI A:link {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em; COLOR: #36c; =
TEXT-DECORATION: underline
}
#extranav DIV.extra LI A:visited {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em; COLOR: #36c; =
TEXT-DECORATION: underline
}
#extranav DIV.extra LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.extra UL LI.more A:link {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.extra UL LI.more A:visited {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#extranav DIV.books {
	BORDER-RIGHT: #fcc 1px solid; BORDER-TOP: #fcc 1px solid; BORDER-LEFT: =
#fcc 1px solid; BORDER-BOTTOM: #fcc 1px solid
}
#extranav DIV.books H3 {
	FONT-SIZE: 70%; MARGIN-BOTTOM: 0px
}
#extranav DIV.books H4 {
	DISPLAY: inline; FONT-WEIGHT: normal; FONT-SIZE: 70%
}
#extranav DIV.books DIV.image {
	MARGIN-TOP: 10px; TEXT-ALIGN: center
}
#extranav DIV.books UL {
	DISPLAY: inline
}
#extranav DIV.books UL LI {
	DISPLAY: inline
}
#extranav DIV.books DIV.border-top {
	BORDER-TOP: #fcc 1px solid; PADDING-TOP: 15px
}
#extranav DIV.books LI A:link {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A:visited {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A:hover {
	DISPLAY: inline; BACKGROUND: none transparent scroll repeat 0% 0%; =
BORDER-LEFT: #000 1px solid
}
#extranav DIV.books LI A.first:link {
	BORDER-LEFT-WIDTH: 0px
}
#extranav DIV.books LI A.first:visited {
	BORDER-LEFT-WIDTH: 0px
}
#extranav DIV.books LI A.first:hover {
	BORDER-LEFT-WIDTH: 0px
}
.collapse {
	WIDTH: 100%
}
DIV.nature-marketing {
	CLEAR: both; BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #999 1px solid; MARGIN-TOP: 1em; PADDING-LEFT: 10px; =
BACKGROUND: #fceeee; PADDING-BOTTOM: 10px; BORDER-LEFT: #999 1px solid; =
PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px solid
}
DIV.nature-marketing H1 {
	FONT-SIZE: 90%; MARGIN: 0px
}
DIV.nature-marketing IMG {
	FLOAT: right
}
DIV.nature-marketing P {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
DIV.nature-marketing A.subscribe {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; COLOR: =
#db1a21
}
H2.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
H3.page {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
MAP.journal-nav UL LI {
	BACKGROUND-COLOR: #fceeee
}
#home #journalnav .image-holder {
	TEXT-ALIGN: center
}
#home #journalnav .image-holder IMG {
	MARGIN-BOTTOM: 10px
}
#home #journalnav .google {
	BORDER-RIGHT: #ccc 1px solid; BORDER-TOP: #ccc 1px solid; MARGIN: 20px =
0px; BORDER-LEFT: #ccc 1px solid; BORDER-BOTTOM: #ccc 1px solid; =
TEXT-ALIGN: center
}
#home #content DIV.issue {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #666 1px =
solid
}
#home #content DIV.issue DIV.cover {
	FLOAT: left; WIDTH: 152px! important; MARGIN-RIGHT: 10px
}
#home #content DIV.issue DIV.issue-links {
	MARGIN-LEFT: 162px
}
#home #content DIV.issue P {
	FONT-SIZE: 90%
}
#home #content DIV.issue IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 150px! important; BORDER-BOTTOM: =
#666 1px solid; HEIGHT: 200px! important
}
#home #content DIV.issue H1 {
	FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px
}
#home #content DIV.issue-links UL.issue-links {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 10px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#home #content DIV.issue-links UL.issue-links LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 4px; PADDING-TOP: 4px
}
#home #content DIV.issue H1 SPAN.title {
	DISPLAY: block; FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #c33
}
#home #content DIV.issue H1 SPAN.issue {
	FONT-SIZE: 90%
}
#home #content DIV.issue UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#home #content DIV.issue H2 {
	FONT-SIZE: 70%; MARGIN: 0px; COLOR: #c33
}
#home #content DIV.article {
	PADDING-BOTTOM: 1em; MARGIN: 1em 0px
}
#home #content DIV.article .image {
	FLOAT: left; WIDTH: 163px! important; MARGIN-RIGHT: 10px
}
#home #content DIV.article .image IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 161px! important; BORDER-BOTTOM: =
#666 1px solid
}
#home #content DIV.article .image2 IMG {
	BORDER-RIGHT: #666 0px solid; BORDER-TOP: #666 0px solid; FLOAT: left; =
BORDER-LEFT: #666 0px solid; WIDTH: 161px! important; BORDER-BOTTOM: =
#666 0px solid
}
#home #content DIV.article .text {
	MARGIN-LEFT: 173px
}
#home #content DIV.article H1 {
	FONT-WEIGHT: bold; FONT-SIZE: 100%
}
#home #content DIV.article H1 SPAN.title {
	DISPLAY: block; FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #c33
}
#home #content DIV.article H1 SPAN.atl {
	FONT-SIZE: 90%
}
#home #content DIV.article P {
	FONT-SIZE: 90%
}
#home #content .featurebox {
	MARGIN-BOTTOM: 20px
}
#home #content DIV.left {
	FLOAT: left; WIDTH: 48%
}
#home #content DIV.right {
	FLOAT: right; WIDTH: 48%
}
#home #content .featurebox UL {
	CLEAR: both; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 80%; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
#home #content .featurebox A.more {
	MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#home #content .featurebox H1 {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-SIZE: 70%; BACKGROUND: =
#db1a21; PADDING-BOTTOM: 3px; TEXT-TRANSFORM: uppercase; COLOR: #fff; =
PADDING-TOP: 3px
}
#home #content .news H1 {
	MARGIN: 0px 0px 10px
}
#home #content .highlight H1 {
	MARGIN: 0px 0px 10px
}
#home #content .news H2 {
	FONT-SIZE: 70%; MARGIN: 1em 0px 0.5em; TEXT-TRANSFORM: uppercase
}
#home #content .highlight H2 {
	FONT-SIZE: 70%; MARGIN: 1em 0px 0.5em; TEXT-TRANSFORM: uppercase
}
#home #content .news A.imagelink {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN-LEFT: 60px
}
#home #content .highlight A.imagelink {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN-LEFT: 60px
}
#home #content .news IMG.newsimage {
	FLOAT: left; WIDTH: 50px; HEIGHT: 50px
}
#home #content .highlight IMG.newsimage {
	FLOAT: left; WIDTH: 50px; HEIGHT: 50px
}
#home #content .news UL {
	MARGIN: 1em 0px 0px
}
#home #content .news LI {
	MARGIN: 1em 0px
}
#home #content .webfocus H1 {
	MARGIN-BOTTOM: 1px
}
#home #content .topten H1 {
	MARGIN-BOTTOM: 1px
}
#home #content .webfocus .title {
	MARGIN-TOP: 0px
}
#home #content .webfocus H2 {
	PADDING-RIGHT: 5px; PADDING-LEFT: 70px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; MIN-HEIGHT: 55px! important; PADDING-BOTTOM: 0px; MARGIN: 0px; =
PADDING-TOP: 5px
}
#home #content .topten P.header {
	PADDING-RIGHT: 5px; PADDING-LEFT: 70px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; MIN-HEIGHT: 55px! important; PADDING-BOTTOM: 0px; MARGIN: 0px; =
PADDING-TOP: 5px
}
#home #content .webfocus P {
	FONT-SIZE: 80%; MARGIN: 1em 0px
}
#home #content .topten H2 {
	FONT-SIZE: 80%; MARGIN: 1em 0px; TEXT-TRANSFORM: uppercase
}
#home #content .topten OL {
	PADDING-LEFT: 23px; FONT-SIZE: 80%; MARGIN: 0px 0px 20px
}
#home #content .topten LI {
	MARGIN: 1em 0px
}
#home #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#home #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#home #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#home #content P.norm {
	FONT-SIZE: 90%
}
#archive #content P {
	FONT-SIZE: 90%
}
#archive #content H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; PADDING-BOTTOM: 0.3em; MARGIN: 0px; =
PADDING-TOP: 0.3em
}
#archive #content H3 SPAN {
	FONT-WEIGHT: normal; FONT-SIZE: 80%
}
#archive #content H3 A:link {
	PADDING-LEFT: 15px; BACKGROUND: url(/common/images/archive_plus.gif) =
no-repeat left center
}
#archive #content H3 A:visited {
	PADDING-LEFT: 15px; BACKGROUND: url(/common/images/archive_plus.gif) =
no-repeat left center
}
#archive #content H3 A:hover {
	BACKGROUND: url(/common/images/archive_plus_red.gif) no-repeat left =
center
}
#archive #content H3.open A:link {
	BACKGROUND: url(/common/images/archive_minus.gif) no-repeat left center
}
#archive #content H3.open A:visited {
	BACKGROUND: url(/common/images/archive_minus.gif) no-repeat left center
}
#archive #content H3.open A:hover {
	BACKGROUND: url(/common/images/archive_minus_red.gif) no-repeat left =
center
}
#archive #content H3.open {
	BACKGROUND: #f7f9fd
}
#archive #content H3.open SPAN {
	FONT-WEIGHT: bold
}
#archive #content H4 {
	PADDING-LEFT: 15px; FONT-SIZE: 80%; BACKGROUND: #f7f9fd; =
PADDING-BOTTOM: 0px; MARGIN: 0px; COLOR: #36c; PADDING-TOP: 0.2em
}
#archive #content UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: #f7f9fd; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: =
none
}
#archive #content UL.listlinks {
	FONT-SIZE: 90%; BACKGROUND: #fff; MARGIN-BOTTOM: 2em
}
#archive #content UL.listlinks A {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat left center
}
#archive #content UL.listlinks A:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#archive #content DIV.container LI {
	MARGIN-LEFT: 15px
}
#archive #content DIV.container LI A:link {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#archive #content DIV.container LI A:visited {
	PADDING-RIGHT: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#archive #content DIV.container LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#archive #content H3.abuts-h2-above {
	MARGIN-TOP: 1em
}
#archive #content H3.abuts-h2-below {
	MARGIN-BOTTOM: 1em
}
#toc #content H1.page-header SPAN.focus {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 5px; FONT-SIZE: 60%; PADDING-BOTTOM: 1px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 1px; BORDER-BOTTOM: #000 1px =
solid; POSITION: relative; TOP: -2px
}
#toc #content H1.page-header {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; FONT-SIZE: 100%; PADDING-BOTTOM: =
1px; PADDING-TOP: 1px; POSITION: relative; TOP: -2px
}
#toc #content DIV.issue {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #666 1px =
solid
}
#toc #content DIV.issue P {
	FONT-SIZE: 90%
}
#toc #content P.norm {
	FONT-SIZE: 90%
}
#toc #content DIV.issue IMG {
	BORDER-RIGHT: #666 1px solid; BORDER-TOP: #666 1px solid; FLOAT: left; =
BORDER-LEFT: #666 1px solid; WIDTH: 150px! important; MARGIN-RIGHT: =
10px; BORDER-BOTTOM: #666 1px solid; HEIGHT: 200px! important
}
#toc #content DIV.issue IMG.first-toc {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: none; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 0px 0px 10px; WIDTH: 413px! important; =
HEIGHT: 165px! important; BORDER-RIGHT-WIDTH: 0px
}
#toc #content DIV.issue DIV.first-toc-centre {
	TEXT-ALIGN: center
}
#toc #content DIV.issue P.mission {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px =
0px 1em; PADDING-TOP: 0px
}
#toc #content DIV.issue DIV.issue-links {
	FLOAT: left; WIDTH: 60%
}
#toc #content DIV.issue UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
 HTML #toc #content DIV.issue DIV.wrapper {
	WIDTH: 49%
}
#toc #content DIV.issue DIV.wrapper {
	FLOAT: left; MARGIN: 0px; WIDTH: 50%
}
#toc #content DIV.issue UL.second {
	MARGIN-LEFT: 10px
}
#toc #content DIV.issue H2 {
	MARGIN-TOP: 0px; FONT-SIZE: 100%; COLOR: #c33
}
#toc #content DIV.issue H2.insight {
	MARGIN-BOTTOM: 0px
}
#toc #content DIV.issue P.volume {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#toc #content DIV.issue H2 SPAN.free {
	FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #009c00
}
#toc #content DIV.issue H3 {
	FONT-SIZE: 90%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px; COLOR: #000
}
#toc #content DIV.issue H3.also {
	CLEAR: both; PADDING-TOP: 1em
}
#toc #content DIV.news {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 15px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 15px; PADDING-BOTTOM: 15px; MARGIN: 1em 0px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 15px; BORDER-BOTTOM: #000 1px =
solid
}
#toc #content DIV.news DIV {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fff; =
PADDING-BOTTOM: 10px; MARGIN: 0px; PADDING-TOP: 5px; opacity: 0.92
}
#toc #content DIV.news H2 {
	MARGIN: 0px; FONT: 170% georgia, serif; COLOR: #ca4439
}
#toc #content DIV.news H2 SPAN {
	COLOR: #fdb7ac
}
#toc #content DIV.news P {
	FONT-SIZE: 90%; MARGIN: 0px 0px 1em
}
#toc #content DIV.news A.special {
	DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; COLOR: =
#db1a21
}
#toc #content UL.anchor A {
	DISPLAY: block
}
#toc #content UL.anchor A.online-only {
	PADDING-LEFT: 25px; BACKGROUND: =
url(/common/images/icons/online_only_anchor.gif) no-repeat left 4px
}
#toc #content P.online-only {
	PADDING-RIGHT: 0px; PADDING-LEFT: 15px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center; =
PADDING-BOTTOM: 3px; MARGIN: 1em 0px; COLOR: #777; PADDING-TOP: 0px
}
#toc #content SPAN.online-only {
	PADDING-LEFT: 15px; BACKGROUND: =
url(/common/images/icons/online_only.gif) no-repeat left center
}
#toc #content DIV.feature {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 10px; MARGIN-BOTTOM: 2em; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #999 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #999 1px =
solid
}
#toc #content DIV.feature H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 100%; PADDING-BOTTOM: =
0.4em; MARGIN: 0px; COLOR: #c33; PADDING-TOP: 0px
}
#toc #content DIV.feature H4 {
	FONT-SIZE: 100%; MARGIN: 0.5em 0px 1em; FONT-FAMILY: Georgia, serif
}
#toc #content DIV.feature H4 SPAN {
	BORDER-RIGHT: #6c481f 1px solid; PADDING-RIGHT: 2px; BORDER-TOP: =
#6c481f 1px solid; PADDING-LEFT: 2px; FONT-SIZE: 70%; BACKGROUND: =
#ebe3db; PADDING-BOTTOM: 1px; BORDER-LEFT: #6c481f 1px solid; COLOR: =
#6c481f; MARGIN-RIGHT: 3px; PADDING-TOP: 1px; BORDER-BOTTOM: #6c481f 1px =
solid; FONT-FAMILY: Verdana, arial, helvetica, sans-serif
}
#toc #content DIV.feature H4 A:link {
	COLOR: #6c481f; TEXT-DECORATION: none
}
#toc #content DIV.feature H4 A:visited {
	COLOR: #6c481f; TEXT-DECORATION: none
}
#toc #content DIV.feature H4 A:hover {
	COLOR: #db1a21; TEXT-DECORATION: none
}
#toc #content DIV.feature IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 60px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px
}
#toc #content DIV.feature P {
	FONT-SIZE: 90%; MARGIN-LEFT: 70px
}
#toc #content DIV.feature P.no-image {
	MARGIN-LEFT: 0px
}
#toc #content DIV.clearfix P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#toc #content H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; PADDING-TOP: =
3px
}
#toc #content H4 {
	FONT-SIZE: 100%; MARGIN: 0px
}
#toc #content H4 SPAN.page {
	FONT-SIZE: 90%; COLOR: #999
}
#toc #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#toc #content H4 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#toc #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#toc #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#toc #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#toc #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#toc #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#toc #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#toc #content A.more-review {
	MARGIN-TOP: 2em; DISPLAY: block; PADDING-LEFT: 7px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/icons/c03/arrow.gif) no-repeat 0px 0.5em; =
COLOR: #db1a21
}
#toc #content DIV.insight {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 10px; BACKGROUND: #f7f9fd; PADDING-BOTTOM: 10px; =
MARGIN: 0px; BORDER-LEFT: #666 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #666 1px solid
}
#toc #content DIV.insight H3 {
	MARGIN-TOP: 0px; PADDING-TOP: 0px
}
#toc #content DIV.insight H3 SPAN {
	FONT-SIZE: 80%; TEXT-TRANSFORM: uppercase; COLOR: #009c00
}
#toc #content DIV.insight P.produced {
	FONT-SIZE: 70%; FLOAT: left; COLOR: #666
}
#toc #content DIV.insight IMG.supporters {
	FLOAT: left; MARGIN-BOTTOM: 10px; MARGIN-LEFT: 20px
}
#toc #content DIV.insight A.backtotop {
	MARGIN-TOP: 0px
}
#toc #content DIV.insight A.fulltoc {
	DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_red.gif) no-repeat left center; MARGIN: 0px 0px =
2em; COLOR: #db1a21
}
#toc #content DIV.insight A.fulltoc:hover {
	BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
COLOR: #36c
}
#aop #content H2 {
	MARGIN-BOTTOM: 1em
}
#aop #content H3 {
	FONT-SIZE: 100%; MARGIN: 0px; COLOR: #000
}
#aop #content H3.category {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#aop #content H4.atl {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; MARGIN-BOTTOM: =
0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#aop #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#aop #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#aop #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#aop #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#aop #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#aop #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#aop #content P.footer {
	FONT-SIZE: 90%
}
#aop #content P.intro {
	FONT-SIZE: 90%
}
#aop #content A.about-aop {
	FONT-SIZE: 90%
}
DIV.reg-rec UL {
	BORDER-RIGHT: #666 1px solid; PADDING-RIGHT: 6px; BORDER-TOP: #666 1px =
solid; PADDING-LEFT: 6px; PADDING-BOTTOM: 6px; MARGIN: 0px; BORDER-LEFT: =
#666 1px solid; PADDING-TOP: 6px; BORDER-BOTTOM: #666 1px solid; =
LIST-STYLE-TYPE: none; BACKGROUND-COLOR: #fceeee
}
DIV.reg-rec UL LI {
	DISPLAY: block; FONT-SIZE: 70%; MARGIN: 4px 0px
}
DIV.reg-rec UL.toc LI {
	BORDER-BOTTOM: #f7f9fd 1px solid
}
DIV.reg-rec UL LI.first {
	MARGIN-TOP: 0.1em
}
DIV.reg-rec UL LI.last {
	MARGIN-BOTTOM: 0px
}
DIV.reg-rec UL A:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 22px; PADDING-BOTTOM: =
0px; COLOR: #000; PADDING-TOP: 0px; TEXT-DECORATION: none
}
DIV.reg-rec UL A:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 22px; PADDING-BOTTOM: =
0px; COLOR: #000; PADDING-TOP: 0px; TEXT-DECORATION: none
}
DIV.reg-rec UL A:hover {
	TEXT-DECORATION: underline
}
DIV.reg-rec UL A.e-alerts {
	BACKGROUND: url(/common/images/icons/fceeee/envelope.gif) no-repeat 0px =
3px
}
DIV.reg-rec UL A.recommend {
	BACKGROUND: url(/common/images/icons/fceeee/tick.gif) no-repeat 0px 1px
}
DIV.reg-rec UL A.newsfeeds {
	BACKGROUND: url(/common/images/icons/fceeee/newsfeeds.gif) no-repeat =
0px 0px; PADDING-BOTTOM: 2px
}
DIV.reg-rec UL A.purchase {
	BACKGROUND: url(/common/images/icons/f7f9fd/purchase.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
DIV.reg-rec UL A.bookmark {
	BACKGROUND: url(/common/images/icons/f7f9fd/bookmark.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
 HTML DIV.reg-rec UL A.japanese {
	BACKGROUND: url(/common/images/icons/f7f9fd/japanese.gif) no-repeat 0px =
3px
}
DIV.reg-rec UL A.japanese {
	BACKGROUND: url(/common/images/icons/f7f9fd/japanese.gif) no-repeat 0px =
1px; PADDING-BOTTOM: 1px; PADDING-TOP: 1px
}
DIV.reg-rec UL.toc {
	BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #f7f9fd
}
#articlenav {
	DISPLAY: block; MARGIN-BOTTOM: 20px
}
#articlenav H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
70%; BACKGROUND: #db1a21; PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #fff; =
PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav DIV.prevnext {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; BACKGROUND: =
#fceeee; PADDING-BOTTOM: 3px; MARGIN: 0px; PADDING-TOP: 3px; TEXT-ALIGN: =
center
}
#articlenav DIV.prevnext A.prev {
	PADDING-LEFT: 7px; BACKGROUND: url(/common/images/arrow_black_left.gif) =
no-repeat left center
}
#articlenav DIV.prevnext A.next {
	PADDING-RIGHT: 7px; BACKGROUND: url(/common/images/arrow_black.gif) =
no-repeat right center
}
#articlenav DIV.prevnext A:link {
	COLOR: #000; TEXT-DECORATION: none
}
#articlenav DIV.prevnext A:visited {
	COLOR: #000; TEXT-DECORATION: none
}
#articlenav DIV.prevnext A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 7px; MARGIN: 1px =
0px 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none; BACKGROUND-COLOR: =
#fceeee; TEXT-ALIGN: left
}
#articlenav UL LI {
	MARGIN: 0px; BORDER-BOTTOM: #fceeee 1px solid; BACKGROUND-COLOR: =
#fceeee
}
 HTML #articlenav UL A:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 14px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav UL A:link {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 14px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_black.gif) no-repeat 5px 8px; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 3px; =
TEXT-DECORATION: none
}
#articlenav UL A:visited {
	PADDING-RIGHT: 5px; DISPLAY: block; PADDING-LEFT: 14px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_black.gif) no-repeat 5px 8px; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #000; PADDING-TOP: 3px; =
TEXT-DECORATION: none
}
#articlenav UL A:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.page {
	BACKGROUND: url(/common/images/arrow_black_down.gif) no-repeat 4px 8px
}
#articlenav UL A.page:visited {
	BACKGROUND: url(/common/images/arrow_black_down.gif) no-repeat 4px 8px
}
#articlenav UL A.page:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
 HTML #articlenav A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav A.toc:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav LI.toc {
	TEXT-ALIGN: center
}
#articlenav A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav A.toc:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 5px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 3px; PADDING-TOP: 3px; TEXT-ALIGN: center
}
#articlenav LI.fulltext {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.download-pdf {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.sendtofriend {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.export {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.permissions {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.save {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.purchase-article {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.purchase-issue {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
#articlenav LI.subscribe {
	BORDER-RIGHT: #fceeee 1px solid; BORDER-LEFT: #fceeee 1px solid; =
BORDER-BOTTOM: #fff 1px solid; BACKGROUND-COLOR: #fff
}
 HTML #articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.fulltext:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.download-pdf:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.sendtofriend:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.export:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.permissions:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.save:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-article:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.purchase-issue:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
 HTML #articlenav UL A.subscribe:hover {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 1px; =
PADDING-TOP: 1px
}
#articlenav UL A.fulltext:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.fulltext:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.sendtofriend:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.sendtofriend:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.export:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.export:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.permissions:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.permissions:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.save:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.save:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-article:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-article:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-issue:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.purchase-issue:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.subscribe:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.subscribe:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 3px; COLOR: =
#000; PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 3px
}
#articlenav UL A.download-pdf:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 27px; PADDING-BOTTOM: 5px; =
PADDING-TOP: 3px
}
#articlenav UL A.fulltext:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.download-pdf:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.sendtofriend:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.export:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.permissions:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.save:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.purchase-article:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.purchase-issue:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.subscribe:hover {
	COLOR: #000; TEXT-DECORATION: underline
}
#articlenav UL A.fulltext:link {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.fulltext:visited {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.fulltext:hover {
	BACKGROUND: url(/common/images/fulltext.gif) #fff no-repeat 5px 4px
}
#articlenav UL A.download-pdf:link {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.download-pdf:visited {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.download-pdf:hover {
	BACKGROUND: url(/common/images/icons/fff/pdf.gif) #fff no-repeat 5px =
4px
}
#articlenav UL A.sendtofriend:link {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.sendtofriend:visited {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.sendtofriend:hover {
	BACKGROUND: url(/common/images/send_to_a_friend.gif) #fff no-repeat 5px =
6px
}
#articlenav UL A.export:link {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.export:visited {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.export:hover {
	BACKGROUND: url(/common/images/icons/fff/export.gif) #fff no-repeat 5px =
1px
}
#articlenav UL A.permissions:link {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.permissions:visited {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.permissions:hover {
	BACKGROUND: url(/common/images/icons/fff/permissions.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.save:link {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.save:visited {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.save:hover {
	BACKGROUND: url(/common/images/icons/fff/connotea1.gif) #fff no-repeat =
5px 1px
}
#articlenav UL A.purchase-article:link {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-article:visited {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-article:hover {
	BACKGROUND: url(/common/images/icons/fff/purchase_article.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:link {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:visited {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.purchase-issue:hover {
	BACKGROUND: url(/common/images/icons/fff/purchase_issue.gif) #fff =
no-repeat 5px 1px
}
#articlenav UL A.subscribe:link {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav UL A.subscribe:visited {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav UL A.subscribe:hover {
	BACKGROUND: url(/common/images/icons/fff/subscribe.gif) #fff no-repeat =
5px 3px
}
#articlenav LI.last {
	PADDING-BOTTOM: 5px
}
#articlenav UL.supplementary {
	PADDING-TOP: 7px
}
#articlenav UL A.on {
	BACKGROUND: url(/common/images/arrow_white.gif) #db1a21 no-repeat 5px =
8px; COLOR: #fff
}
#articlenav UL A.on:visited {
	BACKGROUND: url(/common/images/arrow_white.gif) #db1a21 no-repeat 5px =
8px; COLOR: #fff
}
#articlenav UL A.on:hover {
	COLOR: #fff; TEXT-DECORATION: underline
}
#article #content DIV {
	PADDING-BOTTOM: 1.5em
}
#article #content DIV.hr {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px
}
#article #content H2.nibs {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#article #content H3 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#article #content H3.norm {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: none transparent =
scroll repeat 0% 0%; PADDING-BOTTOM: 0px; MARGIN: 1em 0px 0px; COLOR: =
#000; PADDING-TOP: 0px
}
#article #content H4.norm {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 1em 0px 0px
}
#article #content H3.location {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; BACKGROUND: none transparent =
scroll repeat 0% 0%; MARGIN: 1em 0px 0px; COLOR: #000
}
#article #content H5.norm {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content H5.norm {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content DIV P.norm {
	FONT-SIZE: 90%; MARGIN: 1em 0px
}
#article #content DIV Q.pullquote {
	PADDING-RIGHT: 10%; BORDER-TOP: #eaeaea 1px solid; DISPLAY: block; =
PADDING-LEFT: 10%; FONT-SIZE: 90%; PADDING-BOTTOM: 0.5em; MARGIN: 1em =
0px 0px; PADDING-TOP: 0.5em; BORDER-BOTTOM: #eaeaea 1px solid; =
TEXT-ALIGN: center
}
#article #content DIV BLOCKQUOTE.pullquote {
	PADDING-RIGHT: 10%; BORDER-TOP: #eaeaea 1px solid; PADDING-LEFT: 10%; =
FONT-SIZE: 90%; PADDING-BOTTOM: 0px; MARGIN: 1em 0px 0px; PADDING-TOP: =
0px; BORDER-BOTTOM: #eaeaea 1px solid; TEXT-ALIGN: center
}
#article #content P.follows-h4 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.follows-h5 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content DL {
	FONT-SIZE: 90%
}
#article #content #subjectcategories {
	FONT-SIZE: 70%
}
#article #content #cite {
	FONT-SIZE: 70%
}
#article #content .cite {
	FONT-SIZE: 70%
}
#article #content #errorcor {
	FONT-SIZE: 70%
}
#article #content #errorcor A {
	COLOR: #c03
}
#article #content #artsubhead {
	DISPLAY: block; FONT-SIZE: 70%
}
#article #content #atl {
	FONT-WEIGHT: normal; FONT-SIZE: 130%
}
#article #content #artnote {
	FONT-SIZE: 90%
}
#article #content #aug {
	FONT-SIZE: 90%
}
#article #content P.caff {
	FONT-SIZE: 70%
}
#article #content P.aunote {
	FONT-SIZE: 70%
}
#article #content P.tlnote {
	FONT-SIZE: 70%
}
#article #content P.prdates {
	FONT-SIZE: 70%
}
#article #content P.footnote {
	FONT-SIZE: 90%
}
#article #content P.endnote {
	FONT-SIZE: 90%
}
#article #content P.closenote {
	FONT-SIZE: 90%
}
#article #content P.lead {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content #affiliations-notes {
	MARGIN-TOP: 1em; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#article #content #articlebody {
	MARGIN-TOP: -1em; PADDING-TOP: 0.5em
}
#article #affiliations-notes OL {
	PADDING-LEFT: 0px; LIST-STYLE-POSITION: inside; FONT-SIZE: 70%; =
MARGIN-LEFT: 0px
}
#article #affiliations-notes {
	MARGIN-TOP: -1em
}
#article #content #abs {
	MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: =
0px
}
#article #content #abs H4.abs {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content #abs P.follows-h4 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content #abs DIV {
	MARGIN-TOP: 1em; PADDING-BOTTOM: 0px
}
#article #content DIV.keyw-abbr H4.keywords {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr P.keywords {
	DISPLAY: inline; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr H4.abbreviations {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 70%
}
#article #content DIV.keyw-abbr P.abbreviations {
	DISPLAY: inline; FONT-SIZE: 70%
}
#article DIV.figure-table {
	PADDING-RIGHT: 10px; MARGIN-TOP: 2em; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; PADDING-TOP: 10px; BACKGROUND-COLOR: #fceeee
}
#article DIV.figure-table H5 {
	DISPLAY: block; MARGIN-BOTTOM: 10px
}
#article DIV.figure-table H4.nibs {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; FONT-SIZE: 90%; =
PADDING-BOTTOM: 0px; MARGIN: 0px 0px 10px; PADDING-TOP: 0px
}
#article DIV.figure-table IMG.thumb {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; MARGIN: 10px 10px 0px 0px; WIDTH: 150px; =
BORDER-RIGHT-WIDTH: 0px
}
#article DIV.figure-table P {
	FONT-SIZE: 70%; MARGIN: 10px 0px 10px 160px
}
#article DIV.figure-table A.full {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 25px; BACKGROUND: =
url(/common/images/full_figure.gif) no-repeat left center; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article DIV.figure-table A.high-res {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 25px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/icons/fceeee/high_res.gif) no-repeat left =
center; PADDING-BOTTOM: 4px; MARGIN-LEFT: 160px; PADDING-TOP: 0px
}
#article #content SPAN.journal {
	FONT-STYLE: italic
}
#article #content SPAN.jnumber {
	FONT-WEIGHT: bold
}
#article #content #more DIV.box {
	PADDING-RIGHT: 10px; MARGIN-TOP: 1px; PADDING-LEFT: 10px; BACKGROUND: =
#eaeaea; PADDING-BOTTOM: 20px; PADDING-TOP: 10px
}
#article #content #more DIV.container {
	PADDING-RIGHT: 0px; MARGIN-TOP: 1.5em; PADDING-LEFT: 0px; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#article #content #more P.intro {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more H4.area {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.title {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#article #content #more P.source {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.source SPAN.journal {
	FONT-STYLE: italic
}
#article #content #more P.seeall {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content #more P.seeall A {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_red.gif) =
no-repeat left center; COLOR: #c03
}
#article #content #acknowledgements H4 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content .inline {
	DISPLAY: inline
}
#article #content #acknowledgements H4.footnotes {
	MARGIN-BOTTOM: 0px
}
#article #content #acknowledgements P.pubdate {
	FONT-SIZE: 70%
}
#article #content #acknowledgements P.follows-h4 {
	DISPLAY: inline; FONT-SIZE: 90%
}
#article #content UL.none {
	LIST-STYLE-TYPE: none
}
#article #content #References LI {
	MARGIN-BOTTOM: 0.5em
}
#article #content DIV.ad-right {
	FLOAT: right; PADDING-BOTTOM: 10px; MARGIN: 0px 0px 0px 10px; WIDTH: =
300px! important
}
#article #content DIV.ad-right P {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 70%; PADDING-BOTTOM: =
3px; MARGIN: 0px; COLOR: #ccc; PADDING-TOP: 0px; TEXT-ALIGN: center
}
#article #content DIV.ad-right IMG {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; DISPLAY: block; =
PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content DIV.image-legend {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 0px; BACKGROUND: #fceeee; FLOAT: right; =
PADDING-BOTTOM: 0px; MARGIN: 10px 0px 10px 10px; BORDER-LEFT: #000 1px =
solid; WIDTH: 180px! important; PADDING-TOP: 0px; BORDER-BOTTOM: #000 =
1px solid
}
#article #content DIV.image-legend P {
	PADDING-RIGHT: 5px; BORDER-TOP: #000 1px solid; PADDING-LEFT: 5px; =
FONT-SIZE: 70%; PADDING-BOTTOM: 5px; MARGIN: 0px; PADDING-TOP: 5px
}
#article #content DIV.image-legend IMG {
	BORDER-TOP-WIDTH: 0px; DISPLAY: block; BORDER-LEFT-WIDTH: 0px; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 180px; BORDER-RIGHT-WIDTH: 0px
}
#article #content DIV.image-legend SPAN {
	FONT-STYLE: italic
}
#article #content P.beforeimage-full {
	MARGIN-BOTTOM: 1em
}
#article #content DIV.image-full {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #000 1px =
solid; MARGIN-TOP: 0px; PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
#fceeee; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: =
10px; BORDER-BOTTOM: #000 1px solid; TEXT-ALIGN: center
}
#article #content DIV.image-full IMG {
	BORDER-RIGHT: #000 1px solid; BORDER-TOP: #000 1px solid; BORDER-LEFT: =
#000 1px solid; BORDER-BOTTOM: #000 1px solid; max-width: 427px
}
#article #content DIV.image-full P {
	TEXT-ALIGN: left
}
#article #content DIV.image-full SPAN {
	FONT-STYLE: italic
}
#article #content P.norm {
	FONT-SIZE: 90%
}
#article #content P.abstract {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#article #content H3.norm SPAN.reviewed {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 80%
}
#article #content P.book-aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content P.book-pub {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content H3.listing {
	MARGIN-TOP: 1em; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #000
}
#article #content H3 SPAN.atl {
	FONT-WEIGHT: bold
}
#article #content H3 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 80%; TEXT-TRANSFORM: =
uppercase
}
#article #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#article #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article #content P.seealso {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px 0px
}
#article #content P.seealso SPAN.seealso {
	FONT-WEIGHT: bold; COLOR: #c33
}
#article #content P.aug-explain {
	FONT-SIZE: 70%; FONT-STYLE: italic
}
#article #content OL.questions P.question {
	FONT-WEIGHT: bold
}
#article #content OL.questions {
	PADDING-LEFT: 0px; LIST-STYLE-POSITION: inside; MARGIN-LEFT: 0px
}
#article #content BLOCKQUOTE IMG.quoteleft {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; WIDTH: 12px; MARGIN-RIGHT: 5px; HEIGHT: 10px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content BLOCKQUOTE IMG.quoteright {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; MARGIN-LEFT: 5px; WIDTH: 12px; HEIGHT: 10px; BORDER-RIGHT-WIDTH: =
0px
}
#article #content BLOCKQUOTE.full {
	MARGIN-TOP: 1em; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/dots_vertical.gif) repeat-y left top; MARGIN-LEFT: =
15px
}
#article #content BLOCKQUOTE.full P {
	MARGIN: 0px
}
#article #content BLOCKQUOTE.full P.quote-source {
	FONT-WEIGHT: bold
}
#article #content BLOCKQUOTE.box {
	BORDER-RIGHT: #000 1px solid; BORDER-TOP: #000 1px solid; FLOAT: right; =
MARGIN: 0px 0px 10px 10px; BORDER-LEFT: #000 1px solid; WIDTH: 180px! =
important; BORDER-BOTTOM: #000 1px solid
}
#article #content BLOCKQUOTE.box P.quote {
	MARGIN: 10px
}
#article #content BLOCKQUOTE.box P.quote-source {
	PADDING-RIGHT: 10px; BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; =
BACKGROUND: #fceeee; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 10px; =
PADDING-TOP: 10px
}
#article A.arrow-back {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article A.arrow-back:visited {
	BACKGROUND: url(/common/images/arrow_purple_right.gif) no-repeat left =
center
}
#article A.arrow-back:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article A.arrow-down {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue_down.gif) =
no-repeat left center
}
#article A.arrow-down:visited {
	BACKGROUND: url(/common/images/arrow_purple_down.gif) no-repeat left =
center
}
#article A.arrow-down:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#article-related DIV.prevnext {
	BORDER-TOP: #000 1px solid
}
#article-related DIV.prevnext A:link {
	COLOR: #000
}
#article-related DIV.prevnext A:visited {
	COLOR: #000
}
#article-related DIV.prevnext A:hover {
	COLOR: #db1a21
}
#article-related A.previous:link {
	BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center
}
#article-related A.previous:visited {
	BACKGROUND: url(/common/images/arrow_black_left.gif) no-repeat left =
center
}
#article-related A.previous:hover {
	BACKGROUND: url(/common/images/arrow_red_left.gif) no-repeat left =
center
}
#article-related A.index:link {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat left =
center
}
#article-related A.index:visited {
	BACKGROUND: url(/common/images/arrow_black_up.gif) no-repeat left =
center
}
#article-related A.index:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#article-related A.next:link {
	BACKGROUND: url(/common/images/arrow_black.gif) no-repeat right center
}
#article-related A.next:visited {
	BACKGROUND: url(/common/images/arrow_black.gif) no-repeat right center
}
#article-related A.next:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat right center
}
#article-related DIV.container-sendfriend {
	BACKGROUND: #fceeee
}
#article-related DIV.container-figtab {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image-text {
	BACKGROUND: #fceeee
}
#article-related DIV.container-more {
	BACKGROUND: #fceeee
}
#article-related DIV.container-image-box {
	BACKGROUND: #fceeee
}
#article-related DIV.container-text-box {
	BACKGROUND: #fceeee
}
#article-related DIV.container-figtab A.full {
	BACKGROUND: url(/common/images/icons/fceeee/high_res.gif) no-repeat 0px =
0px; PADDING-BOTTOM: 3px
}
#article-related DIV.container-figtab A.pp {
	BACKGROUND: url(/common/images/icons/fceeee/powerpoint.gif) no-repeat =
0px 0px
}
#article-related DIV.container-extra {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #fceeee; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 0px solid
}
#article-related DIV.container-cite {
	CLEAR: both
}
#article-related DIV.container-image {
	BORDER-TOP: #000 1px solid
}
#article-related DIV.container-text-box {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #000 1px =
solid; PADDING-LEFT: 10px; PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px =
solid; PADDING-TOP: 10px
}
#article-related DIV.container-image-box {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
TEXT-ALIGN: center
}
#article-related DIV.container-image-box P {
	FONT-SIZE: 70%; FONT-STYLE: italic
}
#article-related DIV.container-text-box P {
	FONT-SIZE: 90%
}
#article-related DIV.container-sendfriend {
	FONT-SIZE: 90%
}
#article-related DIV.container-extra H2.norm {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-cite H2.norm {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-extra H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite H2.note {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.note {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.doi {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.aug {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-supplementary DIV.wrapper P.journal {
	FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-extra P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.container-cite P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related DIV.wrapper P.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 70%; MARGIN: 0px
}
#article-related P.viewing {
	FONT-SIZE: 90%; MARGIN: 1em 0px
}
#article-related P.pubmed {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-more A.article {
	MARGIN-TOP: 1em
}
#article-related DIV.container-more {
	BORDER-BOTTOM-WIDTH: 0px
}
#article-related DIV.no-nav {
	BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.container-more UL.auth {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 1em
}
#article-related DIV.container-more UL.auth LI {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0.2em; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#article-related DIV.container-products {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
PADDING-LEFT: 10px; BACKGROUND: #fceeee; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #000 1px =
solid
}
#article-related DIV.container-products H2 {
	FONT-SIZE: 90%; MARGIN: 0px
}
#article-related DIV.container-products UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; =
LIST-STYLE-TYPE: none
}
#article-related DIV.container-products UL LI {
	MARGIN-TOP: 0.5em
}
#article-related DIV.container-products UL A:link {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article-related DIV.container-products UL A:visited {
	PADDING-LEFT: 10px; BACKGROUND: url(/common/images/arrow_blue.gif) =
no-repeat left center
}
#article-related DIV.container-products UL A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#article-related DIV.alphabet {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
PADDING-BOTTOM: 3px; BORDER-LEFT: #000 1px solid; COLOR: #999; =
PADDING-TOP: 3px; BORDER-BOTTOM: #000 1px solid
}
#article-related DIV.alphabet A:link {
	COLOR: #000
}
#article-related DIV.alphabet A:visited {
	COLOR: #000
}
#article-related DIV.alphabet A:hover {
	COLOR: #db1a21
}
#article-related DIV.alphabet SPAN {
	COLOR: #000
}
#article-related DIV.cooperation {
	FONT-SIZE: 70%; FLOAT: left; MARGIN: 1em 0px 10px; COLOR: #999
}
#article-related DIV.cooperation A.natprod {
	FONT: bold 110% georgia; LETTER-SPACING: -0.04em; TEXT-DECORATION: none
}
#article-related DIV.cooperation A.natprod SPAN.first {
	COLOR: #f44
}
#article-related DIV.cooperation A.natprod SPAN.second {
	COLOR: #444
}
#article-related A.pp {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0.5em; DISPLAY: block; PADDING-LEFT: =
25px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/icons/fceeee/powerpoint.gif) no-repeat 0px 0px; =
PADDING-BOTTOM: 4px; PADDING-TOP: 0px
}
#article-related DIV.download-plugins {
	MARGIN-TOP: 1em; FLOAT: left
}
#article-related A.download-plugins:link {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 10px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: =
url(/common/images/arrow_blue_down.gif) no-repeat left center; =
BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; =
BORDER-RIGHT-WIDTH: 0px
}
#article-related A.download-plugins:visited {
	BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 10px; =
BORDER-LEFT-WIDTH: 0px; BACKGROUND: =
url(/common/images/arrow_blue_down.gif) no-repeat left center; =
BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; =
BORDER-RIGHT-WIDTH: 0px
}
#article-related A.download-plugins:hover {
	BACKGROUND: url(/common/images/arrow_red_down.gif) no-repeat left =
center
}
#article-related DIV.container-supplementary {
	BACKGROUND-COLOR: #fceeee
}
#article-related DIV.container-supplementary P {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: =
0px; PADDING-BOTTOM: 0px; PADDING-TOP: 0px; BORDER-RIGHT-WIDTH: 0px
}
#article-related DIV.container-supplementary H2 {
	PADDING-BOTTOM: 0px; COLOR: #000; PADDING-TOP: 0px
}
#article-related DIV.container-supplementary DIV.wrapper {
	PADDING-BOTTOM: 1em; MARGIN: 0px; PADDING-TOP: 1em; BORDER-BOTTOM: =
black 1px solid
}
#article-related DIV.container-supplementary DIV.first {
	BORDER-TOP: black 1px solid
}
#article-related DIV.container-supplementary P.links {
	MARGIN-TOP: 0.5em; FONT-SIZE: 70%
}
#article-related #browser-plugins {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid
}
#article-related #browser-plugins H2 {
	CLEAR: both; FONT-SIZE: 90%; MARGIN: 0px; COLOR: #db1a21
}
#article-related #browser-plugins H3 {
	FONT-SIZE: 90%; MARGIN: 1em 0px 0px; COLOR: #000
}
#article-related #browser-plugins DIV {
	FLOAT: left; MARGIN-LEFT: 3%; WIDTH: 30%
}
#article-related #browser-plugins DIV.first {
	MARGIN-LEFT: 0px
}
#article-related #browser-plugins UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#article-related #browser-plugins LI A:link {
	PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
#article-related #browser-plugins LI A:visited {
	PADDING-LEFT: 10px; FONT-SIZE: 70%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat 0px 0.5em
}
#article-related #browser-plugins LI A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat 0px 0.5em
}
.icon {
	PADDING-RIGHT: 0px; BACKGROUND-POSITION: left center; DISPLAY: block; =
PADDING-LEFT: 20px; PADDING-BOTTOM: 2px; PADDING-TOP: 2px; =
BACKGROUND-REPEAT: no-repeat
}
.i-audio {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/audio.gif)
}
.i-audio-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/audio_grey.gif)
}
.i-bitmap {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/bitmap.gif)
}
.i-bitmap-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/bitmap_grey.gif)
}
.i-compressed {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/compressed.gif)
}
.i-compressed-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/compressed_grey.gif)
}
.i-markup {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/markup.gif)
}
.i-markup-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/markup_grey.gif)
}
.i-movie {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/movie.gif)
}
.i-movie-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/movie_grey.gif)
}
.i-pdf {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/pdf.gif)
}
.i-pdf-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/pdf_grey.gif)
}
.i-postscript {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/postscript.gif)
}
.i-postscript-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/postscript_grey.gif)
}
.i-powerpoint {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/powerpoint.gif)
}
.i-powerpoint-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/powerpoint_grey.gif)
}
.i-svg {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/svg.gif)
}
.i-sif {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/sif.gif)
}
.i-sif-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/sif.gif)
}
.i-svg-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/svg_grey.gif)
}
.i-text {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/text.gif)
}
.i-text-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/text_grey.gif)
}
.i-word {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/word.gif)
}
.i-word-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/word_grey.gif)
}
.i-xls {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/xls.gif)
}
.i-xls-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/xls_grey.gif)
}
.i-microarray {
	BACKGROUND-IMAGE: url(/common/images/icons/fceeee/microarray.gif)
}
.i-chemical-structures {
	BACKGROUND-IMAGE: =
url(/common/images/icons/fceeee/chemical_structures.gif)
}
.plugin-audio {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/audio.gif)
}
.plugin-audio-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/audio_grey.gif)
}
.plugin-bitmap {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/bitmap.gif)
}
.plugin-bitmap-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/bitmap_grey.gif)
}
.plugin-compressed {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/compressed.gif)
}
.plugin-compressed-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/compressed_grey.gif)
}
.plugin-markup {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/markup.gif)
}
.plugin-markup-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/markup_grey.gif)
}
.plugin-movie {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/movie.gif)
}
.plugin-movie-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/movie_grey.gif)
}
.plugin-pdf {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/pdf.gif)
}
.plugin-pdf-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/pdf_grey.gif)
}
.plugin-postscript {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/postscript.gif)
}
.plugin-postscript-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/postscript_grey.gif)
}
.plugin-powerpoint {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/powerpoint.gif)
}
.plugin-powerpoint-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/powerpoint_grey.gif)
}
.plugin-sif {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/sif.gif)
}
.plugin-svg {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/svg.gif)
}
.plugin-svg-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/svg_grey.gif)
}
.plugin-word {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/word.gif)
}
.plugin-word-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/word_grey.gif)
}
.plugin-xls {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/xls.gif)
}
.plugin-xls-grey {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/xls_grey.gif)
}
.plugin-microarray {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/microarray.gif)
}
.plugin-chemical-structures {
	BACKGROUND-IMAGE: =
url(/common/images/icons/eaeaea/chemical_structures.gif)
}
.plugin-text {
	BACKGROUND-IMAGE: url(/common/images/icons/eaeaea/text.gif)
}
 HTML #content #related-links {
	PADDING-TOP: 5px
}
#content #related-links {
	CLEAR: both; BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 10px; =
BORDER-TOP: #000 1px solid; MARGIN-TOP: 1em; PADDING-LEFT: 10px; =
PADDING-BOTTOM: 10px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: #000 1px solid; BACKGROUND-COLOR: #f7fbff
}
#content #related-links H3 {
	PADDING-RIGHT: 0px; MARGIN-TOP: 0px; PADDING-LEFT: 0px; BACKGROUND: =
none transparent scroll repeat 0% 0%; PADDING-BOTTOM: 0px; =
TEXT-TRANSFORM: uppercase; PADDING-TOP: 0px
}
#content #related-links H4 {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 1em 0px 0px; =
TEXT-TRANSFORM: uppercase
}
#content #related-links P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1.5em
}
#content #related-links UL.norm {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#content #related-links UL.norm A:link {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #related-links UL.norm A:visited {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #related-links UL.norm A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#content #nature-products {
	PADDING-BOTTOM: 0px! important
}
#content #nature-products H3 {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px! important; =
BORDER-TOP: black 1px solid; PADDING-LEFT: 10px! important; BACKGROUND: =
none transparent scroll repeat 0% 0%; PADDING-BOTTOM: 5px! important; =
MARGIN: 0px; FONT: bold 100% georgia; BORDER-LEFT: black 1px solid; =
PADDING-TOP: 5px! important; BORDER-BOTTOM: black 1px solid; =
LETTER-SPACING: -0.04em
}
#content #nature-products H3 A {
	TEXT-DECORATION: none
}
#content #nature-products H3 SPAN.first {
	COLOR: #f44
}
#content #nature-products H3 SPAN.second {
	COLOR: #444
}
#content #nature-products DIV.natpro {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: black =
0px solid; PADDING-LEFT: 10px; BACKGROUND: #eaeaea; PADDING-BOTTOM: =
10px; BORDER-LEFT: black 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: =
black 1px solid
}
#content #nature-products DIV.natpro SPAN {
	MARGIN-TOP: 4px; DISPLAY: block; FONT-SIZE: 70%
}
#content #nature-products DIV.natpro H4 {
	FONT-WEIGHT: normal; FONT-SIZE: 80%; BACKGROUND: =
url(/common/images/in_cooperation_biocompare.gif) no-repeat right =
center; PADDING-BOTTOM: 0.5em; PADDING-TOP: 0.5em; BORDER-BOTTOM: black =
1px solid
}
#content #nature-products DIV.natpro UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-SIZE: 90%; PADDING-BOTTOM: =
0px; MARGIN: 0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#content #nature-products DIV.natpro UL A:link {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #nature-products DIV.natpro UL A:visited {
	PADDING-LEFT: 10px; FONT-WEIGHT: bold; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center
}
#content #nature-products DIV.natpro UL A:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#content #nature-products A.natpromore {
	DISPLAY: block; FONT-SIZE: 70%; FLOAT: right; COLOR: #c03; =
TEXT-DECORATION: underline
}
#content DIV#more-like-this {
	BORDER-RIGHT: black 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: black =
1px solid; PADDING-LEFT: 10px; BACKGROUND: #f7fbff; PADDING-BOTTOM: =
10px; MARGIN: 0px; BORDER-LEFT: black 1px solid; PADDING-TOP: 10px; =
BORDER-BOTTOM: black 1px solid
}
#content DIV#more-like-this H3 {
	BACKGROUND: none transparent scroll repeat 0% 0%
}
#content DIV#more-like-this DIV.wrapper {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; MARGIN-BOTTOM: 1.5em; =
PADDING-BOTTOM: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this P.explain {
	FONT-SIZE: 70%; MARGIN: 0px 0px 1.5em
}
#content DIV#more-like-this A.article {
	DISPLAY: block; FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px
}
#content DIV#more-like-this P.journal {
	FONT-SIZE: 70%; MARGIN: 0px; FONT-STYLE: italic
}
#content DIV#more-like-this P.journal SPAN {
	FONT-STYLE: normal
}
#content DIV#more-like-this H4.area {
	FONT-WEIGHT: normal; FONT-SIZE: 70%; MARGIN: 0px; TEXT-TRANSFORM: =
uppercase
}
#content DIV#more-like-this A.allmatches:link {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this A.allmatches:visited {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 70%; =
BACKGROUND: url(/common/images/arrow_blue.gif) no-repeat left center; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px
}
#content DIV#more-like-this A.allmatches:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
#index-archive #content A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#index-archive #content A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#index-archive #content H2.supp {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; PADDING-TOP: =
3px
}
#index-archive #content DIV.supp {
	MARGIN: 0px
}
#index-archive #content DIV.supp-noimage {
	MARGIN: 0px
}
#index-archive #content DIV.supp H3 {
	FONT-SIZE: 100%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px 0px 0px 70px
}
#index-archive #content DIV.supp-noimage H3 {
	FONT-SIZE: 100%; BACKGROUND: none transparent scroll repeat 0% 0%; =
MARGIN: 0px
}
#index-archive #content H3 A.atl {
	FONT-SIZE: 90%
}
#index-archive #content DIV.supp IMG {
	BORDER-TOP-WIDTH: 0px; BORDER-LEFT-WIDTH: 0px; FLOAT: left; =
BORDER-BOTTOM-WIDTH: 0px; WIDTH: 60px; HEIGHT: 60px; BORDER-RIGHT-WIDTH: =
0px
}
#index-archive #content DIV.supp P.norm {
	FONT-SIZE: 90%; MARGIN: 0px 0px 0px 70px
}
#index-archive #content DIV.supp P.support {
	FONT-SIZE: 70%; MARGIN: 0px 0px 0px 70px; COLOR: #666
}
#index-archive #content DIV.supp P.doi {
	FONT-SIZE: 70%; MARGIN: 0px 0px 0px 70px
}
#content SPAN.free-access {
	FONT-SIZE: 70%; TEXT-TRANSFORM: uppercase; COLOR: #090
}
#index-archive #content DIV.archive A.fulltoc {
	DISPLAY: block; PADDING-LEFT: 10px; FONT-SIZE: 90%; BACKGROUND: =
url(/common/images/arrow_blue.gif) no-repeat left center; MARGIN: 0px =
0px 2em
}
#index-archive #content DIV.archive A.fulltoc:hover {
	BACKGROUND: url(/common/images/arrow_red.gif) no-repeat left center
}
UL.sup-anchor {
	FLOAT: left
}
DIV.sup-box {
	WIDTH: 99%; HEIGHT: 110px
}
DIV.sup-reprints {
	BORDER-RIGHT: #746cb0 1px solid; PADDING-RIGHT: 5px; BORDER-TOP: =
#746cb0 1px solid; PADDING-LEFT: 5px; FONT-SIZE: 80%; BACKGROUND: =
#f3fafc; FLOAT: right; PADDING-BOTTOM: 5px; MARGIN: 15px 5px 5px; =
BORDER-LEFT: #746cb0 1px solid; PADDING-TOP: 5px; BORDER-BOTTOM: #746cb0 =
1px solid
}
DIV.sup-reprints UL {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
DIV.sup-reprints UL LI.sup-heading {
	FONT-WEIGHT: bold; MARGIN-BOTTOM: 5px; COLOR: #000
}
#summary #content A.toc:link {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#summary #content A.toc:visited {
	PADDING-RIGHT: 5px; PADDING-LEFT: 10px; BACKGROUND: =
url(/common/images/arrow_black_up.gif) no-repeat left center; =
PADDING-BOTTOM: 2px; PADDING-TOP: 2px
}
#summary #content A.toc:hover {
	BACKGROUND: url(/common/images/arrow_red_up.gif) no-repeat left center
}
#summary #content DIV.prevnext {
	BORDER-TOP: #000 1px solid; MARGIN-TOP: 2em
}
#summary #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#summary #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#sponsor #content IMG.highlit-sponsor {
	FLOAT: left; MARGIN: 0px 10px 10px 0px
}
#sponsor #content P.norm {
	FONT-SIZE: 90%
}
#sponsor #content DIV.container {
	BACKGROUND: url(/common/images/eaeaea.gif) repeat-y center top
}
#sponsor #content DIV.container DIV {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 20px; WIDTH: =
45%; PADDING-TOP: 20px
}
#sponsor #content DIV.container DIV IMG {
	WIDTH: 100%
}
#sponsor #content DIV.container .left {
	FLOAT: left; TEXT-ALIGN: center
}
#sponsor #content DIV.container .right {
	FLOAT: right; TEXT-ALIGN: center
}
#sponsor #content DIV.divider {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BACKGROUND: =
url(/nature_CSS/images/divider_sponsor.gif) no-repeat center top; =
PADDING-BOTTOM: 0px; MARGIN: 0px; PADDING-TOP: 0px; HEIGHT: 1px
}
#footer-sponsor {
	TEXT-ALIGN: center
}
#press #content P.norm {
	FONT-SIZE: 90%
}
#press #content DIV.prevnext {
	BORDER-TOP: black 1px solid
}
#press #content H2 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 0px 0px 0.5em; COLOR: =
#db1a21
}
#press #content H3 {
	FONT-WEIGHT: bold; FONT-SIZE: 90%; MARGIN: 1em 0px 0px
}
#press #content UL.anchor {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#press #content H4 {
	FONT-SIZE: 100%; MARGIN: 0px
}
#press #content H4 SPAN.atl {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#press #content H4 SPAN.artsubhead {
	DISPLAY: block; FONT-WEIGHT: normal; FONT-SIZE: 70%; TEXT-TRANSFORM: =
uppercase
}
#press #content P.abs {
	FONT-SIZE: 90%; MARGIN: 0px
}
#press #content P.aug {
	FONT-SIZE: 90%; MARGIN: 0px
}
#press #content P.doi {
	FONT-SIZE: 70%; MARGIN: 0.5em 0px
}
#press #content P.doi-top {
	FONT-SIZE: 70%; MARGIN: 1em 0px
}
#press #content P.links {
	FONT-SIZE: 70%; MARGIN: 0px
}
#press #content UL.no-h3 {
	PADDING-TOP: 1em
}
#request-copy #content P.norm {
	FONT-SIZE: 90%
}
#request-copy #content P.norm {
	FONT-SIZE: 90%
}
#request-copy #content LABEL {
	FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#request-copy #content LABEL.terms-cond {
	FONT-WEIGHT: normal
}
#request-copy #content .wrapper INPUT {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0.2em 0px 0.5em; WIDTH: auto; PADDING-TOP: 0px
}
#request-copy #content TEXTAREA {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0.2em 0px 0.5em; WIDTH: auto; PADDING-TOP: 0px
}
#request-copy #content INPUT.terms-cond {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0.5em 0px 0px; PADDING-TOP: 0px
}
#request-copy #content .wrapper INPUT {
	WIDTH: 100%
}
#request-copy #content TEXTAREA {
	WIDTH: 100%
}
#request-copy #content FORM {
	PADDING-RIGHT: 15px; PADDING-LEFT: 15px; PADDING-BOTTOM: 10px; =
PADDING-TOP: 10px; BACKGROUND-COLOR: #fceeee
}
#request-copy #content .wrapper SELECT {
	DISPLAY: block; MARGIN: 0.2em 0px 0.5em
}
#request-copy #content INPUT.button {
	MARGIN-TOP: 1em; DISPLAY: block
}
#topten #content P.intro {
	FONT-SIZE: 90%
}
#topten #content H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; PADDING-BOTTOM: 3px; MARGIN: 0px 0px 1em; COLOR: #db1a21; =
PADDING-TOP: 3px
}
#topten #content P.content {
	PADDING-BOTTOM: 0.2em; MARGIN: 0px; PADDING-TOP: 0.2em
}
#topten #content P.author {
	PADDING-BOTTOM: 0.2em; MARGIN: 0px; PADDING-TOP: 0.2em
}
#topten #content P.issue {
	FONT-SIZE: 80%; PADDING-BOTTOM: 0.2em; MARGIN: 0px
}
#topten #content OL {
	MARGIN-TOP: 0px; PADDING-LEFT: 0px; MARGIN-LEFT: 0px
}
#topten #content OL LI {
	LIST-STYLE-POSITION: inside; FONT-SIZE: 90%; PADDING-BOTTOM: 1em
}
#topten #content P.links {
	FONT-SIZE: 80%; MARGIN: 0px
}
#topten #content H3.art {
	DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 100%; MARGIN: 0px
}
#info #content UL.index A {
	FONT-WEIGHT: bold
}
#info #content UL.index P {
	MARGIN-TOP: 0px
}
#info #content UL.subnav {
	PADDING-RIGHT: 0px; DISPLAY: block; PADDING-LEFT: 0px; PADDING-BOTTOM: =
0px; MARGIN: 0px 0px 0px 30px; PADDING-TOP: 0px; LIST-STYLE-TYPE: none
}
#info #content P.norm {
	FONT-SIZE: 90%
}
#info #content UL {
	FONT-SIZE: 90%
}
#info #content P.no-top-margin {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#info #content UL.no-top-margin {
	MARGIN-TOP: 0px
}
#info #content H2 {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; FONT-WEIGHT: bold; FONT-SIZE: =
90%; BACKGROUND: url(/common/images/dots.gif) repeat-x left bottom; =
PADDING-BOTTOM: 3px; MARGIN: 0px; COLOR: #db1a21; PADDING-TOP: 3px
}
#info #content H3.norm {
	FONT-SIZE: 90%; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#info #content DIV.illust IMG {
	BORDER-TOP-STYLE: none; BORDER-RIGHT-STYLE: none; BORDER-LEFT-STYLE: =
none; BORDER-BOTTOM-STYLE: none
}
#info #content UL.illust {
	LIST-STYLE-TYPE: none
}
#info #content UL.illust {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#info #content UL.illust LI {
	PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: =
0px; PADDING-TOP: 0px
}
#info #content DIV.illust {
	TEXT-ALIGN: center
}
#info #content UL.subnav A {
	BACKGROUND: url(/common/images/nav_dots_36c.gif) no-repeat 0px 3px
}
#info #content UL.subnav A:visited {
	BACKGROUND: url(/common/images/nav_dots_639.gif) no-repeat 0px 3px
}
#info #content UL.subnav A:hover {
	BACKGROUND: url(/common/images/nav_dots_db1a21.gif) no-repeat 0px 3px
}
#info #content .natureeditorial P {
	MARGIN-TOP: 0px; FONT-SIZE: 90%
}
#info #content .l {
	CLEAR: left; FLOAT: left; WIDTH: 48%
}
#info #content .r {
	FLOAT: right; WIDTH: 48%
}
#info #content DIV.col2 {
	MARGIN: 10px 0px
}
#info #content DIV.col2 H3 {
	FONT-SIZE: 90%
}
#info #content DIV.col2 H3.col {
	CLEAR: left; FONT-WEIGHT: normal; FONT-SIZE: 90%; FLOAT: left; MARGIN: =
0px; WIDTH: 40%; FONT-STYLE: italic
}
#info #content DIV.col2 H4.col {
	CLEAR: left; FONT-WEIGHT: normal; FONT-SIZE: 90%; FLOAT: left; MARGIN: =
0px; WIDTH: 40%; FONT-STYLE: italic
}
#info #content DIV.col2 H4.col {
	FONT-STYLE: normal
}
#info #content DIV.col2 P.col {
	FONT-SIZE: 90%; FLOAT: left; MARGIN: 0px; WIDTH: 55%
}
#subscribe-now #content DIV.container {
	BORDER-RIGHT: #ccc 1px solid; PADDING-RIGHT: 10px; BORDER-TOP: #ccc 1px =
solid; PADDING-LEFT: 10px; MARGIN-BOTTOM: 1em; PADDING-BOTTOM: 10px; =
BORDER-LEFT: #ccc 1px solid; PADDING-TOP: 10px; BORDER-BOTTOM: #ccc 1px =
solid; BACKGROUND-COLOR: #fafafa
}
#subscribe-now #content DIV.container DIV.column1 {
	PADDING-RIGHT: 1%; BACKGROUND: url(/common/images/eaeaea.gif) repeat-y =
right top; FLOAT: left; WIDTH: 47%
}
#subscribe-now #content DIV.container DIV.column2 {
	PADDING-LEFT: 1%; FLOAT: right; WIDTH: 49%
}
#subscribe-now #content .button {
	BACKGROUND: #db1a21
}
#subscribe-now #content P.intro {
	FONT-SIZE: 90%
}
#subscribe-now #content P.small {
	FONT-SIZE: 70%
}
#subscribe-now #content UL {
	FONT-SIZE: 90%
}
#subscribe-now #content DIV.container P {
	FONT-SIZE: 90%; MARGIN-BOTTOM: 0.5em
}
#subscribe-now #content DIV.container H2 {
	MARGIN-TOP: 0px; FONT-WEIGHT: bold; FONT-SIZE: 90%
}
#subscribe-now #content DIV.container H3.first {
	MARGIN-TOP: 0px
}
#subscribe-now #content DIV.container A.register {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 8px; BORDER-TOP: #eaeaea =
1px solid; PADDING-LEFT: 8px; FONT-WEIGHT: bold; FONT-SIZE: 100%; =
BACKGROUND: #db1a21; PADDING-BOTTOM: 2px; BORDER-LEFT: #eaeaea 1px =
solid; COLOR: #fff; PADDING-TOP: 2px; BORDER-BOTTOM: #999 1px solid; =
TEXT-DECORATION: none
}
#subscribe-now #content DIV.container SPAN.freeaccount {
	FONT-WEIGHT: bold
}
#article-related #content DIV.comic {
	BORDER-RIGHT: #fff 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #fff 1px =
solid; PADDING-LEFT: 0px; BORDER-LEFT: #fff 1px solid; BACKGROUND-COLOR: =
#fff
}
#article-related #content DIV.container-comic H2.at1 {
	MARGIN-BOTTOM: 0px; PADDING-BOTTOM: 0px
}
#article-related #content DIV.container-comic P.atl {
	MARGIN-TOP: 0px; FONT-SIZE: 90%; MARGIN-BOTTOM: 0px; PADDING-BOTTOM: =
0px; PADDING-TOP: 0px
}
#article-related #content DIV.container-comic P.doi {
	MARGIN-TOP: 0px; FONT-SIZE: 80%! important; PADDING-TOP: 0px
}
SPAN.interviewee {
	FONT-WEIGHT: bold
}
SPAN.interviewer {
	FONT-WEIGHT: bold
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/restrict_width/930px.css

#head-er .accessibility-login {
	MARGIN: 0px auto; max-width: 930px
}
#head-er .image-user-services {
	MARGIN: 0px auto; max-width: 930px
}
#head-er .publications-search {
	MARGIN: 0px auto; max-width: 930px
}
DIV.footer-constrain {
	MARGIN: 0px auto; max-width: 930px
}
 HTML #head-er .accessibility-login-wrap {
	TEXT-ALIGN: center
}
 HTML #head-er .image-user-services-wrap {
	TEXT-ALIGN: center
}
 HTML #head-er .publications-search-wrap {
	TEXT-ALIGN: center
}
 HTML DIV.footer-constrain {
	TEXT-ALIGN: center
}
#breadcrumb {
	MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px
}
#constrain {
	CLEAR: both; PADDING-RIGHT: 1%; PADDING-LEFT: 1%; PADDING-BOTTOM: 0px; =
PADDING-TOP: 0px; TEXT-ALIGN: center
}
#constrain .constrain {
	MARGIN-LEFT: auto; MARGIN-RIGHT: auto; TEXT-ALIGN: left; max-width: =
930px
}
BODY DIV.margin-provider#content {
	MARGIN: 0px
}
#content-journalnav {
	MARGIN-LEFT: 0px
}
#content-extranav {
	MARGIN-RIGHT: 0px
}
#extranav {
	MARGIN-RIGHT: 0px
}
#journalnav {
	MARGIN-LEFT: 0px
}
#article-related #content {
	MARGIN-LEFT: 0px; MARGIN-RIGHT: 0px
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: text/css;
	charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/style/print.css

#header {
	DISPLAY: none
}
#breadcrumb {
	DISPLAY: none
}
.no-css {
	DISPLAY: none
}
#journalnav {
	DISPLAY: none
}
#journal-header {
	DISPLAY: none
}
#extranav {
	DISPLAY: none
}
#footer {
	DISPLAY: none
}
#footer-sponsor {
	DISPLAY: none
}
#npglogo {
	DISPLAY: none
}
#footer-copyright {
	CLEAR: both; BORDER-TOP: black 2px solid; MARGIN-TOP: 15px; FONT-SIZE: =
90%; COLOR: #999; PADDING-TOP: 15px
}
#footer-copyright A {
	FONT-WEIGHT: normal; COLOR: #000; TEXT-DECORATION: none
}
#footer-copyright .non-copyright {
	DISPLAY: none
}
.print-header {
	MARGIN-BOTTOM: 15px; PADDING-BOTTOM: 15px; BORDER-BOTTOM: black 2px =
solid
}
BODY {
	FONT-SIZE: 12pt; BACKGROUND: #fff; COLOR: #000; FONT-FAMILY: georgia, =
serif
}
H1 {
	FONT-SIZE: 16pt
}
H2 {
	FONT-SIZE: 14pt
}
H3 {
	FONT-SIZE: 12pt
}
H4 {
	FONT-SIZE: 12pt
}
H5 {
	FONT-SIZE: 12pt
}
H6 {
	FONT-SIZE: 12pt
}
A:link {
	FONT-WEIGHT: bold; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #009; TEXT-DECORATION: underline
}
A:visited {
	FONT-WEIGHT: bold; BACKGROUND: none transparent scroll repeat 0% 0%; =
COLOR: #009; TEXT-DECORATION: underline
}
#content A:link:unknown {
	FONT-WEIGHT: normal; content: " (" attr(href) ") "
}
#content A:visited:unknown {
	FONT-WEIGHT: normal; content: " (" attr(href) ") "
}
#article #content DIV BLOCKQUOTE {
	BORDER-RIGHT: #000 1px solid; PADDING-RIGHT: 0.5em; BORDER-TOP: #000 =
1px solid; PADDING-LEFT: 0.5em; PADDING-BOTTOM: 0.5em; MARGIN: 1.26em =
0px; BORDER-LEFT: #000 1px solid; PADDING-TOP: 0.5em; BORDER-BOTTOM: =
#000 1px solid; TEXT-ALIGN: center
}
#article #content DIV BLOCKQUOTE P {
	MARGIN: 0px
}
#article #content DIV BLOCKQUOTE IMG {
	DISPLAY: none
}
.backtotop {
	DISPLAY: none
}
.back-to-article {
	DISPLAY: none
}
.prevnext {
	DISPLAY: none
}
 HTML #article-related TABLE.data {
	FONT-SIZE: 7pt; WIDTH: 100%
}
#article-related TABLE.data {
	FONT-SIZE: 7pt; WIDTH: 100%
}
#article-related TABLE.data {
	BORDER-RIGHT: #999 1px solid; PADDING-RIGHT: 0px; BORDER-TOP: #999 1px =
solid; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; BORDER-LEFT: =
#999 1px solid; PADDING-TOP: 0px; BORDER-BOTTOM: #999 1px solid; =
BORDER-COLLAPSE: collapse; TEXT-ALIGN: left
}
#article-related TABLE.data THEAD {
	FONT-WEIGHT: bold
}
#article-related TABLE.data THEAD TH {
	BORDER-RIGHT: #999 1px solid; BACKGROUND: #f6f6f6; BORDER-LEFT: #999 =
1px solid
}
#article-related TABLE.data THEAD TH.colspan {
	BORDER-RIGHT: #999 1px solid; BORDER-TOP: #999 0px solid; BORDER-LEFT: =
#999 1px solid; BORDER-BOTTOM: #999 1px solid; TEXT-ALIGN: center
}
#article-related TABLE.data THEAD TH.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TD.last {
	BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY {
	BORDER-TOP: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TBODY TR {
	BACKGROUND-COLOR: #f6f6f6
}
#article-related TABLE.data TBODY TR.odd {
	BACKGROUND-COLOR: #fff
}
#article-related TABLE.data TBODY TD {
	BORDER-RIGHT: #999 1px solid; BORDER-BOTTOM: #999 1px solid
}
#article-related TABLE.data TFOOT {
	POSITION: relative
}
#article-related TABLE.data TFOOT TD {
	FONT-SIZE: 7pt; BACKGROUND-COLOR: #fff
}

------=_NextPart_000_001F_01C67B38.869A4500
Content-Type: application/octet-stream
Content-Transfer-Encoding: quoted-printable
Content-Location: http://www.nature.com/common/scripts/minmax.js

// minmax.js: make IE5+/Win support CSS min/max-width/height=0A=
// version 1.0, 08-Aug-2003=0A=
// written by Andrew Clover <and@doxdesk.com>, use freely=0A=
=0A=
/*@cc_on=0A=
@if (@_win32 && @_jscript_version>4)=0A=
=0A=
var minmax_elements;=0A=
=0A=
minmax_props=3D new Array(=0A=
  new Array('min-width', 'minWidth'),=0A=
  new Array('max-width', 'maxWidth'),=0A=
  new Array('min-height','minHeight'),=0A=
  new Array('max-height','maxHeight')=0A=
);=0A=
=0A=
// Binding. Called on all new elements. If <body>, initialise; check all=0A=
// elements for minmax properties=0A=
=0A=
function minmax_bind(el) {=0A=
  var i, em, ms;=0A=
  var st=3D el.style, cs=3D el.currentStyle;=0A=
=0A=
  if (minmax_elements=3D=3Dwindow.undefined) {=0A=
    // initialise when body element has turned up, but only on IE=0A=
    if (!document.body || !document.body.currentStyle) return;=0A=
    minmax_elements=3D new Array();=0A=
    window.attachEvent('onresize', minmax_delayout);=0A=
    // make font size listener=0A=
    em=3D document.createElement('div');=0A=
    em.setAttribute('id', 'minmax_em');=0A=
    em.style.position=3D 'absolute'; em.style.visibility=3D 'hidden';=0A=
    em.style.fontSize=3D 'xx-large'; em.style.height=3D '5em';=0A=
    em.style.top=3D'-5em'; em.style.left=3D '0';=0A=
    if (em.style.setExpression) {=0A=
      em.style.setExpression('width', 'minmax_checkFont()');=0A=
      document.body.insertBefore(em, document.body.firstChild);=0A=
    }=0A=
  }=0A=
=0A=
  // transform hyphenated properties the browser has not caught to =
camelCase=0A=
  for (i=3D minmax_props.length; i-->0;)=0A=
    if (cs[minmax_props[i][0]])=0A=
      st[minmax_props[i][1]]=3D cs[minmax_props[i][0]];=0A=
  // add element with properties to list, store optimal size values=0A=
  for (i=3D minmax_props.length; i-->0;) {=0A=
    ms=3D cs[minmax_props[i][1]];=0A=
    if (ms && ms!=3D'auto' && ms!=3D'none' && ms!=3D'0' && ms!=3D'') {=0A=
      st.minmaxWidth=3D cs.width; st.minmaxHeight=3D cs.height;=0A=
      minmax_elements[minmax_elements.length]=3D el;=0A=
      // will need a layout later=0A=
      minmax_delayout();=0A=
      break;=0A=
  } }=0A=
}=0A=
=0A=
// check for font size changes=0A=
=0A=
var minmax_fontsize=3D 0;=0A=
function minmax_checkFont() {=0A=
  var fs=3D document.getElementById('minmax_em').offsetHeight;=0A=
  if (minmax_fontsize!=3Dfs && minmax_fontsize!=3D0)=0A=
    minmax_delayout();=0A=
  minmax_fontsize=3D fs;=0A=
  return '5em';=0A=
}=0A=
=0A=
// Layout. Called after window and font size-change. Go through elements =
we=0A=
// picked out earlier and set their size to the minimum, maximum and =
optimum,=0A=
// choosing whichever is appropriate=0A=
=0A=
// Request re-layout at next available moment=0A=
var minmax_delaying=3D false;=0A=
function minmax_delayout() {=0A=
  if (minmax_delaying) return;=0A=
  minmax_delaying=3D true;=0A=
  window.setTimeout(minmax_layout, 0);=0A=
}=0A=
=0A=
function minmax_stopdelaying() {=0A=
  minmax_delaying=3D false;=0A=
}=0A=
=0A=
function minmax_layout() {=0A=
  window.setTimeout(minmax_stopdelaying, 100);=0A=
  var i, el, st, cs, optimal, inrange;=0A=
  for (i=3D minmax_elements.length; i-->0;) {=0A=
    el=3D minmax_elements[i]; st=3D el.style; cs=3D el.currentStyle;=0A=
=0A=
    // horizontal size bounding=0A=
    st.width=3D st.minmaxWidth; optimal=3D el.offsetWidth;=0A=
    inrange=3D true;=0A=
    if (inrange && cs.minWidth && cs.minWidth!=3D'0' && =
cs.minWidth!=3D'auto' && cs.minWidth!=3D'') {=0A=
      st.width=3D cs.minWidth;=0A=
      inrange=3D (el.offsetWidth<optimal);=0A=
    }=0A=
    if (inrange && cs.maxWidth && cs.maxWidth!=3D'none' && =
cs.maxWidth!=3D'auto' && cs.maxWidth!=3D'') {=0A=
      st.width=3D cs.maxWidth;=0A=
      inrange=3D (el.offsetWidth>optimal);=0A=
    }=0A=
    if (inrange) st.width=3D st.minmaxWidth;=0A=
=0A=
    // vertical size bounding=0A=
    st.height=3D st.minmaxHeight; optimal=3D el.offsetHeight;=0A=
    inrange=3D true;=0A=
    if (inrange && cs.minHeight && cs.minHeight!=3D'0' && =
cs.minHeight!=3D'auto' && cs.minHeight!=3D'') {=0A=
      st.height=3D cs.minHeight;=0A=
      inrange=3D (el.offsetHeight<optimal);=0A=
    }=0A=
    if (inrange && cs.maxHeight && cs.maxHeight!=3D'none' && =
cs.maxHeight!=3D'auto' && cs.maxHeight!=3D'') {=0A=
      st.height=3D cs.maxHeight;=0A=
      inrange=3D (el.offsetHeight>optimal);=0A=
    }=0A=
    if (inrange) st.height=3D st.minmaxHeight;=0A=
  }=0A=
}=0A=
=0A=
// Scanning. Check document every so often until it has finished =
loading. Do=0A=
// nothing until <body> arrives, then call main init. Pass any new =
elements=0A=
// found on each scan to be bound   =0A=
=0A=
var minmax_SCANDELAY=3D 500;=0A=
=0A=
function minmax_scan() {=0A=
  var el;=0A=
  for (var i=3D 0; i<document.all.length; i++) {=0A=
    el=3D document.all[i];=0A=
    if (!el.minmax_bound) {=0A=
      el.minmax_bound=3D true;=0A=
      minmax_bind(el);=0A=
  } }=0A=
}=0A=
=0A=
var minmax_scanner;=0A=
function minmax_stop() {=0A=
  window.clearInterval(minmax_scanner);=0A=
  minmax_scan();=0A=
}=0A=
=0A=
minmax_scan();=0A=
minmax_scanner=3D window.setInterval(minmax_scan, minmax_SCANDELAY);=0A=
window.attachEvent('onload', minmax_stop);=0A=
=0A=
@end @*/=0A=

------=_NextPart_000_001F_01C67B38.869A4500--

